june 2019 curriculum vitae - university of florida · june 2019 curriculum vitae desmond arthur...

June 2019

CURRICULUM VITAE

Desmond Arthur Schatz, MD

Professor and Interim Chair

Department of Pediatrics

Division of Endocrinology

Medical Director, University of Florida Diabetes Institute

Past President, American Diabetes Association, 2016

Director, Clinical Research Center, CTSI

Graduate Faculty:

Department of Pathology, Immunology, and Laboratory Medicine

Department of Genetics and Genomics

Department of Food Science and Nutrition

University of Florida

Box 100296 JHMHC

Gainesville, FL 32610

Tel: (352) 273-9270

Fax: (352) 273-9361

Email: [email protected]

Residence:

3639 NW 33 Terrace

Gainesville, FL 32605

(352) 335-4954

BIRTH: Jan 27, 1956: Johannesburg, South Africa

CITIZENSHIP: United States

FAMILY: Married: Nadine Segall; October 7, 1980

Children: Richard Allan; October 3, 1986

Megan Renee; October 10, 1988

Ilyssa Leah; September 26, 1996

EDUCATION/TRAINING:

1962-1973 St. David’s College, Johannesburg, South Africa,

First Class Matriculation Pass, 1973

1974-1979 University of the Witwatersrand Medical School,

Johannesburg, South Africa

Bachelor of Medicine, Bachelor of Surgery (MB BCH), 1979

Desmond A Schatz MD

2

1978 Externship, Department of Pediatrics, University of

California at San Francisco

1980 Intern, Johannesburg Hospital, South Africa

Jan-Jun 1980, Internal Medicine

Jul-Dec 1980, Surgery

1981-1982 Medical Officer, Department of Pediatrics,

1 Military Hospital, Pretoria, South Africa

1983-1986 Pediatric Resident,

University of Florida, Gainesville, Florida

1986-1989 Pediatric Endocrinology Fellow,


ACADEMIC APPOINTMENTS:

1988-1989 Instructor, Pediatric Endocrinology and Pathology,


1989-1994 Assistant Professor, Pediatric Endocrinology,


1994-1999 Associate Professor, Pediatric Endocrinology,


1999-present Professor, Pediatric Endocrinology,


1997-present Medical Director, Diabetes Institute,


2001-present Associate Director, Clinical Research Center (GCRC),


2002-present Associate Chairman, Department of Pediatrics,


2009-present Director, Clinical Research Center (GCRC),


QUALIFICATIONS:

MB BCH, 1979

ECFMG, 1979

Desmond A Schatz MD

3

VQE, 1980

FLEX, 1984

Diploma in Child Health (DCH), College of Medicine of South Africa, 1982

Diplomate, American Board of Pediatrics, 1987

Diplomate, American Board of Pediatric Endocrinology, 1989; renewed 1996, 2002, 2012

SPECIAL ACHIEVEMENTS:

School Honors: Academics, Cricket, Tennis

Director, Child Health Clinic, Riverlea, South Africa, 1978-1979

Special Recognition Award, Pediatric Faculty, University of Florida, 1984

Awards for Scientific Excellence, Pediatric Science Day, University of Florida, 1984-1989

Nordisk-Australia Scholarship, IXth International Workshop on the Immunology of Diabetes,

Melbourne, Australia, 1988

Kokomoor Award, Outstanding Pediatric Fellow, University of Florida, 1988

Subspecialty Program Chairperson, Pediatric Endocrinology Section, Southern Society

for Pediatric Research, New Orleans, 1991

Who’s Who in Health and Medical Services, 1991

Best Doctors in America, 1993-present

Featured Speaker, Society for Pediatric Research, Seattle, Washington, 1994

Who’s Who in the South and Southwest, 1994

Plenary Lecture, International Society for Pediatric and Adolescent Diabetes (ISPAD), Atami,

Japan, 1994

Best Doctors in South and Southeast, 1995

Society for Pediatric Research, 1995

NIH GCRC Site Visitor University of Colorado, 1995

Visiting Professor, Department of Pediatrics, University of Turku, Finland, 1995

Visiting Professor, Department of Pediatrics, University of Witwatersrand, South Africa, 1995

Who’s Who in America, 1995

International Plenary Symposium, Portuguese Diabetes Congress, Lisbon, Portugal, 1996

Plenary Symposium, 5as Jornadas de Diabetes da Madeira, Funchal, Madeira, 1996

Invited Speaker, Prediction of IDDM – Status and Trends

Workshop of ENDIT and IDIG, Gentofte, Denmark, 1996

Distinguished Lecturer, Children’s Hospital of Los Angeles, 1997

Visiting Professor, Department of Pediatrics, Albert Einstein College of Medicine, Montefiore

Medical Center, New York, 1997

University of Florida Bank Award for Teaching Excellence, 1997

Visiting Professor, Department of Pediatrics, University of Rochester Medical Center, New York,

1998

Visiting Professor, Department of Pediatrics, University of Washington, Seattle, 1998

Chair & Invited Speaker, Scientific Session on Prevention of Type 1 Diabetes, ADA Annual

Meeting, San Diego, CA, 1999

Honored Member, Strathmore’s Who’s Who, Millennium Edition 2000-2001

Strategic Planning Committee, NICHD, 2000

Visiting Professor, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota,

2000

Desmond A Schatz MD

4

Session Chair, Immunology of Diabetes Society, Society for Pediatric Research, American Diabetes

Association, 2000-2001

American Diabetes Association Recognition Award, 2000

Study Section, Juvenile Diabetes Foundation/European Association for Study of Diabetes, 2001

Research Professorship, University of Florida, 2002-2004

Grand Rounds, John’s Hopkins University, 2002

State of Art Lecture, German Diabetes Association, 2002

Faculty, ISPAD Science School, Toronto, 2002

Chair, JDRF site visit, Helsinki, Turku, Finland, 2002

Pfizer Visiting Professor, University of Washington, Seattle, 2003

Faculty Research Award in Clinical Sciences, University of Florida, 2004

American Pediatric Society, 2005

Visiting Professor, Washington University, St. Louis, 2006

Macy Nigh-Witner Visiting Professor, University of Oklahoma, 2006

Plenary Address, Midwest Society for Pediatric Research, 2006

Co-organizer, SPR Research Conference: Interplays between early nutrition, GI microbial ecology,

the immune system and subsequent health, Woodlands, TX, 2007

Chair, Organizing Committee, 9th International Congress of the Immunology of Diabetes Society

and American Diabetes Research Symposium, Miami, 2007

Juvenile Diabetes Foundation Award for Clinical Research, 2008

Cure Award, American Diabetes Association, 2009

American Diabetes Association Public Policy Leadership Award, 2010

University of Florida Research Foundation Professor, 2011

Alpha Omega Alpha (AOA) National Medical Society Faculty Member Nominee, 2013

Program Director, Endocrine Fellows Series “Type 1 Diabetes Care & Management,” Chicago,

June 2014

Special Recognition Award, Equal Access Student Volunteer Clinic, 2014

DMDEA Gold Medal Oration Award, Chennai, India, 2015

Jay Skyler Visiting Professor Award, University of Miami, 2016

American Diabetes Association Banting for Leadership and Service Award, 2016

ISPAD Prize of Achievement Award, Valencia, Spain, 2016

College of Medicine’s 2016-17 University Term Professors

UFRF Research Professor, 2017

LICENSURE:

South African Medical and Dental Council, 1980

General Medical Council of Great Britain, 1980

State of Florida, 1984

PROFESSIONAL ORGANIZATIONS:

American Diabetes Association, 1986

American Board of Pediatrics, 1987

International Diabetes Federation, 1987

Southern Society for Pediatric Research, 1988

Desmond A Schatz MD

5

Fellow, American Academy of Pediatrics, 1989

Florida Medical Association, 1989

Florida Pediatric Society, 1989

Alachua County Medical Society, 1989

Lawson Wilkins Pediatric Endocrine Society, 1990

The Endocrine Society, 1991

Society for Pediatric Research, 1996

Immunology of Diabetes Society, 1996

American Pediatric Society, 2005

Alpha Omega Alpha (AOA) National Medical Society, 2013

COMMITTEES/REVIEW BOARDS:

Florida Camp for Children and Youth with Diabetes, 1986

Board of Directors, Florida Camp for Children and Youth with Diabetes, 1991

Science Day Committee, University of Florida, 1988-1996

Director, Pediatric Fellows Training Program, University of Florida, 1989-1998

Housestaff Advisor, University of Florida, 1989-present

Congregation B’nai Israel: Ritual Committee, 1988-1996; Co-chairman, 1989-1990; Chairman,

1991-1995; Board of Directors, 1991-1994, 1996; School Board, 1995; Chairman, 1996-1997

Pharmacy and Therapeutics Committee, University of Florida, 1990-1994

Clinic Task Force, Department of Pediatrics, University of Florida, 1991

Planning Committee, Steering Committee, Safety Monitoring Group, Ancillary Studies Committee,

Treatment Committee: Type 1 Diabetes Prevention Trial (National Institute of Health), 1993-2001

Pediatric Housestaff Selection Committee, 1993-1998

Search Committee, Chief of Pediatric Cardiology, University of Florida, 1993-1994

Reviewer, Diabetes Endocrinology Research Center, University of Washington, Seattle, 1994

Children’s Miracle Network, (CMN) Awards Board, 1994-2006

Search Committee, Chief of Pediatric Hematology-Oncology, University of Florida, 1995

Ad hoc Reviewer, American Diabetes Association Research Grants, 1996

Executive Committee, International Diabetes Immunotherapy Group, 1997-present

Faculty Research Advisory Board, University of Florida, 1997-present

Professional Practice Committee, American Diabetes Association, 1997-1999

Search Committee Chair, Division of Adult Endocrinology, University of Florida, 1997

Abstract Reviewer, Endocrine Society Annual Meeting, 1998-2000

Faculty Advisor, Pediatric Alumnae Association, 1998-present

Faculty: The New ADA Diabetes Guideline: Implications for the Clinical Laboratory, 1998

Scientific Advisor, Ixion Biotechnology, Inc., 1998-2005

Consultant, Bayer Pharmaceuticals, 1999

Scientific Sessions Committee, American Diabetes Association, Professional Education Committee,

Florida Chapter, American Diabetes Association, 1999-2001

Lawson Wilkins Pediatric Endocrine Society, Diabetes Subcommittee, 1999

Insulin National Visiting Professor Academy, Hoechst Marion Roussel, 1999

Executive Committee, Department of Pediatrics, University of Florida, 1998-Grant review,

American Institute of Biological Scientists; Department of Defense Research Appropriation Act,

1999

Desmond A Schatz MD

6

Strategic Planning Committee, In-utero determinants of adult disease, National Institute of Child

Health and Human Diseases, 2000

Secretary, Immunology of Diabetes Society, 2000-2003

Scientific Advisory Board, General Clinical Research Center, University of Florida, 2000-present

Associate Director, General Clinical Research Center, University of Florida, 2001-present

Advisory Committee, Coalition for the Advancement of Diabetes Research and Education

(CADRE), 2001-2010

Chair, NIDDK Workshop: Epidemiology and Etiology of early Type 1 diabetes, 2001

Chair, Committee on Diabetes, Lawson Wilkins Pediatric Endocrine Society, 2001-2002

National Pediatric Endocrinology Advisory Board, Aventis Pharmaceuticals, 2002-2002

Chair, Publications Policy Committee, American Diabetes Association, 2002-2003

Board of Directors, American Diabetes Association, 2003-2006

External Advisory Committee, Pediatric Clinical Research Center, All Children’s Hospital, St

Petersburg, FL, 2003-2005

Consultant, BioMed Immunotech, Inc., 2003-2005

Grant Reviewer, Endocrine Fellows Foundation, 2003-present

Study Section/Reviewer, Canadian Institutes of Health Research, 2004

Chair, NIDDK Workshop: Biostatistical issues in the design of Type 1 diabetes prevention trials,

2005

External Advisory Board, NIH TODAY, STOP 2 Diabetes in Children Studies, 2004-present

Advocacy Committee, American Diabetes Association, 2005-2006

External Advisory Board, NIH/CDC SEARCH Study, 2006-present

DSMB, Australia, INIT Diabetes Prevention study, 2006-present

Youth Strategies Committee, American Diabetes Association, 2007-present

Chair Clinical and Scientific Advisory Board, DiaPep Study, 2007-2015

NIAID Special Emphasis Panel, 2008

Chair, JDRF site visit, DIPP, Turku, Finland, 2008

Expert Committee on Diagnosis of Diabetes, ADA/EASD/IDF initiative, 2008

University of Florida Faculty Compensation, 2006-2010

University of Florida Dean Search Committee, 2009

University of Florida Chair of Medicine Search Committee, 2010

International Telecommunications Educations and Research Association (ITERA), 2010

ADA Awards Committee, 2009-2013

JDF/Canadian government Review/EAB, Type 1 diabetes initiative, 2010-present

Chair, JDRF Review: Research on Biosamples from Type 1 diabetes clinical trials, genetics and

natural history studies, 2011

JDRF/Welcome Trust, UK T Diabetes and Inflammation Laboratory Review 2010-2016

JDRF/NHMRC Australia DVDC Review Committee, 2012-2017

American Diabetes Association/JDRF Type 1 Diabetes Source Book. Editorial Board/Steering

Committee, 2013

Scientific Advisory Board, Diabetes Research Connection, 2013-2014

ADA Board of Directors, 2014-16

President Medicine & Science ADA, 2016

JDRF International Centers Study Review Board, 2017

JDRF Research Advisory Council, 2017

Desmond A Schatz MD

7

EDITORIAL:

Associate Editor

Pediatric Diabetes, 2000-present

Editorial Board

Journal of Pediatric Endocrinology and Metabolism, 2002-present

Pediatric Endocrine Reviews, 2003-present

Journal of Clinical Endocrinology and Metabolism, 2004-2008

Reviews in Endocrinology, 2007-present

Journal of Pediatric Endocrinology, 2009-present

Ad Hoc Reviewer for:

Journal of Pediatrics, 1989-present

Clinical Immunology and Immunopathology, 1989-present

Laboratory and Clinical Medicine, 1990-present

Diabetes Care, 1990-present

Diabetes, 1990-present

Proceedings of the National Academy of Science, 1993

Southern Medical Journal, 1993

Journal of Clinical Endocrinology and Metabolism, 1994-present

Pediatric Research, 1994-present

Pediatrics, 1995

Autoimmunity, 1995-present

Metabolism, 1995-present

Endocrine Reviews, 1996-present

Journal of Pediatric Endocrinology and Metabolism, 1998-present

Nature Clinical Practice Endocrinology & Metabolism, 2006

Pediatric Transplantation, 2009-present

The American Journal of Clinical Nutrition, 2011-present

Diabetes Technology and Therapeutics, 2012-present

Diabetologia, 2001-present

GRANT SUPPORT:

Dean’s Fellowship, University of Florida College of Medicine: 1987-1989

Juvenile Diabetes Foundation (JDF): 1988-1990. Postdoctoral Fellowship

Title: Defective cell mediated immunity in pre-diabetes; the role of suppressor-inducer and

helper-inducer lymphocytes in the immunopathogenesis of insulin dependent diabetes

mellitus

Role: PI

Total Award: $29,000

University of Florida, Division of Sponsored Research: 1990-1993

Research Development Award: RDA 1-22 89-90

Title: Determination of abnormal CD4+CD45RO helper-inducer function in preclinical

insulin dependent diabetes mellitus

Desmond A Schatz MD

8

Role: PI


National Institute of Health (NIH): 1987-1993

R01 HD19469

Title: Islet cell antibodies and the natural history of IDDM

Role: Co-I (PI: Noel Maclaren, MD)

Total Award: $3,386,283


R01 HD19469

Title: Islet cell antibodies and the natural history of IDDM

Role: Co-PI (PI: Noel Maclaren, MD)



P01 DK39079

Title: Disordered cell mediated immunity in insulin dependent diabetes (Project IV;

program Project Grant)

Role: Co-I (PI: Noel Maclaren, MD)


Gynex, Inc.: 1992-1993

Title: A phase III multi-center, double-blind placebo controlled study of the safety and

efficacy of Oxandrolone to increase growth velocity and improve psychosocial status in

boys with constitutional delay of growth

Role: Institutional PI

Total Award: $9,000

Gynex, Inc.: 1992-1995

Title: A phase III multi-center, double-blind placebo controlled study of the safety and

efficacy of Oxandrolone and Growth Hormone to increase growth velocity and improve

psychosocial status in girls with Turner Syndrome

Role: Institutional PI

Total Award: $6,000

Children’s Miracle Network: 1992-1993

Title: How does insulin immunotherapy prevent insulin dependent diabetes?

Role: PI (Co-PI: Andrew Muir, MD)


Juvenile Diabetes Foundation (JDF): 1993-1995

Research Grant

Title: Prophylactic subcutaneous insulin therapy to prevent insulin dependent diabetes in

high-risk relatives

Role: PI

Desmond A Schatz MD

9



GCRC grant: MO1RR000820524

Title: Prophylactic subcutaneous insulin therapy to prevent IDD

Role: PI



Muticenter UO-1 grant

Title: Prevention of Type 1 Diabetes

Role: Center (University of Florida) PI


Center Award: $541,565

Children’s Miracle Network: 1994-1995

Title: Effects of prophylactic insulin therapy on T cell immunity in pre-clinical insulin

dependent diabetes

Role: Co-PI (Co-PI: Michael Clare-Salzler, MD)


National Vitiligo Foundation: 1995-1996

Title: Immunohistochemical study of skin biopsy samples from vitiligo patients:

Correlation with molecular immunogenetics, autoimmune endocrinopathies and the initiation of a

pilot study to arrest disease progression

Role: Co-PI (Co-PI: Noel Maclaren, MD)


Eli Lilly and Company: 1996-1997

Title: The feasibility of oral insulin therapy (oral tolerance) to delay beta cell destruction

in newly-diagnosed patients with insulin-dependent diabetes mellitus

Role: Co-PI (Co-PI: Noel Maclaren, MD)



Title: Mechanisms of immunotherapy in IDD prevention

Role: Co-I (PI: Mark Atkinson, PhD)



Title: Immune function in high and low risk genotypes in IDD

Role: Co-PI (Co-PI: Mark Atkinson, PhD) Program Project Award: PI

Of Project 2 (with Dr. Atkinson)

Total Award: (Program Project Grant): $3,704,592

American Diabetes Association: 1997-1999

Desmond A Schatz MD

10

Title: Diabetes Prevention Trial

Role: Center PI


Eli Lilly and Company: 1997-2000

Title: Hypopituitary Control and Complication Trial (HYPOCS)

Role: PI


Fetzker Institute: 1998-2000

Title: Environmental stress and the development of type 1 diabetes

Role: Co-I (PI: Annette La Greca, PhD: University of Miami)


Title: Quality of care for children with special needs in managed care

Role: Co-I (PI: Elizabeth Shenkman, PhD)


College of Medicine, University of Florida Program Initiative: 1997-2000

Title: Genetic screening of newborn babies for type 1 diabetes

Role: Co-PI (Co-PI: Jin-Xiong She, PhD)


National Institute of Health/Juvenile Diabetes Foundation: 1999-2002

Title: Prospective studies in infants of the immunopathogenesis of type 1 diabetes



Pfizer Inc.: 1999-2000

Title: Efficacy and safety of inhaled human insulin compared with subcutaneous human

insulin in an intensive insulin regimen for adolescents with type 1 diabetes

Role: PI



Title: Efficacy and safety of inhaled human insulin compared with subcutaneous human

insulin in an intensive insulin regimen for 6-11 year old children with type 1 diabetes

Role: PI



Title: Follow-up efficacy and safety study of inhaled human insulin compared with

subcutaneous human insulin in an intensive insulin regimen for children and adolescents

with type 1 diabetes

Role: PI


Desmond A Schatz MD

11


Title: Immune function and the progression to type 1 diabetes

Role: Co-PI (PI: Mark Atkinson, PhD) Program Project Award; Co-PI of Project 3,

Core A

Total Award: (Program Project Grant): $1,628,000

National Institutes of Health (NIH): 2001-2005

Title: Autoantibodies to recombinant autoantigens: predictions/immunogenetics

Role: Investigator (PI: GE Eisenbarth MD PhD; University of Colorado)



Title: Prospective studies in infants of immunopathogenesis of type 1 diabetes




Multicenter U01DK063868

Title: Consortium for the identification of environmental triggers of type 1 diabetes:

Medical College of Georgia/University of Florida Clinical Center and Network

Role: Center Co-PI

Center Award: $1,900,000

Aventis Pharmaceuticals: 2003-2005

Title: Comparison of safety and efficacy of glargine with NPH insulin in adolescents with

Type 1 diabetes

Role: PI



Title: Dendritic cells and the prevention of type 1 diabetes

Role: Co-PI (Co-PI: Michael Clare-Salzler, MD)


Juvenile Diabetes Research Foundation (JDRF): 2004-2006

Title: Transfusion of autologous umbilical cord blood to reverse hyperglycemia in children


Role: PI



Title: Comparison of safety and efficacy of glulisine with lyspro insulin in adolescents


Role: PI


Desmond A Schatz MD

12


Title: Use of glulisine as an adjunct for islet regeneration

Role: PI



Title: Cord blood immunoregulation of type 1 diabetes

Role: Co-PI (PI: Mark Atkinson, PhD)


Lawson Wilkins Pediatric Endocrine Society: 2006-2008

Title: Islet regeneration in animal models of type 1 diabetes

Role: PI Mentor (Co-PI: Dr. Michael Haller)



2MO1RR0082

Title: General Clinical Research Center

Role: Director (PI: Michael Good, MD)

National Institute of Health (NIH): 2007

Title: 9th Immunology of Diabetes Society Research Symposium

Role PI: Meeting Organizer



1PO1AI42288 Program Project Grant

Title: Immune function is high and low risk genotypes in IDD

Role: Co-I (PI: Mark Atkinson, PhD)


Juvenile Diabetes Research Foundation (JDRF) PPG: PI Project I: 2007-2011

Title: Cord blood therapies for type 1 diabetes

Role: Project PI



Multicenter UO-1DK085461-06

Title: TrialNet: University of Florida Clinical Center and Network

Role: Center PI

Center Award: $3,244,105

Jaeb Center for Health Research: 2009-2013

Title: Pediatric Diabetes Consortium

Desmond A Schatz MD

13

Role: PI



CTSA 3-UL1-R-R02-4968-05-S1

Title: Multidisciplinary Approach to Study Type 1 Diabetes with Residual (CTSA Supplement)

Role: PI


3-L1-R-R02-4986-05-S1: 2011-2013

Michigan Institute for Clinical and Health Research (MICHR)

Title: Long Standing Type 1 Diabetes with Residual C-peptide – A Pilot Study

Role: PI


Jaeb Center for Health Research: 2010-2019

Title: T1D Exchange Type 1 Diabetes Network

Role: PI


NIDDK UC4 DK104216 01: 2014-2021

Title: Non-Invasive Diagnosis of Human Beta Cell Damage and Death

Role: PI


25-207-874 Juvenile Diabetes Research Foundation (JDRF): 2007-2019

Title: Network for Pancreatic Organ Donors with Diabetes: Administrative core

Role: Co-I

Total Award $1,507,254

2015PG-T1D032 Helmsley Charitable Trust: 2014-2017

Title: Effects of Low Dose Thymoglobulin Used Alone (ATG) or in Combination with

GCSF (Neulasta) on the Progression of Type 1 Diabetes in New Onset Studies

Role: Co-PI

Total Award $ 2,142,910

1U01AI125057-01A1: 2017-2022

Title: Low-dose IL-2 in established T1D

Role: PI


UC4 DK116274: 2017-2021

Title: Non‐invasive detection of cell death in type 1diabetes: insight into novel disease

Mechanisms

Role: PI


Desmond A Schatz MD

14

National Institute of Health NIAID: 2018-2023

Title: Title: Immune function is high and low risk genotypes in IDD

Role: Co-I (PI Mark Atkinson PhD)

Total Amount: $16,868

PUBLICATIONS:

Peer Reviewed Manuscripts

1. Schatz DA, Barrett DJ: Evolution of the subclass of antibody to type 3 pneumococcal

polysaccharide during childhood. Clin Exp Immunol 70: 449-455, 1987. PMID: 34278929;

PMCID: 1542071

2. Schatz DA, Barrett DJ, Maclaren NK, Riley WJ: Evidence for polyclonality of islet cell

antibodies. Autoimmunity 1: 45-50, 1988. PMID: 2979605

3. Schatz DA, Rosenbloom AL: Diabetic ketoacidosis: Management tactics in young patients

and adolescents. Journal Crit Illness 3: 31-45, 1988.

4. Maclaren NK, Schatz DA, Drash AL, Grave G: The initial pathogenic events in insulin

dependent diabetes. Diabetes 38: 534-538, 1989. PMID: 2647560

5. Schatz DA, Kowa H, Winter WE, Riley WJ: The natural history of incidental hyperglycemia

and/or glycosuria in childhood. J Pediatr 116: 676-680, 1989. PMID: 2681635

6. Schatz DA, Riley WJ, Silverstein JH, Barrett DJ: Long-term immunoregulatory effects of

therapy with corticosteroids and antithymocyte globulin. Immunopharmacology and

Immunotoxicology 11: 269-287, 1989 (selected by Clinical Digest Series as “outstanding in its

field”). PMID: 2695566

7. Herrod HG, Conley ME, Goldblum RM, Barrett DJ, Schatz DA, Wasserman RL, Lederman

HM, Winkelstein JA, Sullivan JL, Burks AW: Chronic mucocutaneous candidiasis in

childhood and complications of non-Candida infection: A report of the Pediatric

Immunodeficiency Collaborative Study Group. J Pediatr 116 (3): 377-382, 1990. PMID:

2308026

8. Rosenbloom AL, Alves C, Cleveland WW, Eidson M, Gonzales-Mendoza LE, Perez-

Rodriguez JE, Bercu BB, Diamond F, Root A, Shulman D, Deeb L, Desrosiers PM, Hoffman

RP, Hsiang H, Schatz DA, Silverstein JH, Winter WE: Height screening in the community:

The commercialization of growth. The role of the pediatrician. Clin Pediatr 29 (5): 228, 1990.

PMID: 2340691

9. Riley WJ, Maclaren NK, Krischer J, Spillar RP, Silverstein JH, Schatz DA, Schwartz S,

Malone J, Shah S, Vadheim C, Rotter JI: A prospective study of the development of diabetes

Desmond A Schatz MD

15

in relatives of patients with insulin-dependent diabetes. N Engl J Med 323: 1167-1172, 1990.

PMID: 2215594

10. Cox BG, Schatz DA, Van Mierop LHS: Scientific writing courses for academic physicians.

Academic Medicine 65: 652-653, 1990. PMID: 2261045

11. Rosenbloom AL, Schatz DA: Minimizing the risk of brain herniation during treatment of

diabetic ketoacidosis (letter). J Pediatr 117: 1009, 1990. PMID: 2123238

12. Zori RT, Schatz DA, Ostrer H, Williams CA, Riley WJ: Autoimmunity and thyroid

dysfunction in children and adults with Down Syndrome. Am J Med Gen 7 (suppl): 238-241,

1990. PMID: 2149955

13. Rosenbloom AL, Schatz DA, Silverstein JH: To scan or not to scan in congenital

hypothyroidism. Clin Pediatr 29: 733-734, 1990.

14. Davidson KM, Richards DS, Schatz DA, Fisher DA: Successful in-utero treatment of a large

fetal goiter and hypothyroidism. N Engl J Med 324: 543-546, 1991. PMID: 1992308

15. Schatz DA, Riley WJ, Maclaren NK, Barrett DJ: Defective inducer T cell function before the

onset of insulin dependent diabetes mellitus. J Autoimmunity 4: 125-136, 1991. PMID:

1827712

16. Mather A, Stekol L, Schatz D, Maclaren NK, Scott ML, Lippe B: The parental origin of the

single X chromosome in Turner syndrome: Lack of correlation with parental age or patient

phenotype. Am J Human Genetics 48: 682-686, 1991. PMID: 1673045

17. Rosenbloom AL, Schatz DA, Silverstein JH: Joint Disease in Diabetes Mellitus. Practical

Diabetology 11: 4-13, 1991.

18. Schatz DA, Lang FP, Cantor AB, Riley WJ, Maclaren NK, Sleasman J, Barrett DJ: CD5+ B

lymphocytes in high risk islet cell antibody positive and newly diagnosed insulin dependent

diabetic subjects. Diabetes 40: 1314-1318, 1991. PMID: 1718800

19. Lang FP, Schatz DA, Riley WJ, Maclaren NK, Barrett DJ: Increased levels of T lymphocytes

bearing the gamma delta T cell receptor in insulin dependent diabetes. J Autoimmunity 4:

925-933, 1991. PMID: 1839880

20. Barrett DJ, Sleasman JW, Schatz DA, Steinitz M: Human anti-pneumococcal

polysaccharide antibodies are secreted by the CD5- B cell lineage. Cellular Immunol

143: 66-79, 1992. PMID: 1377990

21. Gottschalk ME, Schatz DA, Clare-Salzler M, Kaufman DL, Ting GSP, Geffner ME: Transient

neonatal diabetes mellitus preceding permanent insulin-dependent diabetes mellitus. Diabetes

Care 15: 1273-1276, 1992. PMID: 1425088

Desmond A Schatz MD

16

22. Geffner ME, Clare-Salzler M, Kaufman DL, Ting GSP, Gottschalk ME, Schatz DA:

Permanent diabetes developing after transient neonatal diabetes: more than just a chance

association. Lancet 341: 1095, 1993. PMID: 8096989

23. Krischer JP, Schatz DA, Riley WJ, Spillar RP, Silverstein JH, Schwartz S, Malone J, Shah S,

Vadheim CM, Rotter JI, Quattrin T, Maclaren NK: Insulin and islet cell autoantibodies as time

dependent covariates in the development of diabetes in relatives of patients with insulin

dependent diabetes: a prospective study. J Clin Endocrinol Metab 77: 743-749, 1993. PMID:

8370696

24. Winter WE, Chihara T, Schatz DA: The genetics of autoimmune diabetes: approaching a

solution to the problem. Am J Dis Childhood 147: 1282-1290, 1993. PMID: 8249945

25. Muir A, Schatz DA, Pozilli P, Maclaren NK: Intervention therapies for insulin dependent

diabetes. Autoimmunity 16: 301-310, 1993. PMID: 8025209

26. Muir A, Schatz DA, Maclaren NK: Antigen specific immunotherapy: Oral tolerance and

subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabet Metab Rev

9: 279-287, 1993. PMID: 7924825

27. Schatz DA, Krischer J, Horne G, Riley WJ, Atkinson MA, Winter WE, Silverstein JH, Allen

L, Shah S, Malone J, Maclaren NK: Islet cell antibodies predict the development of insulin

dependent diabetes in United States schoolchildren as effectively as in unaffected relatives. J

Clin Invest 93: 2403-2407, 1994. PMID: 8200974; PMCID:294447

28. Lakhdir F, Lawson D, Schatz DA: Fatal parathyroid hormone-related protein-induced humoral

hypercalcemia of malignancy in a 3-month-old infant. Eur J Pediatr 153: 718-720, 1994.

PMID: 7813527

29. Weatherspoon LJ, Kumanyika SK, Ludlow R, Schatz DA: Glycemic control in Black and

White patients with NIDDM in North Central Florida. Diabetes Care 17: 1148-1153, 1994.

PMID: 7821134

30. Schott M, Schatz DA, Atkinson MA, Krischer J, Mehta H, Vold B, Maclaren NK: GAD65

autoantibodies increase the predictability but not the sensitivity of islet cell and insulin

autoantibodies for developing insulin-dependent diabetes mellitus. J Autoimmunity 7: 865-

872, 1994. PMID: 7888042

31. Huang W, She J, Muir A, Laskowska D, Zorovich B, Schatz DA, Maclaren NK: High-risk

HLA-DR/DQ genotypes for IDD confer susceptibility to autoantibodies but DQB1*0602 does

not prevent them. J Autoimmunity 7: 889-897, 1994. PMID: 7888045

32. Wilson DM, McCauley E, Brown DR, Dudley R and the Bio-technology General Co-

operative Study Group (Schatz et al): Oxandrolone Therapy in Constitutionally Delayed

Growth and Puberty. Pediatrics 96: 1095-1100, 1995. PMID: 7491227

Desmond A Schatz MD

17

33. Schatz DA, Atkinson MA: Milk: innocent or guilty - only time will tell! (letter) Diabetes

Prevention and Therapy 9: 1, 1995.

34. Slayton W, Kedar A, Schatz DA: Testosterone-induced priapism in a patient with sickle cell

disease. J Pediatr Endocrinol 8: 199-203, 1995. PMID: 8521195

35. Silverstein JH, Varga-House D, Schatz DA, Kubilis P, Rosenbloom AL: Accuracy of a self-

monitoring blood glucose meter in a high-humidity, high temperature summer camp setting.

Diabetes Care 18: 1200-1201, 1995. PMID: 7587863

36. Cantor A, Krischer J, Schatz DA, Cuthbertson D, Riley WJ, Maclaren NK: The effect of age

and family relationship on the risk of IDDM in relatives. J Clin Endocrinol Metab 80: 3739-

3743, 1995. PMID: 8530627

37. Muir A, Schatz DA: The prevention of type 1 diabetes - 1995. Trends in Endocrinology and

Metabolism 6: 312-317, 1995. PMID: 18406716

38. DPT-1 Study Group: Diabetes Prevention Trial - Type 1 Diabetes (DPT-1): Implementation of

Screening and Staging of Relatives. Transplantation Proceedings 27: 3377, 1995. PMID:

8540003

39. Schatz DA, Maclaren NK: The natural history of pre-type 1 diabetes. Current Opinion in

Endocrinology and Diabetes 2: 31-37, 1995.

40. Schatz DA, Winter WE: Recent advances in the immunopathogenesis of insulin dependent

diabetes mellitus. Current Opinion in Pediatrics 7: 459-465, 1995. PMID: 7581652

41. Li Y, Song Y-H, Rais N, Connor E, Schatz DA, Muir A, Maclaren N: Autoantibodies to the

external domain of the calcium sensing receptor in patients with acquired hypoparathyroidism.

J Clin Invest 97: 910-914, 1996. PMID: 8613543; PMCID: 507135

42. Huang W, Connor E, Dela Rosa T, Muir A, Schatz DA, Silverstein JH, Crockett S, She J-X,

Maclaren NK: Although DR3-DQB1*0201 may be associated with multiple component

diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-

DQB1*0302 is implicated only in beta-cell autoimmunity. J Clin Endocrinol Metab 81: 2559-

2563, 1996. PMID: 8675578

43. Ramiya VK, Shang X-Z, Pharis PG, Wasserfall CH, Stabler TV, Muir AM, Schatz DA,

Maclaren NK: Antigen based therapies to prevent diabetes in NOD mice. J Autoimmunity 9:

349-356, 1996. PMID: 8816970

44. Schatz DA, Rogers D, Brouhard B: Diabetes Prevention Trials. Cleveland Clinic Journal of

Medicine 63: 270-274, 1996. PMID: 8870337

45. Schatz DA, Maclaren NK: Cow's milk and IDDM: innocent until proven guilty! JAMA

(Editorial); 276: 647-648, 1996. PMID: 8773639

Desmond A Schatz MD

18

46. Schatz DA, Maclaren NK: Lack of association of exposure to cow's milk and IDDM. JAMA

(Letter); 276: 1801-1801, 1996. PMID: 8773639

47. Winter WE, House D, Schatz DA: Prospects for the pharmacological prevention of Type 1

diabetes. Drugs 53: 943-956, 1997. PMID: 9179526

48. Winter WE, Schatz DA: Neonatal prevention of IDDM. Diabetes Prevention and Therapy

(letter) 11: 17-18, 1997.

49. Wilson BS, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA,

Atkinson MA, Balk SP, Strominger JL, Hafler DA: Extreme Th1 bias of regulatory V24JQ

T cells in Type 1 diabetes. Nature 391: 177-181, 1998. PMID: 9428763

50. Ellis TM, Schatz DA, Ottendorfer E, Lan MS, Wasserfall C, Salisbury PJ, She J-X, Notkins

AL, Maclaren NK, Atkinson MA: Relationship between humoral and cellular immunity to IA-

2 in IDDM. Diabetes 47: 566-569, 1998. PMID: 9568688

51. Tercyak KP, Johnson SB, Schatz DA: Patient and family perceptions of the use of

subcutaneous insulin injections to prevent IDDM: Implications for future prevention trials.

Journal of Diabetes and its Complications 12: 279-286, 1998. PMID: 9747645

52. Ellis TM, Ottendorfer E, Jodoin E, Salisbury PJ, She J-X, Schatz DA, Atkinson MA: Cellular

immune responses to casein: elevated in but not specific for individuals with IDDM.

Diabetologia 41: 731-735, 1998. PMID: 9662058

53. Schatz DA, Ellis T, Ottendorfer E, Jodoin E, Salisbury P, Barrett D, Maclaren N, Atkinson M:

Age and the cellular response to tetanus. Clin and Lab Immunology 5: 894-896, 1998. PMID:

9801353; PMCID: 96220

54. Ellis TM, Jodoin E, Ottendorfer E, Salisbury PJ, She J-X, Schatz DA, Atkinson MA: Cellular

immune responses against proinsulin: no evidence for enhanced reactivity in individuals with

insulin dependent diabetes mellitus. Diabetes 48: 299-303, 1999. PMID: 10334305

55. Klingensmith GJ, Clark W, Schatz DA, Miller D, Kaufman FR: Care of children with diabetes

in the school setting. Diabetes Care 22: 163-166, 1999. PMID: 10333920

56. Kaufmann F, Silverstein J, Schatz D: The management of diabetes at camp. Diabetes Care 22:

167-169, 1999. PMID: 10333921

57. Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, Clare-Salzler M, She JX,

Malone J, Crockett S, Schwartz S, Quattrin T, DeSilva M, Vander Vegt P, Notkins A,

Krischer J: Only multiple antibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2 beta

predict immune mediated (type 1) diabetes in relatives. J Autoimmun 12: 279-287, 1999.

PMID: 10330299

Desmond A Schatz MD

19

58. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker D, She JX, Hofig A, Dennis

MA, Fuller K, Cook R, Schatz DA, Moldawer LL, Clare-Salzler MJ: Aberrant Prostaglandin

Synthase 2 expression defines an antigen presenting cell defect in humans at risk for insulin-

dependent diabetes mellitus (IDDM). J Clin Inves 104: 515-523, 1999. PMID: 10449443;

PMCID: 408519

59. Schatz DA, Krischer JP, Skyler J: Now is the time to prevent type 1 diabetes. J Clin

Endocrinol Metab 85: 495-498, 2000.

60. Greenbaum CJ, Schatz D, Cuthbertson D, Eisenbarth G, Zeidler A, Krischer J for the DPT-1

Study Group: Islet cell antibody positive relatives with HLA DQA1*0102, DQB1*0602:

identification by the Diabetes Prevention Trial - Type 1. J Clin Endocrinol Metab 85: 1255-

1260, 2000. PMID: 10720072

61. Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG: Reversal of insulin-

dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature Medicine

6: 278-282, 2000. PMID: 10700229

62. Wasserfall C, Atkinson M, Jodoin E, Schatz D, She J-X, Ellis T: Glutamic Acid

Decarboxylase and IA-2 autoantibodies in Type 1 diabetes; comparing sample substrates for

autoantibody determinations. Pediatric Diabetes 1: 10-16, 2000. PMID: 15016237

63. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White N,

Wilson DM, Wolfsdorf J for the DPT-1 Study Group: First phase insulin release during the

intravenous glucose tolerance test as a risk marker for Type 1 diabetes. J Pediatr 138: 244-

249, 2001. PMID: 11174623

64. Bingley PJ, Schatz DA, Bonifacio E, Atkinson MA, Ziegler AG, Eisenbarth G: IDS Position

Statement on prediction of Type 1 diabetes. Diabetes Care 24: 398, 2001. PMID: 11213898

65. Schatz DA, Bingley P: Update on major trials for the prevention of type 1 diabetes: the

American Diabetes Prevention Trial (DPT-1) and European Nicotinamide Diabetes

Intervention Trial (ENDIT). J Pediatr Endocrinol 14: 619-622, 2001. PMID: 11393553

66. LaGreca A, Bearman K, Delamater A, Patino AM, Blumberg M, Marks J, Johnson S, Schatz

D, Anderson B: Early life stress and disease among offspring and siblings of individuals with

Type 1 diabetes. J Pediatr Endocrinol 14: 661-668, 2001. PMID: 11393560

67. Rapaport R, Nuzzo J, Schatz D, Maclaren N: Intervention to delay the onset of diabetes in

very young siblings of children with Type 1 diabetes. J Pediatr Endocrinol 14: 623-626, 2001.

PMID: 11393554

68. Chaudhari M, Cornelius JG, Schatz DA, Peck AB, Ramiya VK: Pancreatic stem cells: a

therapeutic agent that may offer the best approach for curing Type 1 diabetes. Pediatric

Diabetes 2: 195-202, 2001. PMID: 15016187

Desmond A Schatz MD

20

69. Schatz DA, Krischer J, She J-X: To screen or not to screen for pre-type 1 diabetes? Hormone

Research 57 (suppl 1): 12-17, 2002. PMID: 11979016

70. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of

patients with type 1 diabetes mellitus. New Engl J Med 346: 1685-1691, 2002. PMID:

12037147

71. Winter WE, Harris N, Schatz DA: Immunological markers in disease prediction and clinical

course of autoimmune type 1 A diabetes. Clinical Diabetes 20: 183-191, 2002.

72. Peck AB, Cornelius JG, Chaudhari M, Schatz DA, Ramiya VK: Use of in vitro-generated

stem cell-derived islets to cure type I diabetes: How close are we? Ann NY Acad Sci 958: 59-

68, 2002. PMID: 12021084

73. Petrovsky N, Silva D, Schatz DA: Prospects for the prevention of type 1 (insulin-dependent)

diabetes. Drugs 62: 2617-2635, 2002. PMID: 12466001

74. Winter WE, Harris N, Schatz DA: Type 1 diabetes islet autoantibody markers. Diabetes

Technology & Therapeutics 4: 817-839, 2002. PMID: 12614488

75. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz

DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial - Type 1 Study Group:

Screening strategies for the identification of multiple antibody positive individuals. JCEM 88:

103-108, 2003. PMID: 12519837

76. Carmichael SK, Bennett Johnson S, Baughcum A, Lenglet P, Giangola A, North K,5 She J-X,

Schatz DA: Newborn Genetic Screening for Type 1 Diabetes: Implications for Informing

Parents of Diabetes Risk. Med Genetics 5: 77-83, 2003. PMID: 12644776

77. Miller JM, Schatz D: Obese young girl with acanthosis nigricans and vaginal yeast infection.

Pediatric Consultant 5: 181-185, 2003.

78. Litherland SA, She JX, Schatz DA et al: Natural history of monocyte prostaglandin synthase 2

(PGS2) expression in Type 1 diabetes: aberrant PGS2 expression in at-risk populations before

and after disease onset. Pediatric Diabetes 4: 10-18, 2003. PMID: 14655518

79. Maclaren NK, Lan MS, Schatz DA, Malone J, Notkins AL, Krischer J: Multiple

autoantibodies as predictors of type 1 diabetes in the general population. Diabetologia 46:

873-874, 2003. PMID: 12802500

80. Winter WE, Schatz D: Prevention strategies for type 1 diabetes mellitus: current status and

future directions. BioDrugs 17: 39-64, 2003. PMID: 12534319

81. Petrovsky N, Schatz DA: Vaccine therapies for the prevention of type 1 (insulin-dependent)

diabetes. Pediatr Drugs 5: 575-582, 2003. PMID: 12956615

Desmond A Schatz MD

21

82. Schatz DA, Gale, EA: Why can’t we prevent type 1 diabetes? Maybe it’s time to try a

different combination. Diabetes Care 26: 3326-3327, 2003. PMID: 14633822

83. Johnson SB, Baughcum AE, Carmichael SK, She J-X, Schatz DA: Maternal anxiety

associated with newborn genetic screening for type 1 diabetes. Diabetes Care 27 (2): 392-397,

2004. PMID: 14747219

84. Schatz DA, Cuthbertson D, Atkinson M, Clare-Salzler M, Winter W, Muir A, Silverstein J,

Cook R, Maclaren N, She J-X, Greenbaum C, Krischer J: Preservation of C-peptide secretion

in subjects at high risk of developing Type 1 diabetes mellitus – a new surrogate measure of

non-progression. Pediatr Diabetes 5 (2): 72-79, 2004. PMID: 15189492

85. Morales A, Wasserfall C, Brusko T, Carter C, Schatz D, Silverstein J, Ellis T, Atkinson M:

Adiponectin and leptin concentrations discriminate disease forms in children and adolescents

with type 1 and type 2 diabetes. Diabetes Care 27: 2010-2014, 2004. PMID: 15277432

86. Williams CA, Wallace MR, Drury KC, Kipersztok S, Edwards RK, Williams RS, Haller MJ,

Schatz DA, Silverstein JH, Gray BA, Zori RT: Blood lymphocyte chimerism associated with in

vitro fertilization and monochorionic dizygous twinning. Hum Reprod 12: 2816-2821, 2004.

PMID: 15375077

87. Ramiya V, Schatz DA: Islet replacement vs regeneration. Hope or hype? Ped Diabetes 5 Suppl

2: 45-56, 2004. PMID: 15601374

88. Ergun-Longmire B, Marker J, Zicler, A, Rapaport, R, Raskin P, Bode B, Schatz D, Vargas A,

Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK: Oral insulin therapy to prevent

progression of immune mediated (type 1) diabetes. Ann NY Acad Sci 1029: 260-277, 2004.

PMID: 15681764

89. Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz DA, Zeidler A, Orban T,

Wasserfall C, Cuthbertson D, Krischer J, and the DPT-1 study group: High frequency of

abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives of patients with type 1

diabetes. Diabetologia 48: 68-74, 2005. PMID: 15602651

90. Haller M, Schatz D: Autoimmune thyroiditis during leuprolide acetate treatment. J Peds 146:

294, 2005. PMID: 15689930

91. Ramirez-Montealegre D, Chattopadhyay S, Curran TM, Wasserfall C, Pritchard L, Schatz D,

Petitto J, Hopkins D, She J-X, Rothberg, PG, Atkinson M, Pearce DA: Autoimmunity to

glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology 64:

743–745, 2005. PMID: 15728308

92. Shenkman E, Tian L, Nackashi J, Schatz D: Managed care organizational characteristics and

children’s outpatient specialty use. Pediatrics 115: 1547-1554, 2005. PMID: 15930215

Desmond A Schatz MD

22

93. Baughcum AE, Bennett Johnson S, Carmichael SK, Lewin A, She J-X, Schatz DA: Maternal

efforts to prevent Type 1 Diabetes in infants At-Risk. Diabetes Care 28 (4): 916-921, 2005.

PMID: 15793195

94. Neu J, Reverte CK, Mackey, AD, Liboni K, Tuhacek LM, Hatch M, Li N, Schatz DA,

Atkinson MA: Changes in Intestinal Morphology and Permeability in the Biobreeding.

Diabetes-Prone (BBdp) Rat Prior to the Onset of Type 1 diabetes. J Pediatr Gastroenterol

Nutr 40 (5): 589-595, 2005. PMID: 15861021

95. Diabetes Prevention Trial – Type 1 Study Group: Effects of oral insulin in relatives of patients

with type 1 diabetes mellitus. Diabetes Care 28: 1068-1076, 2005. PMID: 15855569

96. Hood KK, Johnson SB, Carmichael SK, Laffel LMB, She J-X, Schatz DA: Depressive

symptoms in mothers of infants identified as genetically at-risk for type 1 diabetes. Diabetes

Care 28 (8): 1898-1903, 2005. PMID: 16043729

97. Haller, MJ and DA Schatz: Insulin needs after CD3-antibody therapy in new-onset type 1

diabetes. N. Engl J Med 353 (19): 2086-2087, 2005. PMID: 16282188

98. Brusko TM, Wasserfall CH, Clare-Salzler M, Schatz DA, Atkinson MA: Functional defects

and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes

54 (5): 1407-1414, 2005. PMID: 15855327

99. Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, Muir A, Hopkins D, Huang Y-H, She

J-X: Expression levels of soluble cytotoxic T-lymphocyte associated antigen-4 in patients with

type-1 diabetes. J Autoimmune Diseases 2: 8, 2005. PMID: 16259622 PMCID:1289290

100. Schatz DA, Atkinson MA: Islet cell autoantibodies: a case of a premature obituary. Editorial.

Pediatr Diabetes 6 (4): 181-3, 2005. PMID: 16390385

101. Collins CD, Purohit S, Podolsky RH, Zhao HS, Schatz D, Eckenrode SE, Yang P, Hopkins D,

Muir A, Eisenbarth G, Hoffman M, McIndoe RA, Rewers M, She JX: The Application of

Genomic and Proteomic Technologies in Predictive, Preventive and Personalized Medicine.

Vascular Pharmacology 45: 258-267, 2006. Epub 18 August 2006. PMID: 17030152

102. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Cuthbertson D, Eisenbarth

GS, Krischer JP, Schatz DA on behalf of the Diabetes Prevention Trial (DPT)-1 Study Group:

Specific HLA DQ influence on expression of anti-islet autoantibodies and progression to type

1 diabetes. J Clin Endocrinol Metab 91: 1705-1713, 2006. Epub 2006 Feb 7. PMID:

16464953

103. Hood KK, Johnson SB, Baughcum AE, She J-X, Schatz DA: Maternal understanding of infant

diabetes risk; the differential effects of maternal anxiety and depression. Genet Med 8 (10):

665-670, 2006. PMID: 17079884

Desmond A Schatz MD

23

104. Schwartz RF, Neu J, Schatz DA, Atkinson MA, Wasserfall C: Comment on: Brugman S et al.

Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-

prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 50 (1):

220-221, 2007. Epub 2006 Nov 21. PMID: 17119915

105. Haller MJ, Shuster JJ, Schatz DA, Melker R: Adverse impact of temperature and humidity on

blood glucose monitoring reliability: A pilot study. Diabetes Technol Ther 9 (1): 1-9, 2007.

PMID: 17316092

106. Shenkman E, Knapp C, Sappington D, Vogel B, Schatz D: Persistence of high health care

expenditures among children in Medicaid. Med Care Res Rev 64 (3): 304-330, 2007. PMID:

17507460

107. Haller MJ, Schatz DA: Endocrine consequences of childhood cancer. Pediatr Endocrinol Rev

4 (3): 196-204, 2007. PMID: 17551480

108. Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A,

Mahmud FH: Peripheral artery tonometry demonstrates altered endothelial function in

children with type 1 diabetes. Pediatr Diabetes 8: 193–198, 2007. PMID: 17659060

109. Johnson SB, Hood K, Rafkin-Mervis LE, Baughcum AE, Schatz DA: Participant and parent

experiences in the parenteral insulin arm of the diabetes prevention trial for type 1 diabetes.

Diabetes Care 30 (9): 2193-2198, 2007. PMID: 17563348

110. Brusko T, Wasserfall C, McGrail K, Moore M, Viener HL, Schatz D, Haller M, Schatz R,

Rockell J, Clare-Salzler M, Atkinson M: No alterations in the frequency of FOXP3+

regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612, 2007. PMID: 17327427

111. Park, JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P: Type 1

diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect

of long-term leptin therapy. J Clin Endocrinol Metab 93 (1): 26-31, 2008. Epub 2007 Oct 16.

PMID: 17940115 PMCID: PMC2729152

112. Simon G, Ramiya V, Wasserfall C, Huang Y, Schwartz RF, Campbell-Thompson M, Tenace

L, Brusko T, Parker M, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M,

Schatz D, Kaplan B, Womer K, Atkinson MA: Murine anti-thymocyte globulin therapy alters

disease progression in NOD mice by a time dependent induction of immunoregulation.

Diabetes 57 (2): 405-414, 2008. Epub 2007 Nov 26. PMID: 18039815

113. Caicedo RA, Li N, des Robert C, Scumpia P, Hubsher CP, Wasserfall CH, Schatz DA,

Atkinson MA, Neu J: Immunological consequences of neonatal nutrition alteration in the BB

rat model of type 1 diabetes. Pediatr Res 63 (3): 303-307, 2008. PMID: 18091354

114. Horsman TA, Schatz DA, Haller M: Cardiomyopathy and hypocalcemia: A unified

explanation? Contemporary Pediatrics 2008 Jan 1. Epub ahead of print

Desmond A Schatz MD

24

115. Haller MJ, Schatz DA: Cytokines and type 1 diabetes complications: casual or causal

association? Editorial. Pediatric Diabetes 9 (1): 1-2, 2008. PMID: 18211629

116. Shuster J, Schatz DA: Letter to Editor. Response to Nissen SE, Wolski K. Effect of

rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N.

Engl J. Med 356: 2457-2471, 2007. Diabetes Care 31 (3): e10, 2008. PMID: 18308673

117. Haller, MJ, HL Viener, C Wasserfal, T Brusko, MA Atkinson, DA Schatz: Autologous

Umbilical cord blood infusion for Type 1 Diabetes. Exp Hematolo 36 (6): 710-715, 2008.

PMCID: PMC18358588 PMCID:2444031

118. Lu Y, Parker M, Pileggi P, Zhang B, Cho Y-K, Molano RD, Wasserfall C, Ricordi C,

Inverardi L, Brantly M, Schatz D, Atkinson M, Song S: Human Alpha 1-Antitrypsin therapy

induces fatal anaphylaxis in NOD mice. Clin Exp Immunol 154 (1): 15-21, 2008. Epub 2008

Aug 28. PMID: 18759852 PMCID:2561098

119. Johnson SB, Hood K Rafkin-Mervis LE. Baughcum AE, Schatz DA: Participant Experiences

in the oral insulin arm of the Diabetes Prevention Trial for Type 1 Diabetes. Diabetes Care 30

(9): 2193-2198, 2007. Epub 2007 Jun 11. PMID: 17563348

120. Stalvey MS, Brusko, TM, Mueller C, Wasserfall CH, Schatz DA, Atkinson MA, Flotte TR:

CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis

related diabetes. Cytokine 44: 154–159, 2008. PMID: 18778952

121. Haller MJ, Schatz DA:What’s in a name? Thyroid autoimmunity in obese patients with T1D

Editorial. Pediatric Diabetes 9 (4, Part 1): 263-265, 2008. PMID: 18768034

122. Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden PType 1

diabetes associated with acquired generalized lipodystrophy and insulin resistance: The effect

of long-term leptin therapy. J Clin Endocrinol Metab 93 (1): 26-31, 2008. PMID:17940115

PMCID:2729152

123. Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D,

Crawford JM, Atkinson MA: Pancreatic adenocarcinoma patients with localised chronic

severe pancreatitis show an increased number of single beta cells, without alterations in

fractional insulin area. Diabetologia 52: 262-270, 2009. Epub 2008 Nov 11. PMID:

19002428

124. Roesch LFW, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Volker M,

Wasserfall CH, Schatz DA, Atkinson MA, Neu J, Triplett EW: Culture-independent

identification of gut bacteria correlated with the onset of diabetes in a rat model. 1–13, 2009

The ISME Journal 3 (5): 536–548. Epub 2009 Feb 19. doi:10.1038/ismej.2009.5. PMID:

19225551 PMCID:2972309

125. Xue S, Wasserfall C, Parker M, McGrail S, McGrail K, Campbell-Thompson M, Schatz DA,

Atkinson MA, Haller MJ: Exendin-4 treatment of non-obese diabetic mice increases beta-cell

Desmond A Schatz MD

25

proliferation and fractional insulin reactive area. J Diabetes Complications 24: 163-167, 2010.

PMID: 19217320

126. Rosenbloom AL, Guevara-Aguirre J, Haller MJ, Malasanos TH, Miller JL, Rohrs HJ, Schatz

DA, Silverstein JH, Weinstein DA: Letter in response to: Consensus Statement on the

diagnosis and treatment of children with idiopathic short stature: A summary of the Growth

Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the

European Society for Pediatric Endocrinology Workshop. J Clin Endocrinol Metab 93: 4210-

4217. Epub 2009 Jan 14. PMID:18782877

127. Roesch LFW, Wurdig F, Casella G, Simell O, Krischer J, Wasserfall C, Schatz D, Atkinson

M, Neu J, Triplett E: Influence of sample storage on bacterial community diversity in fecal

samples. Open Microbiology Journal 3: 40-46, 2009. PMID: 19440250; PMCID: 2681173

128. Haller MJ, Atkinson MA, Schatz DA: The road not taken: A path to curing type 1 diabetes?

Eur J Immunol 39 (8): 2054-2058, 2009. PMID: 19672902; PMCID:4085751

129. Parker M., Xue S., Alexander J., Wasserfall C., Campbell-Thompson M., Battaglia M.,

Gregori S., Mathews C, Song S., Troutt M., Eisenbeis S., Williams J., Schatz D, Haller M.,

Atkinson M: Immune depletion with cellular mobilization imparts immunoregulation and

reverses autoimmune diabetes in NOD mice. Diabetes 58 (10): 2277-2784, 2009. Epub 2009

Jul 23. PMID: 19628781; PMCID:2750219

130. Nathan D., Albright A., Balkau B., Bonora E., Borch-Johnsen K., Buse J., Colagiuri St.,

Davidson M., DeFronzo R., Genuth S., Holman R., Ji L., Kirkman S., Knowler W., Schatz D.,

Shaw J., Sobngwi E., Steffes M., Vaccaro O., Wareham N., Zinman B., Kahn R.: International

expert committee report on the diagnosis of diabetes. The role of the glycated hemoglobin

(A1C) assay in the diagnosis of diabetes in non-pregnant persons. Diabetes Care 32 (7):

1327-1334, 2009. Epub 2009 Jun 5. PMID: 19502545 PMCID: 2699715

131. Gitelman SE, Haller MJ, Schatz DA: Autologous nonmyeloablative hematopoietic stem cell

transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 302 (6): 624-625, 2009.

PMID: 19671901

132. Bierschenk L, Alexander J, Wasserfall, C, Haller, M, Schatz D, Atkinson, M: Vitamin D

levels in subjects with and without Type 1 diabetes residing in a solar rich environment.

Diabetes Care 32 (11): 1977-1979, 2009. Epub 2009 Aug 12. PMID: 19675194; PMCID:

PMC2768192 PMCID:2775921

133. Brusko TM., Wasserfall CH., Hulme MA., Cabrera R., Schatz D., Bluestone JA., Atkinson

MA: Influence of membrane CD25 stability on lymphocyte activity: implications for

immunoregulation. PLOS Medicine 2009 Nov 24; 4 (11): e7980. PMID: 19956753

134. Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, Kelly SS,

Shuster JJ, Atkinson MA, Schatz DA: Autologous umbilical cord blood transfusion in very

Desmond A Schatz MD

26

young children with type 1 diabetes. Diabetes Care 32 (11): 2041-2046, 2009. PMID:

19875605; PMCID: PMC 2768209

135. Pescovitz M., Greenbaum C., Krause-Steinrauf H., Becker D., Gitelman S., Goland R.,

Gottlieb P., Marks J., McGee P., Moran A., Raskin P., Rodriguez H., Schatz D., Anti-CD20

Study Group: Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function. N

Engl J Med 361 (22): 2143-2152, 2009. PMID: 19940299

136. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M,

Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ,

Atkinson MA: Immune depletion with cellular mobilization imparts immunoregulation and

reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 58 (10): 2277-2284, 2009.

PMID: 19628781; PMCID: PMC2750219

137. Gottlieb P., Quinlan S., Srause-Steinrauf H., Greenbaum C., Wilson D., Rodriguez H., Schatz

D., Moran A., Lachin J., Skyler J, Type 1 Diabetes TrialNet MMF/DZB Study Group: Failure

to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy

in patients with new onset type 1 diabetes. Diabetes Care 33 (4): 826-832, 2010. Epub 2010

Jan 12. PMID: 20067954; PMCID:2845036

138. Cernea S., Raz I., Herold K., Hirshberg B., Roep B., Schatz D., Fleming A., Pozzilli P., Little

R., Schloot N., Leslie D., Skyler J., Palmer J: Challenges in developing endpoints for type 1

diabetes intervention studies. Diabetes Metab Res Rev 25 (8): 694-704, 2009. PMID:

19771545

139. Bonifacio E., Yu L., Williams A., Eisenbarth G., Bingley P., Marcinovic S., Koczwara K.,

Ziegler A., Mueller P., Schatz D., Krischer J., Steffes M., Akolkar B: Hormonization of

GAD- and IA-2 autoantibodies assays for NIDDK Consortia. J Clin Endocinol Metab 95 (7):

3360-3367, 2010. Epub 2010 May 5. PMCID: 2928346; PMID: 20519658 2928900

140. Simell O., Winter W., Schatz D.: Enhancing the understanding of pre-type 1 diabetes in the

general population. Editorial. Diabetes Care 33 (6): 1403-1405, 2010. PMID: 20508234;

PMCID: 2875464

141. Li N., Hatch M, Wasserfall C, Douglas-Escobar, Atkinson MA., Schatz DA., Neu J.: Butyrate

and type 1 diabetes: can we fix the intestinal leak? Journal of Pediatric Gastroenterology &

Nutrition 51 (4): 414-417, 2010. PMID: 20706153

142. Valladares R., Sankar D., Li N., Williams E., Mahmaou A., Lai K., Gonzales C., Wasserfall

C., Larkin J., Schatz D., Atkinson M., Triplett E., Neu J., Lorca G.: Lacobacillus johnsonii

N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS ONE 6 (5): e10507,

2010. PMID: 20463897; PMCID: 2865539

143. Ross IL., Boulle A., Soule SG., Levitt NS., Pirie F., Karlsson FA., Mienie LJ., Yang P., Wang

HJ., She JX., Winter WE., Schatz D: Autoimmunity predominates in a large South African

cohort with Addison’s disease despite longstanding disease and is associated with HLA

Desmond A Schatz MD

27

DQB*0201. Clinical Endocrinolgy (Oxf) 73 (3): 291-298, 2010. Epub 2010 Apr 23. PMID:

20455895

144. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, Drew JC, Ilonen J,

Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz DA, Atkinson

MA, Triplett EW: Toward defining the autoimmune microbiome for type 1 diabetes. ISME J

5 (1): 82-91, 2011. Epub 2010 Jul 8. PMID: 20613793; PMCID: 3105672

145. Ma H., Lu Y., Li H., Campbell-Thompson M., Parker M., Wasserfall C., Haller M., Brantly

M., Schatz D., Atkinson M., Song S: Prevention and reversal of type 1 diabetes in NOD mice

by alpha 1 antitrypsin therapy. Diabetologia Oct; 53 (10): 2198-2204, 2010. Epub 2010 Jul 1.

doi: 10.1007/s00125-010-1829-2. PMID: 20593162.

146. The Pediatric Diabetes Consortium: improving care of children with type 1 diabetes through

collaborative research. Diabetes Technol Ther 12 (9): 685-688, 2010.

doi:10.1089/dia.2010.0065. PMID: 20687862

147. Tao B., Pietropaolo M., Atkinson M., Schatz D., Taylor D.: Estimating the cost of type 1

diabetes in the USA propensity score matching method. PLoS ONE 9;5 (7): e11501, 2010.

PMID: 20634976; PMCID: 2901386

148. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H,

Schatz DA, Moran AM, Lachin JM, Skyler JS, for the Type 1 Diabetes TrialNet MMF/DZB

Study Group: Failure to preserve β-cell function with mycophenolate mofetil and daclizumab

combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 33 (4): 826-832,

2010. PMID: 20067954; PMCID: PMC2845036

149. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K,

Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization of

glutamic aciddecarboxylase and islet antigen-2 autoantibody assays for national institute of

diabetes and digestive and kidney diseases consortia. Journal of Clinical Endocrinology &

Metabolism 95 (7): 3360-3367, 2010. PMID: 20444913; PMC3032020

150. Driscoll K., Johnson S., Schatz D., Haller M.: Use of a precious resource: parental decision

making for young children participating in a trial of autologous umbilical cord blood to

interdict type 1 diabetes. Contemp Clin Trials 32 (4): 524-529, 2011. PMID: 21530680:

PMCID: 3129744

151. Sterner Y, Torn C, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Simell O, Ziegler

A, Schatz D, Hagopian W, Rewers M, She J-X, Krischer JP, Akolkar B, Lernmark A, TEDDY

Study Group: Country-specific birth weight and length in type 1 diabetes high-risk HLA

genotypes in combination with prenatal characteristics. J Perinatol 31 (12): 764-769, 2011.

PMID: 21527903; PMCID:3226663

152. Winter W, Schatz DA: Autoimmune markers in diabetes. Clin Chem. 57 (2): 168-175, 2010.

Epub 2010 Dec 2. PMID: 21127152

Desmond A Schatz MD

28

153. Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J, the DPT 1

Study Group: Islet autoantibody seroconversion in the DPT-1 study: justification for repeat

screening throughout childhood. Diabetes Care 34 (2): 358-362, 2011. PMID: 21270193;

PMCID: 3024349

154. Campbell-Thompson M, Albanese-O’Neill A, Stavea T, Nierras C, Kaddis J, Rowe P,

Wasserfall C, Gianani R, Eisenbarth G, Pugliese A, Schatz D, Atkinson M: The network

for pancreatic organ donors with diabetes (nPOD); Tissue biobanking for the purpose of

understanding the causes of and cures for type 1 diabetes. Diabetes Metab Res Rev

28 (7): 608-617, 2012. PMID: 22585677; PMCID: 3456997

155. Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, DPT-1 & TrialNet

Study Groups: Long term outcome of those treated with oral insulin: DPT-1 Oral Insulin Trial.


156. Ize-Ludlow D, Lightfoot YL, Parker M, Xue S, Wasserfall C, Haller MJ, Schatz D, Becker

DJ, Atkinson MA, Mathews CE: Progressive erosion of beta-cell function precedes the onset

of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes 60 (8): 2086-2091,

2011. PMID: 21659497; PMCID:3142079

157. Wasserfall CH., Mathews CE, Schatz DA: The use of leptin as treatment for type 1 diabetes

mellitus: counterpoint. Pediatr Diabetes 13 (1): 74-76, 2012. Epub 2011 Sep 2. PMID:

21884562

158. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,

Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P,

Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet

GAD Study Group: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine

in patients with recent-onset type 1 diabetes: a randomized double-blind trial. Lancet 378

(9788): 319-327, 2011. Epub 2011 June 27. doi: 10. 1016/SO140-6736 (11)60895-7. PMID:

21714999

159. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Schatz D,

Wherrett D, Wilsson DM, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet Abatacept

Study Group: Co-stimulation modulation with abatacept in patients with recent-onset type 1

diabetes: a randomized, double-blind placebo-controlled trial. Lancet 378 (9789): 412-419,

2011. PMID: 21719096; PCMID: 3580128; PMCID: 3462593

160. Rowe PA, Campbell-Thompson ML, Schatz DA, Atkinson MA: The pancreas in human

type 1 diabetes. Semin Immunopathol 33 (1): 29-43, 2011. PMID: 20495921;

PMCID:3022158

161. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M, Haller

Desmond A Schatz MD

29

M, Schatz D, Myhr C, She JX, Wasserfall C, Atkinson M: Reduced serum Vitamin D binding

protein levels are associated with type 1 diabetes. Diabetes 60 (10): 2566-2570, 2011. Epub

2011 Aug 15. PMID: 21844098; PMCID:3178281

162. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer

JP for the TrialNet Natural History Study Group: Development of autoantibodies in the

TrialNet Natural History Study (NHS). Diabetes Care 34 (9): 1897-1901, 2011. Epub 2011

Jul 12. PMID: 21750277; PMCID:3161292

163. Schatz D, Levine R, Atkinson MA. Its time to mow the GRAS in type 1 diabetes.

Diabetes 60 (11): 2669-71, 2011. PMID: 22025772; PMCID:3198084

164. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G,

Drew J, Ilonen J, Knip M, Hyoty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH,

Schatz D, Atkinson MA, Triplett EW: Gut microbiome metagenomics analysis suggests a

functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6 (10);

e25792. Epub 2011 Oct 17. PMID: 22043294; PMCID:3197175

165. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Sumrall TM,

Wingard JR, Theriaque DW, Shuster JJ, Atkinson MA, Schatz DA: Autologous umbilical cord

blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes

Care 34 (12): 2567-2569, 2011. Epub 2011 Oct 19. PMID: 22011412; PMCID:

PMC3220832

166. Sterner Y, Torn C, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Simell O, Ziegler

A, Schatz D, Hagopian W, Rewers M, She J-X, Krischer J, Akolkar B, Lernmark A for the

TEDDY Study Group: Country-specific birth weight and length in type 1 diabetes high-risk

HLA genotypes in combination with prenatal characteristics. J Perinatol 31 (12): 764-769,

2011. Epub 2011 Apr 28. doi: 10.1038/jp.2011.26. PMID: 21527903; PMCID: PMC3226663

167. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ,

Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer

JP, Skyler JS: Effects of canakinumab on the progression of type 1 diabetes in recent

onset subjects: a randomized, double-blind, placebo-controlled trial. Lancet 378 (9789): 412-

419, 2011. Epub 2011 Jun 28. PMID:21719096

168. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,

Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz

D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS. Co-stimulation modulation with

abatacept in patients with recent-onset type 1 diabetes: follow-up one year after cessation of

treatment. Lancet 30: 378 (9789): 412-419, 2011. Epub 2011 Jun 28. doi. 10.1016/SO140-

6736(11)60886-63. PMID: 21719096; PMCID: PMC3462593

169. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T,

Eisenbarth G, Diabetes Prevention Trial – Type 1 and Type 1 diabetes TrialNet Study Groups:

A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1

http://www.ncbi.nlm.nih.gov/pubmed/?term=21527903

Desmond A Schatz MD

30

diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 34 (11):

2435-2437, 2011. Epub 2011 Sep 12. doi: 10.2337/dc11-0981. PMID: 21911777; PMCID:

PMC3198298

170. Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M,

Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-Type

1 and Type 1 Diabetes TrialNet Natural History Study Groups: Performance of HbA1c as an

early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care 35 (9):

1821-1825, 2012. Epub 2012 Jun 14. PMID: 22699293; PMCID: PMC3425003

172. Ross IL, Levitt N, Van der Walt JS, Schatz DA, Johannsson G, Pillay TS: Salivary cortisol

day curves suggest hydrocortisone replacement therapy in Addison’s disease may be supra-

physiological. Horm Metab Res. 45 (1): 62-68, 2013. Epub 2012 Aug 14. doi: 10.1055/s-

0032-1321855. PMID: 22893258

173. Ross IL, Levitt N, Johannsson G, Schatz D. Ethnicity influences the diagnosis of

primary adrenal insufficiency. Clin Endocrinol 78 (5): 800-802, 2013. doi:

10.1111/cen.12063. PMID: 23051632

174. Moran A, Bundy B, Becker D, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold

KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler

JS, for the Type 1 Diabetes TrialNet Canakinumab Study Group, Pickergill L, de Koning E,

Ziegler AG, Boehm B, Badenhoop K, Schloot N,Friis Bak J, Pozzilli P, Mauricio D, Donath

MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T, for the AIDA Study

Group: Interleukin-antagonism in type 1 diabetes of recent onset: two multicenter,

randomized, double-blind placebo-controlled trials. Lancet 381 (9981): 1905-1915, 2013.

Epub 2013 Apr 5. doi: 10.1016/SO140-6736(13)60023-9. PMID: 23562090; PMCID:

PMC3827771

175. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR,

Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz

DA: Autologous umbilical cord blood infusion followed by oral docosahexanoic acid and

vitamin D supplementation for C-peptide preservation in children with type 1 diabetes. Biol

of Blood and Marrow Transplant 19 (7): 1126-1129, 2013. Epub 2013 Apr 20. Doi:

10.1016/j.bbmt.2013.04.011. PMID: 23611977; PMCID: PMC3852705

176. Ross IL, Levitt NS, Van Der Merwe L, Schatz DA, Johannsson G, Dandara C, Pillay TS,

Blom DJ: Investigation of glucocorticoid receptor polymorphisms in relation to metabolic

parameters in Addison’s disease. Eur J Endocrinol 168 (3): 403-412, 2013. doi: 10.1530/EJE-

12-0808. PMID:23239757

177. Ross IL, Bergthorsdottir R, Levitt NS, Schatz DA, Johannsson G, Marais AD: Increased

cardiovascular risk in South African patients with Addison’s Disease. Horm Metab Res 45

(12): 905-910, 2013. Epub 2013 Aug 5. doi: 10.1055/s-0033-1351259. PMID: 23918685

http://www.ncbi.nlm.nih.gov/pubmed/?term=21911777

Desmond A Schatz MD

31

178. Walker AF, Schatz DA, Silverstein JH, Parker KA, Aponick AU, Rohrs HJ: Framing food and

diabetes: exploring the perspectives of youth with type 1 diabetes through photography.

SAGEcan.sagepub.com/content/5/6/347, 2013.

179. Levetan C, Schatz DA: Proposal for generating new beta cells in a muted immune

environment for type 1 diabetes. Diabetes Metab Research Res 29 (8): 604-606, 2013. doi:

10.1002/dmrr.2435. PMID: 23853103; PMCID: PMC4237549

180. Myhr CB, Hulme MA, Wasserfall CH, Hong PJ, Lakshmi PS, Schatz DA, Haller MJ, Brusko

TM, Atkinson MA: The autoimmune disease-associated SNP rs917997 of IL18RAP controls

IFNy production by PBMC. Journal of Autoimmunity 44: 8-12, 2013. Epub 2013 July 24.

doi: 10.1016/j.jaut.2013.06.001. PMID: 23891168; PMCID: PMC3775347

181. Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW,

Cengiz E, Laffel LM, Miller KM, Haller MJ for the T1D Exhange Clinic Network: A contrast

between children and adolescents with excellent and poor control: the T1D Exchange Clinic

Registry experience. Pediatr Diabetes 15 (2): 110-117, 2014. Epub 2013 Aug 19. doi:

10.1111/pedi.12067. PMID: 23957219; PMCID: PMC4164957; PMCID: PMC4164957

182. Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA,


D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept

Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1

diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37 (4): 1069-1075,

2014. Epub 2013 Dec 2. doi: 10.2337/dc13-0604. PMID: 24296850; PMCID: PMC3964491

183. Turner JR, Schatz DA, Cusi K, Strumph P: Healthcare transition from pediatric to adult

medical homes in diabetes mellitus. Endocr Prac 20 (7): 714-720, 2014. PMID:24449671

184. LaBaer J, Miersch S, Bian X, Wallstrom G, Sibani S, Logvinenko T, Wasserfall CH, Schatz

DA, Atkinson M, Qiu J: Serological autoantibody profiling of type 1 diabetes by protein

arrays. J Proteomics 94: 486-496, 2013. Epub 2013 Oct 20. PMID:24148850

185. Giannopoulou EZ, Puff R, Beyerlein A, von Luettichau I, Boerschmann H, Schatz D,

Atkinson M, Haller MJ, Egger D, Burdach S, Ziegler AG: Effect of a single autologous cord

blood infusion on beta cell and immune function in children with new onset type 1 diabetes: a

non-randomized, controlled trial. Pediatric Diabetes 15 (2): 100-109, 2014. Epub 2013 Sept

19. PMID: 24102806

186. Rowe P, Wasserfall C, Croker B, Campbell-Thompson M, Pugliese A, Atkinson M, Schatz D:

Increased complement activation in human type 1 diabetes pancreata. Diabetes Care 36 (11):

3815-3817, 2013. Epub 2013 Sep 16. doi: 10.2337/dc13-0203. PMID: 24041678; PMCID:

PMC3816899

http://www.ncbi.nlm.nih.gov/pubmed/24296850


Desmond A Schatz MD

32

187. Butler K, Schatz D, Hathaway K: Workplace checkup: keeping patients with diabetes

employed and safe on the job. American Diabetes Association, Diabetes and Employment

(Position Statement) Clinical Diabetes 32 (1): 44-48, 2014.

188. Kaminski BM, Klingensmith GJ, Beck RW, Tamborlane WV, Lee J, Hassan K, Schatz

D, Kollman C, Redondo MJ: Pediatric Diabetes Consortium. Body mass index at the

Time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr 162 (4): 736-740,

2013. E1. Epub 2012 Oct 23. doi 10.1016/j.jpeds.2012.09.017. PMID: 23092524

189. Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo

MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood JR for The Pediatric Diabetes

Consortium JR: Race, Socioeconomic status, and treatment center are associated

with insulin pump therapy in youth in the first year following diagnosis of Type

1 diabetes. Diabetes Technol Ther 15 (11): 929-34, 2013. PMID: 23869706

190. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC,

Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet and the Diabetes Prevention

Trial–Type 1 Study Groups. The prediction of type 1 diabetes by multiple autoantibody levels

and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Diabetes Care 36 (9): 2615-2620, 2013. Epub 2013 Jul 1. doi: 10.2337/dc13-0425. PMID:

23818528; PMCID: PMC3747899

191. Greenbaum CJ, Schatz DA, Haller MJ, Sanda, S: Through the fog: recent clinical trials to

preserve -cell function in type 1 diabetes. Diabetes 61 (6): 1323-1330, 2012. doi:

10.2337/db11-1452. PMID:2261876; PMCID: PMC3357268

192. Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, Rowe P, Moraski

JM, Ball S, Jebson L, Schatz DA, Gianani R, Burke GW, Nierras C, Staeva T, Kaddis JS,

Campbell-Thompson M, Atkinson MA: The Juvenile Diabetes Research Foundation Network

for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and

emerging findings. Pediatr Diabetes 15 (1): 1-9, 2014. Epub 2013 Dec 10. PMID: 24325575;

PMCID: PMC4282794

193. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA,

Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer

JP, Skyler JS; and the Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-Lymphocyte

depletion with rituximab and beta-cell function: Two-year results. Diabetes Care 37 (2): 453-

459, 2014. Epub 2013 Sep 11. doi: 10.2337/dc13-0626. PMID: 24026563; PMCID:

PMC3898764

194. Blackman S, Raghinaru D, Adi S, Simmons J, Ebner-Lyon L, Chase P, Tamborlane W,

Schatz D, Block J, Litton J, Raman V, Foster N, Kollman C, DuBose S, Miller K, Beck R:

Insulin pump use in young children in the T1D Exchange clinic registry is associated with

lower hemoglobin A1c levels that injection therapy. Pediatr Diabetes 15 (8): 564-572, 2014.

PMID: 24494980






Desmond A Schatz MD

33

195. Ross IL, Dandara C, Swart M, Lacerda M, Schatz D, Blom DJ: 9β Polymorphism of the

Glucocorticoid Receptor Gene Appears to Have Limited Impact in Patients with Addison's

Disease. PLoS One. 2014 Jan 23. PMID: 24466047 PMCID: PMC3900528

196. Walker A, Rohrs H, Schatz D, Johnson C, Silverstein JH: Disparites in social support systems

for youth with type 1 diabetes. Clin Diabetes 33 (2): 62-69, 2015. Erratum in: Clin Diabetes

33 (3): 159. doi: 10.2337/diaclin.33.2.62. PMID: 25897185

197. Endesfelder D, Castell WZ, Ardissone A, Davis-Richardson AG, Achenbach P, Hagen M,

Pflueger M, Gano KA, Fagen JR, Drew JC, Brown CT, Kolaczkowski B, Atkinson M, Schatz

D, Bonifacio E, Triplett EW, Ziegler AG: Compromised gut microbiota networks in children

with anti-islet cell autoimmunity. Diabetes 63 (6): 2014. doi: 10.2337/db13-1676. PMID:

24608442

198. Krischer J, Schatz DA, Cuthbertson D, Qian X: Distribution of C-Peptide and its determinants

in North American children at risk for Type 1 Diabetes. Diabetes Care 37 (7): 1059-1065,

2014. PMID: 24760262 PMCID: PMC4067394

199. Baker PR, Pugliese A, Schatz DA, Ross I: HLA similarities indicate shared genetic risk in 21-

hydroxylase autoantibody positive South African and United States Addison’s Disease.

Tissue Antigens 84 (4): 361-369, 2014. Epub 2014 Jul 18. doi: 10.1111/tan.12407. PMID:

25040682

200. Nambam B, Hirsch IB, Danne T, Schatz D: Lowering targetes for hemoglobin A1C in

children with type 1 diabetes: raising the bar. Pediatr Diabetes 16 (1): 16-21, 2015. Epub

2014 Nov. 13. doi: 10.1111/pedi.12244. PMID:25394220

201. Nambam B, Winter W, Schatz D Type 1 Diabetes. Reference Module in Biomedical Sciences.

Elsevier. 27-Oct-14 doi: 10.1016/B978-0-12-801238-3.03820-4.

202. Davis-Richardson AG, Ardissone AN, Dias R, Simell V, Leonard MT, Kemppainen KA,

Drew JC, Schatz DA, Atkinson MA, Kolaczkowski B, Ilonen J, Knip M, Toppari J, Nurminen

N, Hyoty H, Veijola R, Simell T, Mykk J, Simell O, Triplett EW: Bacteroides dorei dominates

gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes.

Front Microbiol 10;5: 678, 2014. doi: 10.3389/fmicb.2014.00678. PMID: 25540641 PMCID:

PMC4264809

203. Törn C, Hadley D, Lee HS, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler A, Schatz

D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkänen J, Ilonen J, Rich SS,

She JX, Steck AK, Krischer J; the TEDDY study group: Role of Type 1 diabetes associated

SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes 64 (5): 1818-1829,

2014. Epub 2014 Nov 24. PMID: 25422107

204. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko

TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA: Anti-thymocyte

globulin/G-CSF treatment preserves β cell function in patients with established type 1




Desmond A Schatz MD

34

diabetes. J Clin Invest 125 (1): 448-455, 2015. Epub 2014 Dec 15. doi: 10.1172/JCI78492.

PMID: 25500887

205. Kemppainen KM, Ardissone AN, Davis-Richardson AG, Fagen JR, Gano KA, León-Novelo

LG, Vehik K, Casella G, Simell O, Ziegler AG, Rewers MJ, Lernmark Å, Hagopian W, She

JX, Krischer JP, Akolkar B, Schatz DA, Atkinson MA, Triplett EW; TEDDY Study Group:

Early childhood gut microbiomes show strong geographic differences among subjects at high

risk for type 1 diabetes. Diabetes Care 38 (2): 329-332, 2015. Epub 2014 Dec 17. doi:

10.2337/dc14-0850. PMID: 25519450; PMCID: PMC4302256

206. Walker AF, Schatz DA, Johnson C, Silverstein JH, Rohrs HJ: Disparities in social support

systems for youths with type 1 diabetes. Clin Diabetes 33 (2): 62-69, 2015. doi:

10.2337/diaclin.33.2.62. PMID: 25897185; PMCID: PMC4398009

207. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, Rewers MJ, She

JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E; TEDDY Study Group: The

6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the

TEDDY study. Diabetologia 58 (5): 980-987, 2015. Epub 2015 Feb 10. doi: 10.1007/s00125-

015-3514-y. PMID: 25660258; PMCID: PMC4393776

208. Walker AF, Johnson C, Schatz DA, Silverstein JH, Lyles S, Rohrs HJ: Using photography as a

method to explore adolescent challenges and resilience in type 1 diabetes. Diabetes Spectrum

28 (2): 92-98, 2015. doi: 10.2337/diaspect.28.2.92. PMID: 25987807

209. Clements MA, Foster NC, Maahs DM, Schatz DA, Olson BA, Tsalikian E, Lee JM, Burt-

Solorzano CM, Tamborlane WV, Chen V, Miller KM, Beck RW; T1D exchange clinic

network: Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult

participants in the T1D exchange clinic registry. Pediatr Diabetes 17 (5): 327-336, 2016.

Epub 2015 Jul 8. doi: 10.1111/pedi.12295. PMID: 26153338

210. Walker AF, Schatz DA, Johnson C, Silverstein JH, Rohrs HJ: Erratum: Disparities in social

support for youths with type 1 diabetes. Clin Diabetes 33 (3): 159, 2015. doi:

10.2337/diaclin.33.3.159. PMID: 26202839

211. Xue S, Posgai A, Wasserfall C, Myhr C, Campbell-Thompson M, Mathews CE, Brusko T,

Rabinovitch A, Savinov A, Battaglia M, Schatz D, Haller M, Atkinson M: Combinations

therapy reverses hyperglycemia in NOD mice with established type 1 diabetes. Diabetes 64

(11): 3873-3884, 2015. Epub 2015 Jul 16. PMID: 26185279

212. Mathews CE, Xue S, Posgai A, Lightfoot YL, Li X, Wasserfall C, Haller MJ, Schatz D,

Atkinson MA: Acute versus progressive onset of diabetes in NOD mice. Potential

implications for therapeutic interventions in type 1 diabetes. Diabetes 64 (11): 3885-3890,

2015. Epub 2015 Jul 27. PMID: 26216853




Desmond A Schatz MD

35

213. Campbell-Thompson ML, Kaddis JS, Wasserfall C, Haller MJ, Pugliese A, Schatz DA,

Shuster JJ, Atkinson MA. The influence of type 1 diabetes on pancreatic weight.

Diabetologia 59 (1): 217-221, 2015. PMID: 26358584

214. Meehan C, Fout B, Ashcraft J, Schatz DA, Haller MJ: Screening for T1D risk to reduce DKA

is not economically viable. Pediatr Diabetes 16 (8): 565-572, 2015. Epub 2015 Sep 22. doi:

10.1111/pedi.12313. PMID: 26392298

215. Wherrett DK, Chiang JL, Delmater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold

KC, Lovell Dj, Orhcard TJ, Ryan CM, Schatz DA, Greenbaum CJ, Type 1 Diabetes TrialNet

Study Group. Defining pathways for development of disease-modifying therapies in children

with type 1 diabetes: A consensus report. Diabetes Care 38 (10): 1975-1985, 2015. doi:

10.2337/dc15-1429. PMID:26404927

216. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ,

Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS,

Sosenko JM, Ziegler A: Staging presymptomatic type 1 diabetes. Diabetes Care 38 (10):

1964-1974, 2015. doi: 10.2337/dc15-1419. PMID: 26404926

217. Maahs D, Hermann JH, Holman N, Foster N, Kapellen T, Allgrove J, Schatz D, Hofer S,

Campbell F, Steigler-Schweiger C, Beck R, Warner J, Holl R: The rates of diabetic

ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes

from England, Wales, the United States of America, Austria and Germany. Diabetes Care 38

(10): 1876-1882, 2015. Epub 2015 Aug 17. doi: 10.2337/dc15-0780. PMID: 26283737

218. Campbell-Thompson, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, Atkinson A:

Insulitis and B-Cell mass in the natural history of Type 1 diabetes. Diabetes 65 (3): 719-

731, 2016. Epub 2015 Nov 18. PMID: 26581594

219. Wood JR, Connor CG, Cheng P, Ruedy K, Tamborlane W, Klingensmith G, Schatz D,

Cengiz E, Willi S, Bacha F, Beck R for the Pediatric Diabetes Consortium: Vitamin D

status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes

Consortium (PDC) is not worse than in youth without diabetes. Pediatric Diabetes 17 (8):

584-591, 2016. Epub 2015 Nov 26. doi: 10.1111/pedi.12340. PMID: 26611890

220. Fox LA, Mubasher M, Wolfsdorf JI, Buckingham BA, Peters AL, Tamborlane WV, Schatz

DA, Maahs DM, Miller KM, Beck RW; T1D Exchange Clinic Network: Characteristics of

youth with type 1 diabetes and without a parent with type 1 diabetes in the T1D exchange

clinic registery. J Diabetes 8 (6): 834-838, 2016. Epub 2016 Feb 24. doi: 10.1111/1753-

0407. PMID: 26663683

221. Haller MJ, Atkinson MA, Wasserfall CH, Brusko TM, Mathews CE, Hulme M, Cintron M,

Shuster J, McGrail K, Posgai A, Schatz D: Mobilization without immune depletion fails to

restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.

Clin Exp Immunol 183 (3): 350-7, 2016. Epub 2015 Dec 7. doi: 10.1111/cei.12731. PMID:

26462724

Desmond A Schatz MD

36

222. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky

A, Rubertsson S, Nellgard B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall

CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Humbert A, Maoz M,

Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro

AM, Glaser B, Shemer R, Dor Y: Identification of tissue-specific cell death using

methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 113(13): E1826-1834,

2016. Epub 2016 Mar 14. doi: 10.1073/pnas.1519286113. PMID: 26976580

223. Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L,

Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS,

Sosenko JM, and the Type 1 Diabetes TrialNet Study Group: The HLA-DRB1*15:01-

DQA1*01:02-DQB1*06:02 haplotype protects autoantibody-positive relatives from type 1

diabetes throughout the stages of disease progression. Diabetes 65 (4): 1109-1119, 2016.

Epub 2016 Jan 28. doi: 10.2337/db15-1105. PMID: 26822082

224. Endesfelder D, Engel M, Davis-Richardson A, Ardissone A, Achenbach P, Hummel S,

Winkler C, Atkinson M, Schatz D, Triplett E, Ziegler AG, Castell W: Towards a functional

hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial

communities and butyrate production. Microbiome 26 (4): 17, 2016. doi: 10.1186/s40168-

016-0163-4. PMID: 27114075

225. Walker A, Schatz D, Johnson C, Silverstein J, Lyles S, Rohrs H: Type 1 diabetes through two

lenses: comparing adolescent and parental perspectives with photovoice. Int J Pediatr

Endocrinol 2016: 2, 2016. Epub 2016 Jan 20. doi: 10.1186/s13633-016-0020-z. PMID:

26793242

226. Albanese-O’Neill A, Schatz DA, Bernhardt J, Elder JH: Educational needs and

technological preferences of fathers of youth with type 1 diabetes. Diabetes Educ. 42 (2):

209-19, 2016. Epub 2016 Feb 5. doi: 10.1177/0145721716628649. PMID: 26850045

227. Atkinson MA, Campbell-Thompson M, Schatz DA, Kaddis J: Pancreatic ductal

hyperplasia/dysplasia with obstructive chronic pancreatitis: An association with reduced

pancreatic weight in type 1 diabetes. Diabetologia 59 (4): 870-872, 2016. Epub 2016 Feb

9. doi: 10.1007/s00125-016-3889-4. PMID: 26861059

228. Sherr JL, Ruedy KJ, Foster NC, Piche CA, Dulude H, Iickels MR, Tamborlane WV, Bethin

KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM,

Rampakakis E, Meng L, Beck RW for the T1D Exchange Intranasal Glucagon

Investigators: Glucagon nasal powder: a promising alternative to intramuscular glucagon in

youth with type 1 diabetes. Diabetes Care 9 (4): 555-562, 2016. Epub 2016 Feb 16. doi:

10.2337/dc15-1606. PMID: 26884472

229. Endesfelder D, Engel M, Davis-Richardson AG, Ardissone AN, Achenbach P, Hummel S,

Winkler C, Atkinson M, Schatz E, Triplett E, Ziegler Ag, zu Castell W: Towards a functional

hypothesis relating anti-isle tcell autoimmunity to the dietary impact on microbial

Desmond A Schatz MD

37

communities and butyrate production. Microbiome 26 (4): 17, 2016. doi: 10.1186/s40168-

016-0163-4. PMID: 27114075

230. Wasserfall C, Montgomery E, Liping Y, Michels AW, Gianani R, Pugliese A, Nierras C,

Kaddis J, Schatz D, Bonifacio E, Atkinson M: Validation of a Rapid Type 1 Diabetes

Autoantibody Screening Assay for Community Based Screening of Organ Donors to Identify

Subjects at Increased Risk for the Disease. Clin Exp Immunol 185 (1): 33-41, 2016. Epub

2016 May 4. doi: 10.1111/cei.12797. PMID:27029857

231. Vehik K, Lynch KF, Schatz DA, Akolkar B, Hagopian W, Rewers M, She JX, Simell O,

Toppari J, Ziegler AG, Lernmark A, Bonifacio E, Krischer JP: TEDDY study group.

Reversion of B-Cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes

Care. 39 (9): 1535-1542, 2016. Epub 2016 Jun 16. PMID: 27311490

232. Torn C, Liu X, Hagopian W, Lernmark A, Simell O, Rewers M. Ziegler AG, Schatz D,

Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkanen J, Ilonen J, Rich SS, She

JX, Sharma A, Steck A, Krischer J; TEDDY Study Group: Complement gene variants in

relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY

Study. Sci Rep 6: 27887, 2016. PMID: 27306948

233. Jacobsen LM, Atkinson MA, Campbell-Thompson M, Schatz DA. Presumptive type 1

diabetes with comorbidities and rapid progression despite numerous insulin-positive islets.


234. Jacobsen L, Schatz D. Current and future efforts toward the prevention of type 1 diabetes.

Pediatric Diabetes 17 Suppl (22): 78-86, 2016. PMID: 27411441

235. Haller MJ, Schatz DA. The DIPP project: 20 years of discovery in type 1 diabetes.

Pediatr Diabetes 17 Suppl (22): 5-7, 2016. doi: 10.1111/pedi.12398. PMID: 27411430

236. Schatz D, Cefalu WT. Reevaluation of CMS’ competitive bidding program. Diabetes Care

39 (7):1078-1079, 2016. PMID: 27330123

237. Jacobsen LM, Posgai AL, Campbell-Thompson M, Schatz DA: Diagnostic dilemma: clinical

and histological abnormalities in a Hispanic patient with diabetes. Diabetes Care 39(9), 2016.

PMID: 27555624

238. Bain, X, Wasserfall C, Wallstrom G, Wang J, Wang H Barker K, Schatz D, Atkinson M, Qiu

J, LaBaer, J: Tracking the antibody immunome in type 1 diabetes using protein arrays. J

Proteome Research 2016 Oct 3. PMID: 26450993

239. Schatz D. 2016 Presidential Address: “Diabetes at 212°- Confronting the invisible disease.”

Diabetes Care 39 (10):1657-1663, 2016. PMID: 27660119

240. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA,

Shuster JJ, Zou B, Wasserfall CH, Posgai A, Mathews CE, Brusko TM, Atkinson MA, Schatz

Desmond A Schatz MD

38

DA: Anti-Thymocyte Globulin + G-CSF combination therapy leads to sustained

immunomodulatory and metabolic effects in a subset of responders with established type 1

diabetes. Diabetes 65 (12): 3765-3775, 2016. PMID: 27669730

241. Philips T, Kusmartseva Ir, Gerling I, Campbell-Thompson M, Wasserfall C, Pugliese A,

Longmate JA, Schatz DA, Atkinson MA, Kaddis JS: Factors that influence the quality of

RNA from the pancreas of organ donors. Pancreas 46 (2): 252-259, 2017. doi:

10.1097/MPA.0000000000000717. PMID: 27984510

242. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop Per-Henrik,

Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA,

Sosenko JM, Wilding JPH, Ratner RE: Differentiation of diabetes by pathophysiology,

natural History and prognosis. Diabetes 66 (2): 241-255, 2017. doi: 10.2337/db16-0806.

PMID: 27980006

243. Albanese-O’Neill A, Wu M, Miller K, Jacobsen L, Haller MJ, Schatz D for the T1D Exchange

Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes

Care 40 (4): e38-e39, 2017. Epub 2017 Jan 18. doi: 10.2337/dc16-2620. PMID: 28100607

244. Campbell-Thompson M, Posgai AL, Schatz DA, Haller MJ, McGrail KM, Brusko TM,

Wasserfall C, Schultz AR, Xia LI, Shuster JJ, Muir AB: Serum Trypsinogen levels in type 1

diabetes. Diabetes Care 40 (4): 577-582, 2017. Epub 2017 Jan 23. doi: 10.2337/dc16-1774.

PMID: 28115475

245. Posgai A, Atkinson MA, Schatz D, Wasserfall C: Plant-based vaccines for oral delivery of

type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease

prevention in NOD mice. Sci Rep 7: 42372, 2017. doi: 0.1038/srep42372.

PMID: 28205558

246. Nambam B, Bratina N, Schatz D: Immune Interventions for Type 1 Diabetes Mellitus.

Diabetes Technol Ther 19 (S1): S74-S81, 2017. doi: 10.1089/dia.2017.2507. PMID: 28192018

247. Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen

LM, Schatz DA, Lernmark A: Type 1 diabetes mellitus-a Primer. Nat Rev Dis Primers Mar 3:

17016, 2017. doi: 10.1038/nrdp.2017.16. PMID: 28358037

248. Walker A, Schatz DA, Johnson C, Salazar KR, Rohrs H: Socioeconomic status and the

domestic allocation of type 1 diabetes care. PLAID doi: 10.17125/plaid.2017.97.

249. Jacobsen LM, Haller MJ, Parish A, Gurka MJ, Levine R, Wasserfall C, Campbell-Thompson

M, Kaddis J, Pugliee A, Atkinson MA, Schatz DA: High Illicit Drug Abuse and Suicide in

Organ Donors With Type 1 Diabetes. Diabetes Care 40 (9): e122-e123, 2017. Epub 2017 Jul

5. doi: 10.2337/dc17-0996. PMID: 28679687

250. Beyerein A, Uusitalo UM, Virtanen SM, Vehik K, Yang J, Winkler C, Kersting M,

KoletzkoS, Schatz D, Aronsson CA, Larsson HE, Krisher JP, Ziegler AG, Norris JM, Hummel

https://www.ncbi.nlm.nih.gov/pubmed/27669730



Desmond A Schatz MD

39

S, for the TEDDY Study Group: Intake of energy and protein is associated with overweight

risk at age 5.5 years: Results from the prospective TEDDY study. Obesity (Silver Spring) 25

(8): 1435-1441, 2017. Epub 2017 Jun. doi: 10.1002/oby.21897. PMID: 28650578

251. Sanyoura M, Jacobsen L, Carmody D, Gaudio DD, Alkorta-Aranburu G, Arndt K, Hu YY,

Kobiernicki F, Kusmartseva I, Atkinson MA, Philipson LH, Schatz D, Campbell-Thompson

M, Greeley SAW: Pancreatic histopathology of human monogenic diabetes due to causal

variants in KCNJ11, HNF1A, GATA6, and LMNAJ Clin Endocrinol Metab 102 (1): 35-45,

2018. doi: 10.1210/jc.2017-01159. PMID: 28938416

252. Walker AF, Schatz DA, Johnson C, Rohrs HJ, Salazar KR: Socioeconomic status and the

domestic allocation of type 1 diabetes care. The Plaid Journal 3 (1): Spring 2017.

253. Johnson SB, Lynch KF, Roth R, Schatz D and the TEDDY study group: My child is islet

autoantibody positive: Impact on parental anxiety. Diabetes Care 40 (9): 1167-1172, 2017.

https://doi.org/10.2337/dc17-0166. PMID: 28663383

254. Kusmartseva I, Beery M, Philips T, Selman S, Jadhav P, Wasserfall C, Muller A, Pugliese A,

Longmate JA, Schatz D, Atkinson MA, Kaddis JS: Hospital time prior to death and pancreas

histopathology: implications for future studies. Diabetologia 61 (4): 954-958, 2018. Epub

2017 Nov 11. doi: 10.1007/s00125-017-4494-x. PMID: 29128936

255. Kemppainen KM, Vehik K, Lynch KF, Larsson HE, Canepa RJ, Simell V, Koletzko S, Liu E,

Simell OG, Toppari J, Ziegler AG, Rewers MJ, Lernmark Å, Hagopian WA, She JX, Akolkar

B, Schatz DA, Atkinson MA, Blaser MJ, Krischer JP, Hyöty H, Agardh D, Triplett EW;

Environmental Determinants of Diabetes in the Young (TEDDY) Study Group: Association

between early-life antibiotic use and the risk of islet or celiac disease autoimmunity. JAMA

Pediatr 2017 Oct 9. doi: 10.1001/jamapediatrics. 2017.2905. PMID: 29052687

256. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP,

Schatz DA, Bundy B, Skyler JS, Greenbaum CJ.: Effect of oral insulin on prevention of

diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318

(19): 1891-1902, 2017. doi: 10.1001/jama.2017.17070. PMID: 29164254

257. Nambam B, Schatz DA: The Growth Hormone and Insulin-like Growth Factor-1 Axis in Type

1 Diabetes Reference. Growth Horm IGF Res 38: 49-52, 2018. Epub 2017 Dec 13. doi:

10.1016/j.ghir.2017.12.005. PMID: 29249623

258. Jacobsen LM, Haller M, Schatz DA: Understanding pre-type 1 diabetes: The key to

prevention. Front Endocrinol 9: 70, 2018. PMID: 29559955

259. Perry D, Wasserfall C, Oram R, Williams M, Posgai A, Muir A, Haller MJ, Schatz DA,

Wallet MA, Mathews CE, Atkinson MA, Brusko TM. Application of a genetic risk score to

racially diverse type 1 diabetes populations demonstrates the need for diversity in risk-

modeling. Sci Rep 8 (1): 4529, 2018. doi: 10.1038/s41598-018-22574-5. PMID: 29540798

https://doi.org/10.2337/dc17-0166

Desmond A Schatz MD

40

260. Nambam B, Bratina N, Schatz D: Immune intervention for type 1 diabetes.

Diabetes Technol Ther 20 (S1): S86-S93, 2018. doi: 10.1089/dia.2018.2507. PMID: 29437480

261. Albanese-O’Neill A, Beauchamp G, Thomas N, Westen S, Johnson N,

Schatz D, Haller MJ: Transisiton education for young adults with type 1 diabetes:

Feasibility of a group telehealth intervention. JMIR Diabetes. 2018 Oct-Dec; 3(4): e10909.

Epub 2018 Nov 5. doi: 10.2196/10909 PMCID: PMC6246967 PMID: 30401674

262. Walker AF, Hall JM, Shenkman EA, Gurka MJ, Morris HL, Haller MJ, Rohrs HJ,

Salazar KR, Schatz DA: Geographic access to endocrinologists for Florida’s publicly

insured children with diabtes. Am J Manag Care 24 (4 Spec No.): SP106-

SP109, 2018. PMID: 29689143

263. Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC,

Atkinson MA. Strength in numbers: opportunities for enhancing the development of

effective treatments for type 1 diabetes-The TrialNet experience. Diabetes 67 (7): 1216-1225,

2018. Epub 2018 May 16. doi:10.2337/db18-0065. PMID: 29769238

264. Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P,

Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group:

A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and

development of type 1 diabetes in individuals at risk. Diabetes Care 41 (9): 1887-1894, 2018.

Epub 2018 Jul 12. doi: 10.2337/dc18-0087. PMID: 30002199

265. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA,

Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC,

Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ: Type 1

diabetes TrialNet ATG-GCSF Study Group. Low-dose Anti-Thymocyte Globulin

(ATG) preserves β-cell function and improves HbA1c in new-onset type 1 diabetes. Diabetes

Care 41 (9): 1917-1925, 2018. Epub 2018 Jul 16. doi: 10.2337/dc18-0494. PMID: 30012675

266. Westen S, Haller MJ, Albanes-O’Neill, Warnick JL, Entessari M, Janicke D, Schatz D:

Objectively-measured adherence in adolescents with type 1 diabetes on multiple daily

injections and insulin pump therapy. J Pediatr Psychol 44 (1): 21-31, 2019. doi:

10.1093/jpepsy/jsy064. PMID: 30184209

267. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf DI,

Schatz D. Type 1 Diabetes in Children and Adolescents: A Position Statement

by the American Diabetes Association Diabetes Care 41 (9): 2026-2044, 2018. Epub 2018

Aug 9. doi: 10.2337/dci18-0023. PMID: 30093549

268. Endesfelder D, Engel M, Davis-Richardson AG, Ardissone AN, Achenbach P, Hummel S,

Winkler C, Atkinson M, Schatz D, Triplett E, Ziegler AG, Castel W: Towards a functional

hypothesis relatinganti-islet cell autoimmunity to the dietaryimpact on microbial communities

andbutyrate production. Endesfelder et al. Microbiome 4:17, 2016.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246967/

https://dx.doi.org/10.2196%2F10909


Desmond A Schatz MD

41

269. Rewers M, Hyty H, Lernmark A, Hagopian W, She J, Schatz D, Ziegler AG, Toppari J,

Akolkar B, Krischer J, the TEDDY study group: The environmental determinants of diabetes

in the young (TEDDY) study: 2018 update. Curr Diab Rep 18 (12): 136, 2018. doi:

10.1007/s11892-018-1113-2. PMID: 30353256

270. Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH,

Gurka MJ, Atkinson MA, Schatz DA, Haller MJ: Relative pancreas volume is reduced in first-

degree relatives of patients with type 1 diabetes. Diabetes Care 42 (2): 281-287, 2019. Epub

2018 Dec 14. doi: 10.2337/dc18-1512. PMID: 30552130

271. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexandar CM, Battelino T,

Ampudia-Blasco J, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E,

Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin

CG, Pieber TR, Robard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M:

International consensus on risk management of diabetic ketoacidosis in patients with type 1

diabetes treated with sodium-glucose contransporter (SGLT) inhibitors. Diabetes Care 2019

Feb 6. doi: 10.2337/dc18-2316. [Epub ahead of print]. PMID: 30728224

272. Nambam B, Bratina N, Schatz D. Immune intervention in type 1 diabetes. Diabetes Technol

Ther 21 (S1): S95-S100, 2019. doi: 10.1089/dia.2019.2507. PMID: 30785317

273. Schatz D: Prevention of T1D: Where Are We in 2019? Diabetes Mellitus and Glucose

Metabolism. 2019 (in press).

274. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer

SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman

SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE,

Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group: Low-dose

Anti-Thymocyte Globulin Preserves C-Peptide and Reduces A1c in New Onset Type 1

Diabetes: Two Year Clinical Trial Data. Diabetes. 2019 Apr 9. doi: 10.2337/db19-0057.

[Epub ahead of print]. PMID: 30967424

Books, Chapters, and Symposia Proceedings

1. Schatz DA, Maclaren NK, Lippe BM: Autoimmunity in Turner Syndrome. In: Rosenfeld R,

Grumbach M (eds): Turner Syndrome. New York: Marcel Dekker Inc, 205-220, 1989.

2. Riley WJ, Hitchcock CL, Schatz DA: Lymphocyte subsets in pre diabetes. In: Cammarini

Davalos A, Cole HS (eds): Advances in Experimental Medicine and Biology: Prediabetes.

New York and London: Plenum Press, 109-114, 1989. PMID: 3074645

3. Maclaren NK, Riley WJ, Silverstein JS, Schatz DA, Atkinson MA: Progress towards the

prevention of insulin dependent diabetes. In: Andreani D, Kolb H, Pozzili P (eds):

Immunotherapy of type I diabetes. Chichester: Wiley & Sons Ltd, 147-155, 1989.

Desmond A Schatz MD

42

4. Riley WJ, Maclaren NK, Spillar RP, Schatz DA, Krischer J, Silverstein JH, Schwartz S,

Malone J, Rotter JI: The use of islet cell autoantibodies in identifying prediabetes. In:

Proceedings of the 13th International Diabetes Foundation Congress. Sydney, Australia.

Excerpta Medical International Congress Series. Netherlands: Elsevier Science Publications,

263-267, 1989.

5. Schatz DA, Winter WE, Maclaren NK: Immunology of insulin dependent diabetes mellitus.

In: Volpe JJ (ed): Immunology of Endocrine Disease. Florida: CRC Press, 241-296, 1990.

6. Riley WJ, Maclaren NK, Schatz DA: Comparison of islet autoantibodies in pre diabetes and

recommendations for screening. In: Proceedings of the IXth International Workshop on the

Immunology of Diabetes. Melbourne, Australia. J Autoimmunity 51-67, 1990. PMID:2187460

7. Barrett DJ, Schatz DA, Sleasman JW: Immunoregulatory CD4+ T cell subpopulations:

Enumeration, activation and functional analyses in normals and autoimmune disease. In: Bercu

B, Pomerance H (eds): Topics in Pediatrics. New York: Springer Verlag, 83-95, 1990.

8. Silverstein JH, Maclaren NK, Riley WJ, Schatz DA, Krischer J: Relatives at risk; strategies for

intervention. In: Diabetes 1991. Proceedings of the 14th International Diabetes Federation

Congress. Washington DC. Excerpta Medica. Elsevier Scientific Publishers. Amsterdam,

Netherlands; 1317-1320, 1991.

9. Muir A, Schatz DA, Maclaren NK: Addison's Disease. In: Bach J-F (ed) Seminars in

Immunopathology: Immune Endocrinology 14: 275-284, 1992. PMID: 8438210

10. Muir A, Schatz DA, Maclaren NK: Pathogenesis, prediction and prevention of Type 1

Diabetes. In: Karam JH (ed) Endocrinology and Metabolism Clinics of North America. W.B.

Sanders. Philadelphia, PA, 199-219, 1992. PMID: 1612064

11. Maclaren N, Muir A, Silverstein J, Song Y-H, She J-X, Krischer J, Atkinson M, Schatz D:

Early diagnosis and treatment of insulin dependent diabetes mellitus. In: Allison AC, Lafferty

KJ, Fliri H (eds): Proceedings of the New York Academy of Sciences. 696: 343-350, 1993.

12. Muir A, Schatz DA, Maclaren NK: Polyglandular Failure Syndromes. In: DeGroot L (ed):

Endocrinology 3rd ed WB Saunders, Philadelphia, PA: 3013-3024, 1994.

13. Schatz DA: Hypoglycemia in childhood diabetes. In: Rosenbloom AL (ed). Pediatric Annals

289-291, 1994. PMID: 8078705

14. Rosenbloom AL, Schatz DA: Diabetic ketoacidosis in childhood. In: Rosenbloom AL (ed):

Pediatric Annals 284-288, 1994. PMID: 8078704

15. Winter WE, House DV, Schatz DA: Hyperlipidemia in the pediatric patient: testing, evaluation

and therapy. Current Opinion in Pediatrics 16: 96-105, 1999.

Desmond A Schatz MD

43

16. Schatz DA: Prevention of Type 1 Diabetes. In: Medscape: Conference Summaries of the 59th

Annual Scientific Sessions of the ADA; June 22, 1999; San Diego, CA. Available at:

http://www.medscape.com/Medscape/CNO/1999/ADA/Story.cfm?story_id=751

17. Julius M, Schatz DA, Silverstein JH: Prevention of Type 1 Diabetes. In: Pediatric Annals 28,

585-588, 1999. PMID: 10496000

18. Schatz DA, Winter WE: Future diabetes prevention trials: from bench to bedside. In:

Medscape: Conference Summaries of the 60th Annual Scientific Sessions of the ADA; June

12, 2000; San Antonio, TX. Available at:


19. Schatz DA, Winter WE: Differentiating slowly developing type 1 from true type 2. 2000.

Available at: http://www.medscape.com/viewarticle/412406

20. Schatz DA, Winter WE: Strategies for the early detection and prevention of IDDM. In: Meet

the Professor Symposia, 2000 Endocrine Society Meeting.

21. Schatz DA, Winter WE: Diagnosis and treatment of possible maturity onset diabetes of youth.

2001. Available at: http://www.medscape.com/viewarticle/412378

22. Chaudhari M, Schatz DA: Management of diabetes mellitus in children and adolescents. In:

Rakel Re, Bope ET (eds) Conn's Textbook of Therapy. W.B. Sanders Philadelphia, PA: 580-

586, 2001.

23. Morales A, She J-X, Schatz DA: Prediction and prevention of Type 1 diabetes. Current

Diabetes Reports 1: 28-32, 2001. PMID: 12762954

24. Winter, W.E., Schatz, D.A.: Pediatric Lipid Disorders in Clinical Practice. emedicine,2001,

Available at: http://www.emedicine.com/ped/topic2787.html

25. Schatz DA, Winter WE: Autoimmune Polyglandular Syndromes. Pediatric Endocrinology. Ed:

Mark Sperling. W.B. Sanders Philadelphia, PA 671-688, 2002.

26. Schatz DA, Winter WE: Autoimmune Polyglandular Syndrome II: Clinical Syndrome and

Therapy. Endocrinol Metab Clin North Am. 31: 339-52, 2002. PMID:12092454

27. Winter WE, Schatz DA: Characteristics of atypical diabetes mellitus. 2002. Available at:

http://www.medscape.com/viewarticle/412403

28. Petrovsky N, Schatz DA: Immunology of insulin-dependent diabetes mellitus. In: Textbook of

Diabetes. Williams G, Pickup J (eds). Blackpoole Scientific Press, Liverpool, England Ch 18,

18.1-14, 2002.

29. Schatz DA, Silverstein JH: Will Vitamin D Supplementation to reverse the rising incidence of

type 1 diabetes? Editorial. AAP Newletter, 2002



http://www.emedicine.com/ped/topic2787.html

Desmond A Schatz MD

44

30. Schatz DA, Winter WE: What have been the outcomes from type 1 diabetes prevention trials?

Medscape Diabetes & Endocrinology, 2003. Available at:

medscape.com/viewarticle/436017?srcmp=endo-062102

31. Winter WE, Schatz DA: Role of the oral glucose tolerance test (OGTT) in the diagnosis and

management of diabetes mellitus. Medscape Diabetes & Endocrinology 5(1), 2003. Available

at: http://www.medscape.com/viewarticle/448038

32. Winter WE, Schatz DA: Performing an oral glucose tolerance test in a pregnant woman with

severe emesis. Medscape Diabetes & Endocrinology 5(1), 2003. Available at:


33. Winter WE, Schatz DA: Glucose dose in oral glucose tolerance testing of obese patients.

Medscape Diabetes & Endocrinology 5(1), 2003. Available at:


34. Schatz DA: Type 2 diabetes: a growing epidemic in children. Infectious Diseases in Children

Infectious Disease News. Slack Inc., April, 2003.

35. Haller, MJ, Schatz DA: Strategies for the prediction of Type 1 diabetes. Clinical Laboratory

International 27: 8-10, 2003.

36. Schatz D, Winter W: Distinguishing between type1, type 2, and other forms of diabetes in

childhood and adolescence. CADRE Current Diabetes Practice 2, 6-7, 2003.

37. Daaboul J, Schatz DA: Overview of prevention and intervention trials for type 1 diabetes.

Reviews in Endocrine and Metabolic Disorders. Le Roith D, Pietropaolo M (eds) Kluwer

Academic Publishers 4: 317-323, 2003.

38. Schatz DA: Benefits of Type1 diabetes screening. Advances for Medical Laboratory

Professionals 15: 13, 2003.

39. Schatz DA, Winter WE: Status of neonatal risk assessment for type 1 diabetes? Available at:

Medscape Diabetes & Endocrinology 2003 http://www.medscape.com/viewarticle/463393

40. Morales A, She J-X, Schatz DA: Genetics of Type 1 diabetes. Pediatric Endocrinology:

Mechanisms, Manifestations, and Management. Ed: Pescovitz OH & Eugster E.

41. Lippincott, Williams and Wilkins, Philadelphia, PA, Ch 27, 402-410, 2004.

42. Miller J, Winter WE, Schatz DA: Type 1 Diabetes. Encyclopedia of Endocrine Diseases.

Academic Press; 2004.

43. Schatz DA: Treatment plans for adolescent type 2 diabetes. CADRE Current Diabetes Practice

4, 3-4, 2005.



Desmond A Schatz MD

45

44. Haller MJ, Schatz DA: Diabetes screening in children: when and how. Consultant 44: 1609-

1610, 2004.

45. Haller MJ, Schatz DA: How to manage insulin resistance in children. Consultant 45: 600-610,

2005.

46. Haller MJ, Schatz DA: Screening for susceptibility to Type 1 diabetes mellitus. Trends in

Diabetes Research (ed) Ashley Ford. Nova Biomedical Books, NY, NY 71-100, 2005.

47. Haller MJ, Atkinson MA, Schatz DA: Type 1 diabetes in children and adolescents. Pediatr

Clin North America (ed) Mark Sperling, 52:1553-1178, 2005.

48. Caicedo RA, Li N, Atkinson MA, Schatz DA, Neu J: Neonatal nutritional interventions in the

prevention of Type 1 diabetes. NeoReviews 2005; 6; e220-e226. DOI: 10.1542/neo.6-5-e220

49. Petrovsky N, Winter W, Schatz DA: Genetics and Immunology of Type 1 Diabetes. Clinical

Diabetes. Ed Fonseca V. Elsevier, 6-20, 2006.

50. Winter WE, Schatz DA: Case Study. Insulin. Ed Edelman SV, LeRoith D 2: 192-193, 2007.

51. Haller MJ, Gottlieb PA, Schatz DA: Intervention trials 2007: where are we and where are we

going? Curr Opin Endocrinol Diabetes Obes 14: 283-7, 2007. PMID:17940453

52. Winter WE, Schatz DA: Case Report. Insulin LeRoith D, Edelman SV (eds) 2: 192-193, 2007.

53. Rohrs HJ, Schatz DA, Haller MJ: Current trials in type 1 diabetes prevention and early

intervention: implications for PCPs. Review of Endocrinology 26: 26-29 2007.

54. Schatz DA: Diabetes tactics. Insulin LeRoith D, Edelman SV (eds) 3: 114-115193, 2007.

55. Haller MJ, Winter WE, Schatz DA: Autoimmune Polyglandular Syndromes. Pediatric

Endocrinology (ed) Mark Sperling. W.B. Sanders Philadelphia, PA 770-787, 2008.

56. Rohrs HJ, Schatz DA, Winter WE, Davis V: Ped Pediatric lipid disorders in clinical practice.

eMedicine. http://www.emedicine.com/ped/topic2787.htm 2008

57. Stalvey MS, Schatz DA: Childhood diabetes explosion. “Controversies in treating diabetes:

clinical & research aspects (Eds) LeRoith D, Vinik A. Humana Press 179-200, 2008.

58. Rohrs HJ, Schatz DA: Conflicting recommendations for lipid screening and management in

children: the need for consensus. Pediatric Consultant 7: 350-352, 2008.

59. Sanjeevi CB, Schatz DA, Atkinson MA: Immunology of Diabetes V. From Bench to Bedside.

(eds) Annals of the New York Academy of Sciences. Vol 1150, 2009.

http://www.emedicine.com/ped/topic2787.htm%202008

Desmond A Schatz MD

46

60. Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, Campbell-

Thompson M, Schatz DA, Atkinson MA, Haller MJ: Exendin-4 therapy in new onset NOD

mice increases regulatory T cell frequency. Ann NY Acad Sci 1150:152-158, 2008.

PMID:19120286

61. TEDDY Study Group: The environmental determinants of diabetes in the young (TEDDY)

Study. Immunology of Diabetes V: Ann NY Acad Sci 1150:1-13, 2008.

62. Rohrs HJ, Schatz DA: Interpretation of the oral glucose tolerance test. Diabetes Self-

Management 26: 5, 2009.

63. Winter WE, Schatz DA: Clinical management of diabetes mellitus: What laboratorians need to

know about how diabetes is treated. AACC 2009.

64. Rohrs HJ, Schatz D, Winter WE, Davis V: Pediatric Lipid disorders in clinical practice.

eMedicine. Updated June 15, 2009. http://emedicine.medscape.com/article/901837-overview

65. Winter WE., Schatz DA., Bertholf RL: The thyroid gland. Tietz Texbook of Clinical Chemistry

and Molecular Diagnostics, 5th Edition, C Burtis, E Ashwood, D Bruns (eds), Elsevier

Saunders, St. Louis, MO, 806-823, 2012.

66. Winter WE., Schatz D.: Laboratory support for diabetes testing certificate program; found at

http://aacc.org/events/online_progs/certificates/diabetes/pages/default.aspx. AACC Diabetes

certificate program (2009)

67. Rohrs H., Schatz D., Winter W., Davis V.: Pediatric lipid disorder in clinical practice. Apr 23,

2008; http://www.emedicine.com/ped/TOPIC2787.HTM.

68. Winter W., Schatz D. Autoimmune markers in diabetes. Clincal Chemistry 57 (2): 168-75,

2011. PMID:21127152

69. Schatz DA: Tracking obesity (Ed.) CADRE 9;1 2011.

70. Winter WE, Schatz DA: Small steps forward: 2012 update on recent efforts to interdict type 1

diabetes. American Academy of Pediatrics Endo Newsletter 22: 4-7, 2012.

71. Rohrs HJ, Schatz D, Winter WE, Davis V: Pediatric lipid disorders in clinical

practice. eMedicine from WebMD. Updated July 13, 2012 Available at:

http://emedicinemedscape. Com/article/1825087-overview.

72. Chiang JL, Haller MJ, Schatz DA: Update on global intervention studies in type 1 diabetes.

Endocrinol Metab Clin North AM. Rappaport R, LeRoith D (eds). Elsevier 41 (4): 695-712,

2012. Doi: 10.1016/j.ecl.2012.07.003. PMID:23099265

http://emedicine.medscape.com/article/901837-overview

http://emedicine/

Desmond A Schatz MD

47

73. Haller MJ, Winter WE, Schatz DA: Autoimmune polyglandular syndromes. Sperling

9781455748587; Chapter 20, 901-919, 2013.

74. Nambam B, Winter WE, Schatz DA: IgG4 antibodies in autoimmune polyglandular disease

and IgG4-related endocrinopathies: pathophysiology and clinical characteristics. Curr Opin

Pediatr 26(4):493-9, 2014. PMID:24905103

75. Rohrs HJ, Schatz D, Winter WE, Davis V: Pediatric lipid disorders in clinical practice.

Medscape Reference. Updated January 29, 2015.

76. Nambam B, Bratina N, Schatz D: Immune intervention in Type 1 Diabetes. ATTD 2015

Yearbook Advanced Technologies & Treatments For Diabetes, 7th edition. Chapter 7, 138-

150.

77. Schatz DA: The medical crisis without a headline. The Huffington Post Aug 16, 2016.

78. Schatz DA: Diabetes: the invisible epidemic not enough are talking about. Baltimore Sun Nov

25, 2016; Miami Herald Nov 20, 2016.

79. Schatz DA: Diabetes is an invisible epidemic. Gainesville Sun Dec 16, 2016.

80. Nambam B, Bratina N, Schatz D: Immune intervention in Type 1 Diabetes. ATTD 2016

Yearbook Advanced Technologies & Treatments For Diabetes, 8th edition. Chapter 8, 145-161.

81. Nambam B, Winter W, Schatz D: (2014) Type 1 Diabetes. Reference Module in Biomedical

Sciences. Elsevier. 27-Oct-14 doi: 10.1016/B978-0-12-801238-3.03820-4.

82. Nambam B, Bratina N, Schatz D: Immune intervention for Type 1 diabetes. ATTD 2017

Yearbook Advanced Technologies & Treatments For Diabetes, 9th edition. Chapter 7, 171-185.

83. Nambam B, Winter W, Schatz D: Type 1 Diabetes. Ilpo Huhtaniemi and Luciano Martini,

(eds), Encyclopedia of Endocrine Diseases, Second Edition, vol. 1, 110-115. Oxford:

Academic Press. Elsevier Inc, 2019.

84. Bruggeman BS, Schatz DA: Enhanced understanding of the Natural History of Pre-Type 1

diabetes: Fundamental to prevention. Pediatr Endocrinol Rev 16 (3): 359-368, 2019. doi:

10.17458/per.vol16.2019.bs.pretype1diabetes. PMID: 30888126

ABSTRACTS (papers presented indicated by asterisk)

1. Schatz DA, Reimer C, Barrett DJ: IgG subclass response to group A streptococcal

carbohydrate antigen. Pediatric Res 20: 299A, 1986.

*2. Schatz DA, Barrett DJ: Delayed ontogeny of the pneumococcal polysaccharide type 3 IgG2

subclass antibody. Clin Res 35: 67A, 1987.

*3. Schatz DA, Barrett DJ: Ontogeny of the subclass of antibody to pneumococcal

polysaccharide type 3. Pediatr Res 21: 317A, 1987.

Desmond A Schatz MD

48

4. Schatz DA, Barrett DJ, Riley WJ: Evidence that islet cell antibodies (ICA) are polyclonal.

Diabetes 36: 71A, 1987.

5. Skordis N, Schatz DA, Puig V: Influence of sex, multiple pedigree and HLA on onset of

insulin dependent diabetes before the age of 2 years. Diabetes 36: 71A, 1987.

*6. Schatz DA, Riley WJ, Caballero S, Barrett DJ: Abnormal inducer T cell (CD4) function in

pre-clinical insulin dependent diabetes. Pediatr Res 23: 396A, 1988.

7. Schatz DA, Riley WJ, Caballero S, Stephens JA, Barrett DJ: Defective T cell

immunoregulation in pre-diabetes. Diabetes 37: 201A, 1988.

*8. Sleasman JW, Schatz DA, Barrett DJ: Abnormal expression of immature B cell markers in

humoral immunodeficiencies. Pediatr Res 25: 202A, 1989.

*9. Schatz DA, Riley WJ, Kozak R, Maclaren NK, Barrett DJ: Diminished interleukin-2 and

interferon production in pre-clinical insulin dependent diabetes mellitus. Pediatr Res 25:

169A, 1989.

*10. Zori RT, Schatz DA, Ostrer H, Williams CA, Riley WJ: The relationship of autoimmunity

to thyroid dysfunction in children and adults with Down syndrome. Proceedings of the

International Symposium on Trisomy 21:139, 1989. Presented at the International

Symposium on Trisomy 21, Rome, Italy.

*11. Schatz DA, Riley WJ, Kowa H, Winter WE: Natural history of incidental hyperglycemia

&/or glycosuria of childhood. Diabetes 38: 77A, 1989. PMID:2681635

*12. Riley WJ, Schatz DA, Maclaren NK, Dush P, Spillar RP, Barrett DJ: Helper-inducer CD4

T cell dysfunction and decreased IL-2 production in "pre-diabetes." Diabetes 38: 87A,

1989.

*13. Schatz DA, Riley WJ, Maclaren NK, Barrett DJ: Pre-clinical IDD is associated with

defective inducer CD4 T cell immunoregulation. J Autoimmunity 3:90, 1990. Presented at

the IXth International Workshop on the Immunology of Diabetes, Melbourne, Australia,

November 1989.

*14. Schatz DA, Riley WJ, Sleasman JW, Dush P, Barrett DJ: Increased CD5+ B lymphocytes in

"pre-diabetic" and newly diagnosed diabetic subjects. Ped Res 27: 192A, 1990. Pediatr Res

25:169A, 1989.

*15. Sleasman JW, Schatz DA, Harville TO, Barrett DJ: CD5+ B lymphocytes decrease during

childhood but are normal in polysaccharide vaccine non-responders. Ped Res 27: 162A,

1990.

*16. Davidson KM, Richards DS, Schatz DA: Successful in utero treatment of a large fetal goiter

and hypothyroidism in intra-amniotic L-thyroxine administration. Ped Res 27: 74A, 1990.

*17. Lang F, Schatz DA, Riley WJ, Barrett DJ: Increased T lymphocytes bearing the gamma

delta T cell receptor in insulin dependent diabetes. Program B38. Presented at the Clinical

Immunology Society: 5th Annual Conference on Clinical Immunology and CIS Specialized

Meetings: Molecular and Cellular Mechanisms in Clinical Immunology. Chicago, IL, Nov

1990.

*18. Riley W, Schatz D, Dush P, Barrett D: CD4 defect in prediabetes. Diabetes 40:146A 1991.

*19. Sleasman JW, De Severino A, Schatz D, Barrett DJ. HIV infected children with lymphoid

interstitial pneumonitis (LIP) express low numbers of CD5+ B cells. Ped Res 29: 163A,

1991.

*20. Dong J, Muir A, Schatz D, Luchetta R, Hao W, Atkinson M, Maclaren N: Oral

administration of insulin prevents diabetes in NOD mice. Diab Res Clin Prac 14; Suppl 1:

Desmond A Schatz MD

49

S55,1991. XI th International Immunology and Diabetes Workshop, Tokyo, Japan,

November 1991.

*21. Muir A, Dong J, Schatz D, Luchetta R, Hao W, Atkinson M, Maclaren N: Insulin

autoantibodies (IAA) predict time of onset of diabetes in NOD mice. Diab Res Clin Prac

14; (Suppl) 1: S87,1991. XIth International Immunology and Diabetes Workshop, Tokyo,

Japan, November 1991.

*22. Schatz DA, Riley WJ, Dush P, Barrett DJ: Persistent defects in helper-inducer T cell

function predict progression to diabetes in ICA+ nondiabetic subjects. Pediatr Res 31:188A,

1992.

*23. Muir A, Luchetta R, Schatz D, Maclaren N: Insulin-specific immunomodulation

ameliorates diabetes in nonobese diabetic (NOD) mice. Diabetes 41: 39A, 1992.

*24. Muir A, Schatz DA, Luchetta R, Maclaren NK: Antigen specific immunotherapy prevents

insulin dependent diabetes in nonobese diabetic mice. Pediatr Res 33: 194A, 1993.

*25. Maclaren N, Schatz D, Song Y, Muir A: Antigen directed therapies to prevent insulin

dependent diabetes. Pediatr Res 33: Suppl: S4, 1993.

*26. Krischer JP, Schatz DA, Silverstein JH, Maclaren NK: Islet cell antibodies (ICA) predict

the development of IDD in the school age general population as effectively as in unaffected

relatives. J Autoimmunity 15: (Suppl) 74, 1993.

*27. Schott M, Schatz D, Atkinson M, Krischer J, Mehta H, Vold B, Maclaren N: GAD65

autoantibodies (GAD65A) increases the specificity but not the sensitivity of islet cell

antibodies (ICA) in prediabetic subjects. Proceedings of the 13th International Immunology

and Diabetes Workshop, Paris, France, June 1994.

28. Atkinson M, Clare-Salzler M, Bowman M, Campbell L, Darrow B, Schatz D, Maclaren N:

Cellular immune responses to insulin-dependent diabetes. Proceedings of the 13th

International Immunology of Diabetes Workshop, Paris, France, June 1994.

29. DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Diabetes 43:

(Suppl) 159A, 1994.

*30. Schatz DA, Schott M, Huang W, She J-X, Atkinson M, Krischer J, Maclaren NK: IDD

prediction in relatives and the general population. International Symposium of Type 1

(Insulin-Dependent) Diabetes, Nagasaki, Japan, November, 1994.

*31. Maclaren N, Schatz D, Schott H, Wei H, She J-X, Pusateri A, Maclaren S, Atkinson M,

Krischer J: The predictability and possible prevention of insulin dependent diabetes (IDD).

Diabetes in the Young, 30: A69, 1994. Presented at XXth Annual Meeting of the

International Society for Pediatric and Adolescent Diabetes, Atami, Japan, November, 1994.

32. Schatz DA for the DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes

(DPT-1): Design and implementation of the oral antigen (insulin) protocol. Diabetes 44:

(Suppl) 77A, 1995.

*33. DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):

Implementation of screening and staging of relatives. Diabetes 44: (Suppl) 129A, 1995.

*34. Wasserfall C, Schatz DA, Mehta HB, Vold B, Krischer J, Atkinson M, Maclaren NK:

Glutamic acid decarboxylase antibodies measured by ELISA powerfully predict impending

IDD in the general population. Diabetes 44: (Suppl) 77A, 1995.

*35. Ramiya V, Muir A, Wasserfall C, Schott M, Schatz DA, Maclaren NK: Protection from

diabetes by prophylactic oral insulin and GAD feedings in NOD mice. Diabetes 44: (Suppl)

164A, 1995.

Desmond A Schatz MD

50

*36. Song Y-H, Li Y, Schatz DA, Pusateri A, Maclaren NK: Autoantibodies against the insulin

receptor but not the glucose-transporter 2 in human-insulin-dependent diabetes. Diabetes 44:

(Suppl) 78A, 1995.

*37. Huang W, She J-X, Balducci P, Connor E, Schatz DA, Silverstein JH, Maclaren NK: The

only components of the autoimmune polyglandular syndromes associated with HLA-DR,

DQ are IDD and Graves disease, not vitiligo, Hashimoto or Addison disease. Diabetes 44:

(Suppl) 161A, 1995.

*38. Wasserfall C, Schatz D, Krischer J, Mehta H, Vold B, Lan M, Notkins A, Maclaren N:

Autoantibodies to ICA, GAD65 and IA-2 to predict IDD in relatives and schoolchildren. J

Autoimmunity 21: A150, 1995.

*39. Ramiya V, Muir A, Wasserfall C, Shang XZ, Schatz D, Maclaren N: Autoantigen-specific

immunotherapies in the prevention of diabetes in NOD mice. J Autoimmunity 21: A261,

1995.

*40. Hofig A, Xie T, Schatz D, Maclaren N, Moldawer L, Clare-Salzler M: Spontaneous

expression of prostaglandin synthase-2 (PGS-2) in monocytes of ICA positive prediabetic

subjects. J Autoimmunity 21: A0268, 1995.

*41. Schatz D for the DPT-1 Study Group: Update on the Type 1 Diabetes Prevention Trial

(DPT-1). JAMA 3, (ed. Port): 23, 1996.

*42. Schatz D, Krischer J, Wasserfall C, Lan M, Notkins A, Muir A, Maclaren N: ICA,

GAD65A, IAA and IA-2 to screen for IDD in Schoolchildren and Unaffected Relatives.

Diabetes 45: 80A, 1996.

*43. Wasserfall C, Schatz D, Lan M, Notkins A, Maclaren N: Multiple autoantibodies predict

IDD in a low-risk school population. Autoimmunity 24: (Suppl) A198, 1996.

*44. Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler JS and the Diabetes Prevention

Trial Study Group, USA: Differential expression of autoantibodies by DQQ1 *0102,

DQB1*0602 relatives of the Diabetes Prevention Trial-1. Autoimmunity 24: (Suppl) A189,

1996.

*45. Ramiya V, Wasserfall C, Lan M, Notkins A, Muir A, Schatz D, Maclaren N: Immunization

therapies in diabetes prevention. Autoimmunity 24 (suppl): AO54, 1996.

*46. Litherland SA, Hofig A, Xie T, Schatz D, Maclaren N, Clare-Salzler M: Individuals at risk

for IDDM spontaneously express prostaglandin synthase (PGS2) in the absence of monocyte

activation. Autoimmunity 24 (suppl): A081, 1996.

*47. Tercyak K, Johnson S, Schatz DA: Patient and family perceptions of the use of

subcutaneous insulin to prevent IDDM: implications for future prevention trials. Diabetes 46

(suppl): 15A, 1997.

48. Ellis T, Schatz D, Lan M, Ottendorfer E, Wasserfall C, Notkins A, Maclaren N, Atkinson

M: Relationship between humoral and cellular immunity to IA-2 in IDD. Diabetes 46

(suppl): 195A, 1997.

49. Ellis T, Schatz D, Ottendorfer E, Wasserfall C, Maclaren N, Atkinson M: Cellular

immune reactivities against proinsulin in insulin dependent diabetes. Diabetes 46

(suppl): 347A, 1997.

*50. DPT-1 Study Group, Nationwide, USA. The Diabetes Prevention Trial - Type 1 Diabetes

(DPT-1): Progress report. 16th International Diabetes Federation Congress, Helsinki,

Finland, 1997.

Desmond A Schatz MD

51

*51. DPT-1 Study Group, Nationwide, USA. The Diabetes Prevention Trial - Type 1 Diabetes

(DPT-1): Demographics of relatives screened and ICA positive. 16th International Diabetes

Federation Congress, Helsinki, Finland, 1997.

*52. Eisenbarth GS, J. Krischer, C. Greenbaum, D. Schatz, J. Skyler for the DPT-1 Study Group,

Nationwide, USA. Role of DQA1*0102/DQB1*0602 in risk characterization: The Diabetes

Prevention Trial - Type 1 Diabetes (DPT-1). 16th International Diabetes Federation

Congress, Helsinki, Finland, 1997.

*53. Eastman RC, C.C. Cowie, J. Harmon, and the DPT-1 Study Group: Potential cost-

effectiveness of primary prevention of insulin-dependent diabetes mellitus. 16th

International Diabetes Federation Congress, Helsinki, Finland, 1997.

*54. Leon BH, Schatz D, Zori R, Sleasman JW: Sarcoidosis after successful bone marrow

transplantation for Omenn Syndrome. AAAI Annual Meeting, 1998.

*55. Atkinson M, Ellis T, Ottendorfer T, Jodoin E, Schatz D: Cellular and humoral immune

responses to islet cell autoantigens in individuals undergoing prophylactic insulin therapy

for the prevention of diabetes. Diabetes 47 (suppl): 33A, 1998.

*56. Coutant R, Zeidler A, Rappaport R, Schatz D, Schwartz D, Malone J, Raskin P, Rogers D,

Bode B, Crockett S, Marks J, Deeb L, Chalew S, Maclaren N: Oral insulin therapy in newly

diagnosed type 1 diabetes. Preliminary analysis of a randomized double blind placebo

controlled study. Diabetes 47 (suppl): 97A, 1998.

*57. Litherland SA, Xie TX, Whittaker DS, Hutson AD, Schatz D, Moldawer LL, Clare-Salzler

MJ: Aberrant monocyte prostaglandin synthase 2 (PGS2) expression: a novel cellular

marker for IDD risk. Diabetes 47 (suppl): 215A, 1998.

*58. Jodoin E, Ellis T, Ottendorfer E, Salisbury P, She J-X, Schatz D, Atkinson M: Cellular

immune responses against casein: elevated but not specific for individuals with IDDM.

Diabetes 47 (suppl): 216A, 1998.

*59. Wasserfall C, Wilson B, Kent S, Hafler D, Strominger J, She J-X, Schatz D, Atkinson M,

Ellis T: Increased serum interleukin-4 (IL-4) in IDDM: evidence for inheritance in multiplex

families of a trait associated with protection from disease. Diabetes 47 (suppl): 217A, 1998.

*60. Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J and the DPT-

1 Study Group: Characteristics of HLA DQA1*0102 DQB*0602 relatives identified in the

Diabetes Prevention trial - Type 1. Diabetes 47 (suppl): 236A, 1998.

*61. Chase HP, Cuthbertson D, Dolan L, Kauffman F, Krischer J, Schatz D, White N, Wilson D,

Wolfsdorf J: First phase insulin release (FPIR) during the initial intravenous glucose

tolerance test (IVGTT) in the Diabetes Prevention Trial (DPT-1). Diabetes 48 (suppl):

238A, 1999.

*62. Carmichael SLK, Johnson SB, Fuller KG, Taylor KR, She JX, Schatz DA: Newborn genetic

screening for Type 1 diabetes: Psychological impact and factors predicting study

participation Diabetes 48 (suppl): 322A, 1999.

*63. Carmichael SLK, Johnson SB, Fuller KG, Taylor KR, She JX, Schatz. DA: Newborn

genetic screening for Type 1 diabetes: Maternal understanding of infant risk. Diabetes 48

(suppl): 323A, 1999.

*64. Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J and the DPT-

1 Study Group: ICA+ relatives with DQA1*0101/DQB1*0602 identified by the Diabetes

Prevention Trial (DPT-1): presence of other risk factors for diabetes. 4th Immunology of

Diabetes Society Congress, Fiuggi, Italy; Abstract Book p 53, 1999.

Desmond A Schatz MD

52

*65. Litherland SA, Xie TX, Muir A, Schatz D, Sje JX, Atkinson M, Clare-Salzler MJ:

Prostaglandin synthase 2 expression as a risk assessment tool for IDDM: a new avenue for

prevention and intervention? 4th Immunology of Diabetes Society Congress, Fiuggi, Italy;

Abstract Book p 114, 1999.

*66. Wasserfall C, Atkinson M, Jodoin E, Schatz D, She JX, Ellis T: Glutamic acid

decarboxylase (GAD) and IA-2 autoantibodies in Type 1 diabetes: comparing sample

substrates for autoantibody determination. 4th Immunology of Diabetes Society Congress,

Fiuggi, Italy; Abstract Book p 120, 1999.

*67. Schatz D, Muir A, Fuller K, Atkinson M, Crockett S, Hsiang H, Winter W, Ellis T, Saites C,

Dukes M, Fang Q, Clare-Salzler M, She JX: Prospective assessment in newborns for

diabetes autoimmunity (PANDA): a newborn diabetes screening program in the general

population of Florida. Diabetes 49 (suppl): 67A, 2000.

*68. La Greca A, Johnson S, Delameter A, Anderson B, Bearman K, Patino A-M, Blumberg M,

Marks J, Schatz D, Ricker A: Environmental stress and infectious disease: Do they predict

ICA status among youths participating in DPT-1. Diabetes 49 (suppl): 317A, 2000.

*69. La Greca A, Johnson S, Delameter A, Anderson B, Bearman K, Patino A-M, Blumberg M,

Marks J, Schatz D, Ricker A: Environmental stress and infectious disease: Do they predict

ICA status among adults participating in DPT-1. Diabetes 49 (suppl): 317A, 2000.

*70. Carmichael SL, Johnson SB, Weiss A, Fuller KG, She JX, Schatz DA: Psychological impact

of screening programs in mothers of children at-risk for Type 1 diabetes. Diabetes 49

(suppl): 317A, 2000.

*71. La Greca AM, Bearman KJ, Delamater A, Patino AM, Blumberg M, Marks J, Johnson S,

Schatz DA, Anderson B: Early life stress and disease among offspring and siblings of

individuals with type 1 diabetes. 9th Annual, Bellinson-Schneider Symposium, Maagan

Village, Israel (Oral), Sept 2000.

*72. Schatz DA. Update on Major Trials for Prevention of Type 1 Diabetes in Relatives 1) US

Diabetes Prevention Trial (DPT-1) 2) European Nicotinamide Diabetes Intervention Trial

(ENDIT). 9th Annual, Bellinson-Schneider Symposium, Maagan Village, Israel (Oral), Sept,

2000.

*73. Litherland, SA, Xin, T, Davoodi-Semiromi, A., Schatz, D., Clare-Saltzler, M: (2000)

Prolonged GM-CSF activation of STAT5 in type 1 diabetes: possible mechanism for

aberrant prostaglandin synthease 2 (PGS2) expression by autoimmune monocytes and

macrophages. 2000 FASEB Summer Research Conferences, USA.

*74. Morales A, Anderson JA, Jodoin E, Novak D, Schatz D, Ellis T, Atkinson M, Wasserfall C:

Age related association of autoantibodies to tissue transglutaminase in a US population of

children and persons with Type 1 diabetes. Diabetes 50 (suppl): 208A, 2001.

*75. Krischer J, Ten S, Marker J, Coutant R, Kukreja A, Zhang C, Raskin P, Bode B, Vargas A,

Rogers D, Schatz D, Deeb L, Marks J, Schwartz S, Malone J, Rapaport R, Zeidler A,

Maclaren N: Endogenous insulin retention by oral insulin in newly diagnosed antibody

positive Type 1 diabetes. Diabetes 50 (suppl): 44A, 2001.

*76. Marker JD, Chopra M, Ten S, Su K, Zeidler A, Raskin P, Rapaport R, Schatz D, Vargas A,

Malone J, Bode B, Krischer J, Maclaren N: Islet autoantibodies in Type 1 or Type 2 diabetes

in four US racial groups. Diabetes 50 (suppl): 262A, 2001.

*77. Fineberg SE, Schatz D, Krasner A: Results of insulin antibody monitoring during phase 2

and phase 3 clinical studies of inhaled insulin (Exubera) in patients with Type 1 or Type 2

Diabetes. EASD, 2002.

Desmond A Schatz MD

53

*78. Mackey AD, Tuhacek LM, Hatch H, Reverte C, Neu J, Schatz DA: Investigating the early

events in pre-type 1 diabetes: changes in intestinal morphology and permeability in the

Biobreeding Diabetes Prone (Bbdp) Rat. Society for Pediatric Research, 2003.

*79. Fineberg SE, Schatz DA, Krasner A: Insulin antibody binding in clinical studies of inhaled

insulin (Exubera®) in patients with type 1 or type 2 diabetes. AACE, 2003.

*80. Baughcum A, Johnson S, She J-X, Lewin A, Walsh J, Carmichael S, Schatz D: High rates of

maternal behavior change resulting from newborn genetic screening for risk of type 1

diabetes. Diabetes 52 (suppl) 410A, 2003.

*81. Wherrett D, Chase P, Eisenbarth G, Schatz D, Wilson D, Cuthbertson D for the Diabetes

Prevention Trial-Type 1 Study Group: Longitutindal screening for autoantibodies: factors

associated with antibody development in Diabetes Prevention Trial-Type 1. IDS, 2004.

*82. Karounos D, Atkinson M, Wherrett D, Chase P, Maclaren N, Cuthbertson D, Krischer J,

Schatz D for DPT-1 Study Group: Influence of titer of antibodies and age on evolution of

loss of first phase insulin release (FPIR), impaired glucose tolerance (IGT) and diabetes.

IDS, 2004.

*83. Redondo MJ, Schatz DA, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson D, Krischer J,

Eisenbarth GS, on behalf of DPT-1 Study Group: Diabetes Prevention Trial: Influence of

high-risk HLA-DQ alleles and genotypes on autoantibody expression and progression to

type 1 diabetes. IDS, 2004.

*84. TEDDY Investigators: The environmental determinants of diabetes in the young study.

IDS, 2004.

*85. Carmichael SLK, Bennett Johnson S, Baughcum AE, She J-X, Schatz DA: Genetic

Screening for Type 1 Diabetes in Newborns: The Impact of a Tailored Print Intervention on

Maternal Risk Perception, Anxiety, and Intentions to Participate in a Longitudinal Screening

Study. Diabetes 53 (suppl) 437A, 2004.

*86. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson D, Eisenbarth GS, Krischer J,

Schatz DA: Diabetes Prevention Trial: Influence of high-risk HLA-DQ alleles and

genotypes on autoantibody expression and progression to type 1 diabetes.

Diabetes 53 (suppl) 29A, 2004.

*87. Williams CA, Wallace MR, Drury KC, Kipersztok S, Edwards RK, Williams RS, Haller MJ,

Schatz DA, Silverstein JH, Gray BA, Zori RT: Blood lymphocyte chimerism associated with

in vitro fertilization and monochorionic dizygous twinning. American Society of Human

Genetics Meeting, 2005. PMID: 15375077

*88. Haller MJ, Seldona R, Liu B, Viener HL, Schatz DA, Ramiya V: Cyclopamine represses the

sonic hedgehog gene and leads to the differentiation of insulin-expressing cells from mouse

embryonic (ES) cells. Pediatr Res Abstract 1567; 2005.

*89. Viener HL, Haller MJ, Liu BS, Schatz DA, Ramiya VK: De-differentiation of a human

exocrine pancreatic duct derived cell line into insulin-expressing cells. Pediatr Res Abstract

200; 2005.

*90. Stalvey M, Wasserfall C, Brusko T, Schatz D, Atkinson M, Flotte T: A pro-inflammatory

state is associated with hyperglycemia in a novel model of cystic fibrosis related diabetes:

cystic fibrosis transmembrane conductance regulator (CFTR) knockout mice. Pediatr Res

Abstract 2386; 2005. PMID:16804061

*91. Caicedo R, Liboni KC, Neu M, Li N, Atkinson M, Schatz D, Neu J: abnormal early

intestinal barrier tight junction expression and inflammation in a rodent model of type 1

diabetes. Pediatr Res Abstract 1566, 2005.

Desmond A Schatz MD

54

*92. Haller M, Cooper S, Putnam A, Freed B, Brusko T, Chase P, Atkinson M, Schatz D:

Autologous cord blood transfusion associated with prolonged honeymoon in a child with

type 1 diabetes. Diabetes 54 (suppl): 485A, 2005.

*93. Stalvey M, Wasserfall C, Brusko T, Flotte T, Schatz D, Atkinson M: A pro-inflammatory

state and hyperglycemia are associated with a cystic fibrosis related diabetes mouse model.

Diabetes 54 (suppl): 645A, 2005.

*94. Brusko TM, Wasserfall C, Clare-Salzler MJ, Schatz DA, Atkinson MA: Functional defects

and the influence of age on the frequency of CD4+CD25+ T cells in Type1 diabetes.

Diabetes 54 (suppl): 60A, 2005. PMID: 15855327

*95. Ramiya VK, Viener HL, Haller MJ, Liu B, Atkinson MA, Schatz DA: Differentiation of a

human exocrine pancreatic-duct derived cell line into insulin-expressing cells. Diabetes 54

(suppl): 652A, 2005.

*96. Stalvey M, Muller C, Wasserfall C, Brusko T, Schatz D, Atkinson M, Flotte T: Modeling

Cystic Fibrosis Related Diabetes In CFTR-Deficient Mice: Effects of CFTR genotype on

glycemic control after sub-lethal beta cell injury or pulmonary sensitization and challenge.

Ped Pulm 40, S28: 354-355, 2005.

*97. Stalvey M, Schwartz T, Brusko T, Muller C, Wasserfall C, Schatz D, Flotte T, Atkinson M:

Increase inflammatory reactivity of cystic fibrosis-transmembrane conductance resistance-

regulator-deficient (CFTR-/-) mice is not associated with insulin resistance. Diabetes 55

(suppl): 574A, 2006.

*98. Brusko T, Wasserfall C, McGrail C, Huegal A, Moore M, Schatz DA, Atkinson MA:

Regulatory T cells require serum for suppression of effector T cell proliferation and express

stable membrane-bound CD25. FOCIS 2007.

*99. Xue S, Loiler S, Lira A, Cruz P, Wasserfall C, Schatz D, Flotte T, Atkinson M, Ramiya V:

Reversal of diabetes in streptozotocin-induced diabetic mice following direct intra-

pancreatic gene delivery of adeno-associated virus vector encoding Glucagon-like peptide

(GLP-1). Diabetes 56 (suppl): A73, 2007.

*100. Brusko T, Wasserfall C, McGrail K, Huegel A, Moore M, Schatz D, Atkinson M:

Regulatory T cells require serum for suspension of effector t cell proiferation and express

stable membrane-bound CD25. Diabetes 56 (suppl): A83, 2007.

*101. Escobar-Douglas M, Schatz D, Atkinson M, Wasserfall C, Li N, Caicedo R, Neu J: Sodium

Butyrate prevents Type 1 Diabetes in Biobreeding Diabetes Prone (BBDP) Rats. Diabetes

56 (suppl):) A321, 2007.

*102. Stalvey M, Brusko T, Muller C, Wasserfall C, Schatz D, Flotte T, Atkinson M:

Hyperglycemia exacerbates TH2 immune reactivity in a cystic fibrosis related diabetes

mouse model. Diabetes 56 (suppl): A482, 2007.

*103. Haller MJ, Viener H-L, Brusko T, Wasserfall C, McGrail K, Staba S, Cogle C, Atkinson M,

Schatz DA: Insulin requirements, HbA1c and stimulated c-peptide following autologus

umbilical cord blood transfusion in children with T1D. Diabetes (suppl): A82, 2007.

*104. Viener H-L, Brusko T, Wasserfall C, McGrail K, Staba S, Cogle C, Atkinson M, Schatz DA,

Haller MJ: Changes in regulatory T Cells following autologous umbilical cord blood

transfusion in children with Type 1 Diabetes. Diabetes 56 (suppl): A82, 2007.

*105. Park JY, Cochran EK, Haller MJ, Schatz DA, Gordon P: Insulin resistance and generalized

lipodystrophy associated with Type 1 Diabetes: the response to leptin therapy. Diabetes 56

(suppl): A165, 2007.

Desmond A Schatz MD

55

*106. Baughcum AE, Johnson SB, She J-X, Lewin AB, Schatz DA: Risk underestimation and

study participation among mothers of children at risk for type 1 diabetes. Diabetes 56

(suppl): A500, 2007.

*107. Batlivala S, Schatz DA: A rare cause of neonatal electrolyte imbalances. AAP Symposium,

San Francisco, 2007.

*108. Ross IL, Soule S, Levitt NS, She J-X, Mienie J, Pirie F, A Boulle A, Winter WE, Karlsson

A, Schatz DA on behalf of the South African Addison Study Group: Aetiology of Addison’s

Disease in South Africa: a retrospective study. Journal of Endocrinology Metabolism and

Diabetes of South Africa 12:44, 2007.

*109. Schatz DA: Novel cellular therapies for the prevention and amelioration of type 1 diabetes.

Ped Diabetes 9: (suppl): 4, 2008.

*110. Wasserfall C, Schatz DA, Xue S, Parker M, McGrail S, Haller M, Atkinson M: Combination

therapies for the reversal of Type 1 Diabetes: the NOD mouse model. Ped Diabetes 9:

(suppl): 26, 2008.

*111. Bierschenk L, Schatz D, Moore M, McGrail K, Atkinson M, Wasserfall C: Serum 25 OH

vitamin D status is similar in healthy controls and subjects with or at risk for type 1 diabetes.

Ped Diabetes 9: (suppl): 56, 2008.

*112. Haller M., Wasserfall C., McGrail K., Viener H., Cintron M., Gaitan S., Brusko T., Wingard

J., Cogle C., Kelly S., Slayton W., Atkinson M., Schatz D.: Autologous umbilical cord

blood transfusion in very young children with t1D: 1 year follow-up. Diabetes 58 (suppl):

A7, 2009. PMCID: PMC2768209

*113. Ma H., Lu Y., Li W., Wasserfall C., Haller M., Campbell-Thompson M., Brantly M., Schatz

D., Atkinson M., Song S: Prevention and reversal of type 1 diabetes by alpha 1 antitrypsin

(AAT) given intradermally in NOD mice. Diabetes 58 (suppl): A50, 2009.

*114. Ramiya V., Wasserfall C., Xue S., Parker M., Haller M., Schatz D., Atkinson M.

Combination therapy with IL-2 and rapamycin reverses type 1 diabetes in non-obese

diabetic (NOD) mice. Diabetes 58 (suppl): A87, 2009.

*115. Bierschenk L., Alexander J., Wasserfall C., Haller M., Schatz D., Atkinson M: Suboptimal

vitamin D levels are not limited to those with type 1 diabetes. Diabetes 58 (suppl): A583,

2009.

*116. Ize-Ludlow D., Luzardo Y., Wasserfall C., Schatz D., Atkinson M., Mathews C: Progressive

erosion of beta cell function precedes the onset of type 1 diabetes in the NOD mouse.

Diabetes 58 (suppl): A327, 2009.

*117. Rowe P, Campbell-Thompson M, Wasserfall C, Fernanda Martino M, Albanese-O’Neil A,

Schatz D, Atkinson M: Network for pancreatic organ donors with type 1 diabetes (nPOD):

progress and donor demographics. Diabetes 58 (suppl): A410, 2009.

*118. Bonifacio E., Yu L., Williams A., Eisenbarth G., Bingley P., Koczwara K., Mueller P.,

Schatz D., Krischer J., Steffes M., Akolkar B., and the TEDDY Steering Committee:

Harmonization of GAD- and IA-2 autoantibodies assays for NIDDK consortia improves

concordance. Presented at Immunology of Diabetes Society Meeting, Malmo, Sweden 2009.

*119. Miersch S., Sibani S., Logvineko T., Atkinson M., Schatz D., LaBaer J: Serological

screening for novel autoantibodies associated with type 1 diabetes using nucleic acid

programmable protein arrays. Presented at Immunology of Diabetes Society Meeting,

Malmo, Sweden 2009.

120. Sosenko J., Skyler J., Palmer J., Krischer J., Cuthbertson D., Yu L., Schatz D., Orban T.,

Eisenbarth G., The DPT-1 Study Group: Quantitative changes in ICA512 and GAD65

Desmond A Schatz MD

56

autoantibodies with progression to type 1 diabetes in the diabetes prevention trial-type 1

(DPT-1). Diabetes 59 (suppl), 2010.

121. Miersch S., Wallstrom G., Sibani S., Logvinenko T., Schatz D., Atkinson M., Wasserfall C.,

LaBaer J.: Identification and verification of candidate T1D autoantibodies by comparative

analysis of serum-challenged nucleic acid programmable protein arrays. US HUPO 2010.

*122. Rowe P., Campbell-Thompson M., Wasserfall C., Fernanda-Martino M., Albanese-O’Neill

A., Atkinson M., Schatz D.: Clinical Findings in U.S. organ donors with type 1 diabetes

mellitus. Diabetes 59 (suppl): A353, 2010.

*123. Parker M., Wasserfall C., Xue S., Campbell-Thompson M., Mathews C., Schatz D., Haller

M., Atkinson M.: Granulocyte colony stimulating factor enhances both ATG and Anti-CD2

mAb-mediated reversal of type 1 diabetes in NOD mice. Diabetes 59 (suppl1): A117, 2010.

*124. Campbell-Thompson M., Rowe P., Wasserfall C., Pietras R., Albanese-O’Neill A., Gianani

R., Schatz D., Atkinson M.: Histopathology of type 1 diabetes in U.S. organ donors.

Diabetes 59 (suppl): A58, 2010.

*125. Myhr C., Wasserfall C., Haller M., Schatz D., Atkinson M.: Unique gene expression

profiles from peripheral blood in subjects with type 1 diabetes. Diabetes 59 (suppl): A331,

2010.

*126. Rowe P., Wasserfall C., Fernanda-Martino F., Albanese-O’Neill A., Schatz D., Atkinson

M.: Islet glucagon staining in pancreata from diabetic organ donors may be inversely related

to in-vivo -cell insulin function. Diabetes 59 (suppl1): A455, 2010.

*127. Blanton D., Hong P., Alexander J., Myhr C., Han Z., Wasserfall C., Schatz D., Atkinson M.:

QRT-PCR and custom immune system phenotyping arrays for characterizing gene

expression in type 1 diabetes. Diabetes 59 (suppl1): A631, 2010.

*128. Sosenko J., Skyler J., Palmer J., Krischer J., Cuthbertson d., Yu L., Schatz D., Orban T.,

Eisenbarth G.: Changes in ICA512 and GAD65 autoantibodies with progression to type 1

diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes 59 (suppl1): A19, 2010.

*129. Vehik K., Beam C., Haller M., Sosenko J., Schatz D., Mahon J., Krischer J., Skyler J.,

Trialnet Study Group, TampaFL, Gainesville FL., Miami FL., London On, Canada.

Development of autoantibodies in the TrialNet natural history study (NHS). Diabetes 59

(suppl1): A57, 2010.

130. Schatz D. Immunosuppression studies aimed at interdicting and preventing type 1 diabetes

(T1DM). ISPAD, 2010.

131. The Pediatric Diabetes Consortium: Improving care of children with type 1 diabetes through

collaborative research. Diabetes Technology & Therapeutics Vol 12 Num 9, 2010. PMID

20687862

132. Myhr C., Wasserfall C., Haller M., Schatz D., Atkinson M.: IL-23/IL-17 Axis Profiling in

type 1 diabetes. (Submitted 2010)

*133. Schatz DA: Immunosuppression studies aimed at interdicting and preventing type 1

diabetes (T1DM). Pediatric Diabetes 11 (Suppl 14): 12, 2010.

*134. Brown CT, Giongo A, Davis-Richardson AG, Gand KA, Crabb DB, Mukherjee N, Casella

G, Drew JC, Ilonen Jorma, Mikael K, Hyoty H, Veijola R, Simell T, Simell O, Neu J,

Wasserfall CH, Schatz D, Atkinson MA, Triplett EW: The autoimmune metagenome for

type 1 diabetes reveals differences in the metabolic potential of an aberrant gut microbiota.

Diabetes 60 (suppl1): A3, 2011.

Desmond A Schatz MD

57

*135. Xue S, Wasserfall C, Parker M, Mathews C, Burn P, Rabinovitch A, Savinov A, Schatz D,

Atkinson M, Haller M: Multi-drug combination therapy reverses diabetes in NOD mice with

established disease. Diabetes 60 (suppl1): A73, 2011.

*136. Xue S, Wasserfall C, Brusko T, Mathews C, Haller M, Burn P, Atkinson M, Schatz D:

Multi-drug combination therapy increases the frequency of regulatory T- and B- cells in

NOD mice with established disease. Diabetes 60 (suppl1): A91, 2011.

*137. Han Z, Whitener R, Atkinson MA, Haller MJ, Schatz DA, Bluestone JA, Brusko TM:

Generation of antigen-specific regulatory T cells from human umbilical cord blood.

Diabetes 60 (suppl1): A122, 2011.

*138. Vehik K, Beam CA, Boulware D, Schatz DA, Krischer JP, TrialNet Study Group:

Autoantibody reversion in the TrialNet natural history study. Diabetes 60 (suppl1): A353,

2011.

*139. Myhr C, Wasserfall C, Schatz D, Haller M, Atkinson M: Th1 and Th17 associated gene

expression profiles in subjects with type 1 diabetes. Diabetes 60 (suppl1): A397, 2011

*140. Rowe P, Campbell-Thompson M, Wasserfall C, Martino M, Kaddis J, Eisenbarth G,

Gianani R, Albanese-O’Neil A, Atkinson M, Schatz D: Correlation of pancreatic

histopathology in U.S. organ donors with type 1 diabetes of longstanding duration. Diabetes

60 (suppl1): A399, 2011.

*141. Hulme M, Wasserfall CH, Brusko TM, Haller MJ, Schatz DA, Ostrov DA, Atkinson MA:

Small molecule modification of the IL-2 receptor: implications for therapy in type 1

diabetes. Diabetes 60 (suppl1): A401, 2011.

*142. Rowe P, Posgai AL, Campbell-Thompson M, Wasserfall C, Martino MF, Albanes-O’Neil

A, Schatz D, Atkinson M: Islet cell autoantibody reactivity on pancreatic tissue from donors

with type 1 diabetes. Diabetes 60 (suppl1): A669, 2011.

*143. Lau K, Benitez P, Ardissone A, Wilson TD, Collins EL, Lorca G, Li N, Sankar D,

Wasserfall C, Neu J, Atkinson MA, Schatz D, Triplett EW, Larkin J: 3rd J Immunol 186 (6):

3538-3546, 2011. Epub 2011 Feb 11. PMID: 21317395

*144. Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, Gonzalez CF,

Wasserfall CH, Larkin J, Schatz D, Atkinson MA, Triplett EW, Neu J, Lorca GL: PLoS One

5 (5): e10507, 2010. PMID: 20463897

*145. Campbell-Thompson M, Wasserfall C, Kaddis J, Rowe P, Pugliese A, Schatz D, Atkinson

M: Pancreatic islet phenotypes in organ donors with increased β-cell proliferation rates.

Presented Keystone 2012.

146. Vehik K, Cuthbertson D, Boulware D, Rodriguez H, Schatz DA, Krischer JP, Diabetes

Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Natural History study groups: Rising

hemoglobin A1c in the non-diabetic range accelerates time to development of type 1

diabetes in high-risk relatives.

147. Campbell-Thompson M, Wasserfall C, Kaddis J, Albanese-O’Neill A, Staeva T, Nierras C,

Moraski J, Rowe P, Gianani R, Eisenbarth G, Crawford J, Schatz D, Pugliese A, Atkinson

M: Network for pancreatic organ donors with diabetes (nPOD): developing a tissue biobank

of type 1 diabetes. Diabetes Metab Res Rev 28 (7): 608-617, 2012. PMID: 22585677

*148. Sosenko J, Skyler J, Eisenbarth G, Krischer J, Yu L, Mahon J, Beam C, Boulware D, Rafkin

L, Schatz D, Palmer J, The Type 1Diabetes TrialNet Study Group: The prediction of type 1

diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk

score in the trialnet natural history study. 72nd ADA Scientific Session, June 2012,

Philadelphia, PA.

Desmond A Schatz MD

58

*149. Haller MJ, Wasserfall CH, McGrail K, Cintron M, Brusko TM, Slayton W, Clare-Salzler MJ,

Wingard JR, Atkinson MA, Schatz DA: Pilot study of autologous umbilical cord blood

(UCB) and vitamin D (VitD) supplementation in children with type 1 diabetes (T1D) 72nd

ADA Scientific Session, June 2012 Philadelphia, PA. Poster

*150. Gregg B, Kollman C, Wong-Jacobson S, Schatz D, Cengiz E, Harris B, Tamborlane W,

Klingensmith G, Lee JM, Pediatric Diabetes Consortium: Weight gain in the first year after

diagnosis of type 1 diabetes. 72nd ADA Scientific Session, June 2012 Philadelphia, PA.

Poster

*151. Cengiz E, Buckingham B, Klingensmith G, Redondo MJ, Schatz D, Tamborlane W, Wong-

Jacobson S, Kollman C, Pediatric Diabetes Consortium: Partial remission (PR) during the

first 12 months of treatment in youth with type 1 diabetes (T1D) in the pediatric diabetes

consortium cohort (PDC). 72nd ADA Scientific Session, June 2012 Philadelphia, PA. Poster

*152. Walker A, Schatz DA, Silverstein J, Parker K, Albanese-O’Neill A, Rohrs H: Increased

social networks and higher socioeconomic status improve metabolic control in type 1

diabetes. 72nd ADA Scientific Session, June 2012 Philadelphia, PA. Poster

*153. Klingensmith GJ, Miller KM, Beck RW, Cruz E, Laffel LM, Lipman TH, Schatz DA,

Tamborlane WV, Willi SM, T1D Exchange Clinic Network: Racial disparities in insulin

pump therapy and hemoglobin A1c (A1c) among T1D exchange participants. 72nd ADA

Scientific Session, June 2012 Philadelphia, PA. Poster

*154. Rowe PA, Croker BP, Wasserfall C, Campbell-Thompson, Schatz D, Atkinson M: Pancreatic

complement activation in pancreata of patients with or at increased risk for Type 1 Diabetes.

Atkinson M. 72nd ADA Scientific Session, June 2012 Philadelphia, PA. Poster

155. Albanese-Oneill Anastasia, Elder, Jennifer, Chaney, Elizabeth H, Schatz, Desmond A:

Evaluation of knowledge assessment instruments in type 1 diabetes. 2013 Annual

Conference of the Southern Nursing Research Society. Feb 2013. Poster

156. American Diabetes Association, Anderson JE, Greene MA, Griffin JW Jr, Kohrman

DB, Lorber D, Saudek CD, Schatz D, Siminerio L: Diabetes and employment. Diabetes

Care 35 Suppl 1: S94-8, 2012. PMID: 22187477

157. Clarke W, Deeb LC, Jameson P, Kaufman F, Klingensmith G, Schatz D, Silverstein JH,

Siminerio LM: Diabetes Care 35 Suppl 1: S76-80, 2012. PMID: 22187474

*158. Pugliese A, Boulware D, Babu S, Marks JB, Schatz DA, Dmeglio L, Harrison LC,

Greenbaum C, Becker DJ, Steck AK, Rodriguez H and the Type 1 Diabetes Trialnet

Study Group:The high risk HLA DR4-DQB1*03:02 haplotype is associated with

increased progression to T1D in relatives with a single autoantibody specificity. 73rd

ADA Scientific Sessions July 2013 Chicago, IL

*159. Walker AF, Schatz DA, Johnson C, Silverstein J, Parker K, Lyles S, Dougherty E,

Patrick S, Albanese-O’Neill A, Rohrs H: Framing challenge and resilience in youth

with type 1 diabetes: the diabetes photo project. 73rd ADA Scientific Sessions July

2013 Chicago, IL. Poster

*160. Posgai A, Wasserfall C, Atkinson M, Schatz D, Daniel H: Oral delivery of a novel

plant-derived insulin and GAD delays type 1 diabetes onset in NOD mice. 73rd ADA

Scientific Sessions July 2013 Chicago, IL. Poster

*161. Albanese-O’Neill A, Elder JH, Schaffer S, Bernhardt J, Schatz DA: Development of an

educational intervention for fathers of children with diabetes. 28th Annual conference of the

Southern Nursing Research Society. Feb 2014. Poster Abstract

Desmond A Schatz MD

59

*162. Warner JT, Hermann J, Kapellen T, Holl RW, Maahs DM, Dubose S, Schatz D, Beck R:

DKA during diabetes therapy: multinational comparison with 59,191 pediatric patients from

England, Wales, the United States, Austria and Germany. ESPE 2014 Dublin.

*163. Rami-Merhar B, Maahs D, Warner J, Hofer S, Tamborlane W, Hermann J, Icks A, Schatz D,

Foster N, Holl RW: Pump use is less frequent in minority youth: transatlantic analysis in

three large registries representing Austria, Germany, England, Wales and the United States.

Poster EASD 2014.

164. Fox LA, Mubasher M, Buckingham BA, Peters AL, Tamborlane WV, Schatz DA, Maahs

DM, Miller KM, Beck RW: A comparison of characteristics of youth with type 1 diabetes

(T1D) with and without a family history of T1D in the T1D Exchange clinic registry.

ISPAD, 2014.

165. Yoon YM, Wasserfall C, Lewis J, Haller M, Schatz D, Keselowsky B, Atkinson M.:

Prevention of Type 1 Diabetes in NOD mice with a Subcutaneous Tolerogenic Matrix

Containing Insulin. 12th International Immunology of Diabetes Society Conference,

Victoria, BC, Canada. 2014.

166. Wasserfall C, H. Nick, D. Beachy, I. Kusmartseva, T. Heiple, M. Campbell-Thompson, D.

Schatz, M. Atkinson: Unexpectedly Normal Proinsulin but Low Insulin and c-peptide in the

Pancreas of Type 1 Diabetes Subjects. IDS, 2015.

167. Campbell-Thompson, M, J.S. Kaddis, C. Wasserfall, M.J. Haller, A. Pugliese, D. Schatz, J.J.

Shuster, M.A. Atkinson: Reduced relative pancreas weights in organ donors with type 1 and

type 2 diabetes. IDS, 2015.

168. Posgai A, Wasserfall C, Atkinson M, Schatz D, Daniell H: Oral Delivery of a Novel Plant-

Derived Insulin and GAD Delays Type 1 Diabetes Onset in NOD Mice [abstract]. Diabetes

62 (suppl 1): A433-444, 2015.

169. Posgai A, Wasserfall C, Atkinson M, Schatz D, Kwon K, Daniell H: Short Course Oral

Therapy with Plant-Derived Autoantigens Delays Type 1 Diabetes Onset in NOD Mice.

(Abstract # 0198) Immunology of Diabetes Society (IDS). 2015

170. Posgai A, Wasserfall C, Atkinson M, Schatz D, Kwon K, Daniell H: Utilizing Oral

Combination Therapy with Plant-Expressed Proinsulin, GAD65, and Exendin 4 to Prevent

Type 1 Diabetes in NOD Mice. (Abstract #10316). Immunology of Diabetes Society (IDS).

2015.

171. Posgai A, Wasserfall C, Atkinson M, Schatz D, Kwon K, Daniell H: Utilizing Oral

Combination Therapy with Plant-Expressed Proinsulin, GAD65, and Exendin 4 to Prevent

Type 1 Diabetes in NOD Mice [abstract]. Diabetes 2015; 64 (suppl 1).

*172. Johnson SB, lynch KF, Baxter J, Roth R, Smith LB, Swartling U, Schatz D, The TEDDY

Study Group: Impact of child antibody results on parent anxiety in the environmental

determinants of diabetes in the young (TEDDY) study. ADA 75th Scientific Session, Boston

MA June 2015. Oral

*173. Walker AF, Schatz D, Johnson C, Parker K, Silverstein J, Lyles S, Rohrs H: Type 1

diabetes through two lenses: comparing adolescent and parental perspectives with

photovoice. ADA 75th Scientific Session, Boston MA June 2015. Oral

*174. Sherr JL, Ruedy KJ, Foster NC, Piche CA, Dulude H, Rickesl MR, Tamborlane WV, Bethin

KE, Dimeglio LA, Wadwa P, Fox LA, Schatz DA, Nathan BM, Marconvia SM, Beck RW:

Glucagon nasal powder: an effective alternative to intramuscular glucagon in youth with

type 1 diabetes. ADA 75th Scientific Session, Boston MA June 2015. Poster

Desmond A Schatz MD

60

*175. Nambam B, Haller MJ, Schatz DA, Shuster JJ, Williams JJ, Beegle R, Cintron M, Ferguson

J, Atkinson MA, Campbell-Thompson M: Is pancreas volume a marker of type 1 diabetes

progression? A preliminary report. ADA 75th Scientific Session, Boston MA June 2015.

Poster

*176. Vehik K, Lynch K, Akolkar B, Hagopian WA, Rewers M, She J, Simell OG, Toppari J,

Ziegler AG, Lernmark A, Schatz D, Bonifacio E, Krischer JP, The TEDDY study: GAD

autoantibody remission associated with risk of type 1 diabetes: TEDDY study. ADA 75th

Scientific Session, Boston MA June 2015. Poster

*177. Posgai, A, Wasserfall C, Atkinson MA, Schatz D, Kwon K, Daniell H: utilizing oral

combination therapy with plant-expressed proinsulin, GAD65, and exendin 4 to prevent type

1 diabetes in NOD mice. ADA 75th Scientific Session, Boston MA June 2015. Poster

*178. Michels AW, Boulware D, Beam CA, Marks JB, Schatz D, Dimeglio LA, Evans- Molina

C, Sosenko JM, Harrison LC, Palmer JP, Greenbaum CJ, Becker DJ, Steck A, Rodrigues H,

Gottlieb PA, Pugliese A: HLA-DR and DQ genes confer significant type 1 diabetes (T1D)

risk in single autoantibody-positive relatives. ADA 76th Scientific Session, New Orleans,

LA, June 2016. Oral

*179. Walker AF, Schatz D, Johnson C, Lyles S, Silverstein J, Rohrs H: Socioeconomic status

and the domestic allocation of Type 1 diabetes care. ADA 76th Scientific Session, New

Orleans, LA, June 2016. Poster

*180. Walker AF, Bell RA, Morris HL, Haller MJ, Shuster J, Shenkman B, Sun Y, Schatz D:

Healthecare utilization for publicly insure children with Type 1 Diabetes in Florida and

Texas. ADA 76th Scientific Session, New Orleans, LA, June 2016. Poster

*181. Jacobsen L, Haller MJ, Kaddis J, Wasserfall C, Levine RS, Campbell-Thompson M,

Pugliese A, Atkinson MA, Schatz D: Causes of death in the first 100 Type 1 Diabetes

(T1D) donors in the network for pancreatic organ donors with diabetes (nPOD). ADA 76th

Scientific Session, New Orleans, LA, June 2016. Poster

*182. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Baiming Z,

Brusko TM, Hulme M, Wasserfall CH, Perry D, Mathews CE, Atkinson MA, Schatz DA:

ADA 76th Scientific Session, New Orleans, LA, June 2016. Poster

*183. Lin A, Haller MJ, Atkinson MA, Mcgrail K, Schatz D, Brantly M, Mathews CE: Type 1

diabetes results in changes in neutrophils, but not neutron-philic enzymes. ADA 76th

Scientific Session, New Orleans, LA, June 2016. Poster

184. Morgan C, Sancho A, Hosford JL, Correa-Tapia M, Garcia-Hurtado J, Hansen T, Piemonti

L, Schatz D, Ferrer J: Circulating beta cell miRNAs and beta cell damage. HIRN 2016

185. Albanese-O’Neill A, Haller MJ, Bernier A, Schatz D: Mobile diabetes education for fathers

of youth with type 1 diabetes: mDAD ADA 77th Scientific Session, San Diego CA, June

2017. Oral

186. Westen SC, Sanders K, Warnick J, Gillen S, Albanese-O’Neill A, Haller MJ, Schatz D,

Janicke D: Parent fear of hypoglycemia predicts frequency of adolescent blood glucose

monitoring. ADA 77th Scientific Session, San Diego CA, June 2017. Poster

187. Walker AF, Schatz D, Rohrs H, Weinbrenner D, Shenkman E, Salazar K, Haller MJ:

Assessing the needs of publicly insure children with type 1 and type 2 diabetes in primary

care settings. ADA 77th Scientific Session, San Diego CA, June 2017. Poster

188. Shapiro ER, Wasserfall CH, McGrail SM, Haller MJ, Schatz DA, Atkinson MA, Brusko

TM: Diminished insulin-like growth factors in pre-type 1 diabetes. ADA 77th Scientific

Session, San Diego CA, June 2017. Poster

Desmond A Schatz MD

61

189. Jacobsen LM, Schatz DA, Filipp SL, Gurka MJ, Haller MJ, Atkinson MA, Campbell-

Thompson M: Islet autoantibodies are associated with insulitis but not eta cell loss in type 1

diabetes. ADA 77th Scientific Session, San Diego CA, June 2017. Oral

190. Morris H, Donahoo W, Bruggeman B, Zhong W, Schatz D: Development of a computable

phenotype for youth with Type 1 Diabetes. Amerian Public Heath Association (APHA).

Oral

191. Albanese-O’Neill, Beauchamp G, Thomas N, Schatz D, Haller MJ: Diabetes education for

young adults via telehealth is highly feasible. ICHP Research Day. April 2017. Poster

192. Morris H, Donahoo WT, Zhong W, Schatz DA: Development of a computable

phenotype for youth with Type 1 Diabetes. APHA’S 2018 Annual Meeting & Expo, San

Diego, CA. Nov 2018

193. Albanese-O’Neill A, Westen SC, Thomas NT, Haller MJ, Schatz D: It was all trial and

error- the perspective of parents of emerging adults with type 1 diabetes during the

transistion to independence. ADA 78th Scientific Session, Orlandonnual FL, June 2018.

Poster

194. Walker AF, Johnson C, Anez-ZabalaC, Dorvil SR, Haller MJ, Gurka MJ, Bruggeman BS,

Guiffre D, Atkinson MA, Schatz I, Schatz D: Content analysis of text messages in a type 1

diabetes peer mentoring program – the importance of shared interests. ADA 78th Scientific

Session, Orlando FL, June 2018. Poster

195. Warnick J, Westen SC, Albanes-O’Neill A, Schatz, D, Haller MJ, Janicke D: Examination

of accuracy of self-reported blood glucose using mHeath data collection.

ADA 78th Scientific Session, Orlando FL, June 2018. Poster

196. Westen SC, Warnick J, Entessari M, Albanese-O’Neill A, Schatz D, Haller MJ, Janicke

DM: Poor adherence in adolescents with Type 1 diabetes associated with distress, fear of

hypoglycemia, and executive functioning. ADA 78th Scientific Session, Orlando FL, June

2018. Poster

197. Walker AF, Haller MJ, Gurka MJ, Morris HL, Anez-Zabala C, Bruggeman BS, Guiffre D,

Rohrs III H, Atkinson MA, Schatz D: Promoting health equity in type 1 diabetes through

peer mentorship-finding from the ALL for One randomized controlled trial. ADA 78th

Scientific Session, Orlando FL, June 2018. Poster

198. Wood J, Boyle C, Qyinn M, Wong JC, Haller MJ, Nelson BA, Schatz D, Tamborlane WV,

Fox L, Prahalad P, Corathers S, Maahs DM, Alonso GT, Desalvo DJ, Wadwa RP, Dimeglio

L: Impact of target HbA1c change in pediatric participants in the T1D exchange clinic

registry. ADA 78th Scientific Session, Orlando FL, June 2018. Poster

199. Ross J, Wasserfall C, Perry DJ, McGrail KM, Posgai AL, Brusko TM, Schatz D, Haller MJ,

Atkinson MA: Exocrine pancreatic function as a novel biomarker in pre-T1D.

ADA 78th Scientific Session, Orlando FL June 2018. Poster

200. Jacobsen LM, Ismail HM, Clements MA, Schatz D, Sosenko J: Comparision of HbA1c and

index 60 thresholds for identifying autoantibody positive individuals at high risk for type 1

diabetes (T1D). ADA 78th Scientific Session, Orlando FL June 2018. Poster

201. Ismail HM, Sims EK, Geyer S, Redondo MJ, Evans-Molina C, Libman I, Dimeglio L,

Becker DJ, Palmer JP, Skyler JS, Krisher J, Schatz D, Pugliese A, Sosenko J: The influence

of parental type 1 diabetes (T1D) on the progression to T1D in autoantibody-positive

offspring. ADA 78th Scientific Session, Orlando, FL, June 2018. Poster

Desmond A Schatz MD

62

202. Thompson-Cambell M, Atkinson MA, Flipp SL, Gurka MJ, Beegle R, Schatz D. Haller MJ,

Type 1 Diabetes Study Group: Relative pancreas volume is reduced in autoantibody

negative first-degree relatives and subjects with pre-type 1 diabetes. ADA 78th Scientific

Session, Orlando, FL, June 2018. Poster

203. Shapiro M, Wasserfall C, Schultz AR, McGrail SM, Haller MJ, Schatz D, Atkinson MA,

Brusko TM: Insulin-like growth-factor axis collectively identifies pre-type 1 diabetes.

ADA 78th Scientific Session, Orlando, FL, June 2018. Poster

204. Russell J, Roesch L, Atkinson MA, Schatz D, Triplett EW, Ludvigsson J: Genetic risk for

type 1 diabetes profoundly influences the ocre gut microbiome in children. ADA 78th

Scientific Session, Orlando, FL, June 2018. Poster

205. Balzano L, Ramirez R, Zamkovaya T, Daley J, Ardissone A, Chamala S, Schatz D,

Atkinson M, Haller M, Concannon P, Triplett E, Conesa A: Multiblock integration of

transcripomics and metabolomics to study Type 1 Diabetes progression. Poster

PSGDREAM2018

206. Haller MJ, Greco MN, Schatz D, Atkinson MA, Brusko TM, Mathews CE, Jacobsen LM,

Herold KC, Gitelman SE, Krischer J, Bundy BN. Efficacy of new-onset Type 1 diabetes

(T1D) intervention trials: variation in 1-year outcomes. ADA 79th Scientific Session, San

Francisco, CA June 2019. Oral

207. Albanese-O’Neill A, Macinnes JW, Thomas NT, Haller MJ, Schatz D, Silverstein J, Adams

J, Oyetoro R, Kershaw BA, Anderson K, Bernier A. Validation of a clinically relevant

knowledge assessment in pediatric type 1 diabetes. ADA 79th Scientific Session, San

Francisco, CA June 2019. Poster

208. Westen SC, Anderson LM, Barry SA, Look S, Pinto S, Albanese-O’Neill A, Kemp CA,

Haller MJ, Papadakis JL, Schatz D, Olsen BT., Janicke DM, Weissberg-Benchell J, Johnson

N. Barriers and faciltators of participation in clinical trials among youth and young adults

with type 1 diabetes and their caregivers. ADA 79th Scientific Session, San Francisco, CA

June 2019. Poster

209. Bruggeman BS, Campbell-Thompson M, Posgai AL, Atkinson MA, Schatz D, Jacobsen

LM. Effect of substance use on type 1 diabetes (T1D) pancreas histopathology. ADA 79th

Scientific Session, San Francisco, CA June 2019. Poster

210. Jacobsen LM, Clements MA, Redondo MJ, Nathan BM, Schatz D, Sosenko JM.

Comparison of combined C-Peptide and glucose intermediate endpoints for identifying

individuals at very high risk for type 1 diabetes. ADA 79th Scientific Session, San

Francisco, CA June 2019. Poster

211. Lynch KF, Feng T, Qian X, Hagopian W, Lernmark A, Ziegler A, Toppari J, Rewers M, She

J, Schatz D, Akolkar B, Krisher J, Huang S, Vehik K. A rule-based discovery of gene-

environment interatctions on risk of islet autoimmunity TEDDY study. ADA 79th Scientific

Session, San Francisco, CA June 2019. Poster

Collaborative Authorship

TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study

Manuscripts)

1) * DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1).

Implementation of Screening and Staging of Relatives. Transplant Proc 27: 3377, 2015.

PMID: 8540003

Desmond A Schatz MD

63

2) * Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP, The

Diabetes Prevention Trial–Type 1 Study Group: Islet Cell Antibody-Positive Relatives With

Human Leukocyte Antigen DQA1*0102, DQB1*0602: Identification by the Diabetes

Prevention Trial-Type 1. J Clin Endocrinol Metab 85: 1255-1260, 2000. PMID: 10720072

3) * Greenbaum CJ, Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1

Diabetes Study Group: Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance

Test Criteria. Diabetes 50: 470-476, 2001. PMID: 11272162

4) * Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH,

Wilson DM, Wolfsdorf J, The Diabetes Prevention Trial–Type 1 Study Group: First-phase

Insulin Release During The Intravenous Glucose Tolerance Test As A Risk Factor For Type

1 Diabetes. J Pediatr 138: 244-249, 2001. PMID: 11174623

5) * Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS,

Krischer JP, DPT-1 Participating Investigators: Expression of GAD65 and Islet Cell

Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With

Eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 50: 1735-1740, 2001. PMID:

11473032

6) * Diabetes Prevention Trial - Type 1 Diabetes Study Group: Effects of Insulin in Relatives of

Patients with Type 1 Diabetes Mellitus. N Engl J Med 346: 1685-1691, 2002. PMID:

12037147

7) * Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators:

Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) Autoantibodies by

Relationship to Proband. Ann N Y Acad Sci 958: 254-258, 2002. PMID: 12021118

8) * Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz

DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial–Type 1 Study Group:

Screening Strategies for the Identification of Multiple Antibody Positive Relatives of

Individuals with Type 1 Diabetes. J Clinl Endocrinol Metab 88: 103-108, 2003. PMID:

12519837

9) * Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS; on

behalf of the DPT-1 Study Group: Expression of Beta-Cell Autoimmunity Does Not Differ

Between Potential Dizygotic Twins and Siblings of Patients with Type 1 Diabetes. J

Autoimmun 3: 275-279, 2004. PMID: 15501398

10) * Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group:

Male Sex Increases the Risk of Autoimmunity But Not Type 1 Diabetes. Diabetes Care

27:1985-1990, 2004. TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes

Ancillary Study Manuscripts). PMID: 15277428

11) Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM,

Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-Peptide is the Appropriate Outcome

Measure for Type 1 Diabetes Clinical Trials to Preserve Beta-Cell Function: Report of an

ADA Workshop. Diabetes 53:250-264, 2004. PMID: 14693724

12) Lachin JM: The Role of Measurement Reliability in Clinical Trials. Clin Trials 1:553-566,

2004. PMID: 16279296

13) * Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T,

Wasserfall C, Cuthbertson D, Krischer J, DPT-1 Study Group: High Frequency of Abnormal

Glucose Tolerance in DQA1*0102/DQB1*0602 Relatives Identified as Part of the Diabetes

Prevention Trial – Type 1 Diabetes. Diabetologia 48:68-74, 2005. PMID: 15602651

Desmond A Schatz MD

64

14) * Diabetes Prevention Trial - Type 1 Diabetes Study Group: Effects of Oral Insulin in Relatives

of Patients with Type 1 Diabetes Mellitus. Diabetes Care 28:1068-1076, 2005. PMID:

15855569

15) * Rhodes, ET, Wolfsdorf, JI, Cuthbertson, DD, Feldman, HA, Ludwig, DS; Diabetes

Prevention Trial-Type 1 Study Group: Effect of Low-Dose Insulin Treatment on Body

Weight and Physical Development in Children and Adolescents at Risk for Type 1 Diabetes.

Diabetes Care 28: 1948-1953, 2005. PMID: 16043737

16) Lachin JM: Maximum Information Designs. Clin Trials 2: 453-464, 2005. PMID: 16315649

17) Lachin JM: A Review of Methods for Futility Stopping Based on Conditional Power. Stat

Med 24: 2747-2764, 2005. PMID: 16134130

18) * Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White

NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention

Trial-1 Study Group: Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes

Prevention Trial–Type 1. Diabetes Care 29: 643-649, 2006. PMID: 16505520

19) * Tsai EB, Sherry NA, Palmer JP, Herold KC, and the DPT-1 Study Group: The Rise and Fall

of Insulin Secretion in Type 1 Diabetes Mellitus. Diabetologia 49: 261-270, 2006. PMID:

16404554

20) * Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D,

Eisenbarth GS, Krischer JP, Schatz D, and the DPT-1 Study Group: Specific HLA DQ

Influence on Expression of Anti-Islet Autoantibodies and Progression to Type 1 Diabetes. J

Clin Endocrinol Metab 91: 1705-1713, 2006. PMID: 16464953

21) Lachin JM: Operating Characteristics of Sample Size Re-estimation with Futility Stopping

Based on Conditional Power. Stat Med 25: 3348-3365, 2006. PMID: 16345019

22) * Barker JM, McFann K, Harrison LC, Fourlanos S, Krischer JP, Cuthbertson D, Chase HP,

Eisenbarth GS, and the DPT-1 Study Group: Pre-Type 1 Diabetes Dysmetabolism: Maximal

sensitivity achieved with both Oral and Intravenous Glucose Tolerance Testing. J Pediatr

150:31-36, 2007. TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes

Ancillary Study Manuscripts) PMID: 17188609

23) * Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White

NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention

Trial-1 Study Group: Increasing the Accuracy of Oral Glucose Tolerance Testing and

Extending its Application to Individuals with Normal Glucose Tolerance for the Prediction of

Type 1 Diabetes: the Diabetes Prevention Trial- Type 1. Diabetes Care 30: 38-42, 2007.

PMID: 17192330

24) * Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group: Effect of Oral

Insulin on Insulin Autoantibody Levels in the Diabetes Prevention Trial Type 1 Oral Insulin

Study. Diabetologia 50: 1603-1606, 2007. PMID: 17583798

25) * Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-

Type 1 Study Group: The Role of Insulin Resistance in Predicting the Progression to Type 1

Diabetes. Diabetes Care 30: 2314–2320, 2007. PMID: 17536068

26) * Johnson SB, Baughcum AE, Hood K, Rafkin-Mervis LE, Schatz, DA, for the DPT-1 Study

Group: Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes

Prevention Trial for Type 1 Diabetes. Diabetes Care 30: 2193–2198, 2007. PMID: 17563348

27) Lachin JM, Younes N: A Composite Design for Transition from a Preliminary to a Full-Scale

Study. Stat Med 26: 5014–5032, 2007. PMID: 17577245

Desmond A Schatz MD

65

28) * Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D,

Lachin JM, Skyler JS, and the Diabetes Prevention Trial-1 Study Group: A Risk Score for

Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes Prevention

Trial-Type 1. Diabetes Care 31: 528-533, 2008. PMID 18000175

29) * Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler

JS, and the DPT-1 Study Group: Glucose and C-peptide Changes in the Perionset Period of

Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 31: 2188-2192,

2008. PMID 18650369, PMCID: PMC2571043

30) * Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study

Group: Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in

at-risk individuals of the DPT1 trial. Diabetes 57: 2348-2359, 2008. PMID 18556337,

PMCID: PMC2518486

31) * Sherr J, Sosenko J, Skyler JS, Herold K: Prevention of Type 1 diabetes. The Time Has Come.

Nat Clin Pract Endocrinol Metab 4: 334-343, 2008. PMID 18446141

32) Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and

the Type 1 Diabetes TrialNet Study Group: Type 1 Diabetes TrialNet – An International

Collaborative Clinical Trials Network. Ann N Y Acad Sci 1150: 14-24, 2008. PMID

19120262, PMCID: PMC2918900, NIHMS225039

33) Skyler JS and the Type 1 Diabetes TrialNet Study Group: Update on Worldwide Efforts to

Prevent Type 1 Diabetes. Ann N Y Acad Sci 1150: 190-196, 2008. PMID 19120293, PMCID:

PMC2928677, NIHMS225042 TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15

(Includes Ancillary Study Manuscripts)

34) Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, Battelino T, Haastert B,

Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research

Group and The European C-peptide Trial Study Group: Mixed-Meal Tolerance Test Versus

Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in

Type 1 Diabetes. Diabetes Care 31: 1966-1971, 2008. PMID 18628574, PMCID:

PMC2251636.

35) * Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group:

Participant and Parent Experiences in the Oral Insulin Study of the Diabetes Prevention Trial

for Type 1 Diabetes. Pediatr Diabetes 10: 177-183, 2009. PMID 18823410, PMCID: PMC

4206940

36) * Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum

CJ, Cowie CC, Skyler JS, and the DPT-1 Study Group: Incident Dysglycemia and the

Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1.

Diabetes Care 32: 1603-1607, 2009. PMID 19487644, PMCID: PMC2732147

37) * Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group: Diabetic subjects diagnosed

through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal

A1C at diabetes onset. Diabetes Care 32: 769-773, 2009. PMID 19407074*, PMCID:

PMC2671125

38) * Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP,

Schatz D, Eisenbarth G, and the DPT-1 Study Group: Pancreatic Islet Cell Autoantibodies as

Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes

Care 32: 2269-2274, 2009. PMID 19741189, PMCID: PMC2782989

39) Mahon J, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C,

Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet

Desmond A Schatz MD

66

Natural History Committee and Type 1 Diabetes TrialNet Study Group: The TrialNet Natural

History Study of the Development of Type 1 Diabetes: Objectives, Design, and Initial

Results. Pediatr Diabetes 10:97-104, 2009. PMID 18823409

40) Chase HP, Leschek E, Rafkin-Mervis L, Krause-Steinrauf H, Chritton S, Asare SM, Adams

S, Skyler JS, Clare-Salzler M, and the Type 1 Diabetes TrialNet NIP Study Group:

Nutritional Intervention to Prevent (NIP) Type 1 Diabetes; A Pilot Trial. ICAN: Infant, Child,

& Adolescent Nutrition 1:98-107, 2009.

41) Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R,

Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz D, Wherrett

D, Wilson DM, Lachin JM, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study

Group: Rituximab, B-lymphocyte Depletion and Preservation of Beta-cell Function. N Engl J

Med 361: 2143-2152, 2009. PMID 19940299

42) Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb P, Reijonen H,

Arif S, Spain LM, Thompson C, Lachin JM, and The Type 1 Diabetes TrialNet Research

Group: Validity and Reproducibility of Measurement of Islet Autoreactivity by T-cell Assays

in Subjects with Early Type 1 Diabetes. Diabetes 58: 2588-2595, 2009. PMID 19675135,

PMCID: PMC2768166 TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes

Ancillary Study Manuscripts)

43) Bingley PJ, Matthews CL: Type 1 Diabetes TrialNet: Working Together to Prevent, Delay or

Slow the Progression of Type 1 Diabetes. Pract Diab Int 27: 98-99, 2010.

44) * Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth

GS, Skyler JS, and the DPT-1 Study Group: Trends of Earlier and Later Responses of C-

Peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in Diabetes

Prevention Trial-Type 1 Participants. Diabetes Care 33: 620-625, 2010. PMID 20032282,

PMCID: PMC2827520

45) * Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, for the DPT-1 Study Group.

Progression to Diabetes in Relatives of Patients with Type 1 Diabetes: Mechanisms and

Mode of Onset. Diabetes 59:679-685, 2010. PMID 20028949, PMCID: PMC2828663

46) Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H,

Schatz DA, Moran AM, Lachin JM, Skyler JS, and the TrialNet MMF/DZB Study Group:

Failure to Preserve Beta-Cell Function with Mycophenolate Mofetil and Daclizumab

Combined Therapy in Patients with New Onset Type 1 Diabetes. Diabetes Care 33: 826-832,

2010. PMID 20067954, PMCID: PMC2845036

47) * Sosenko J, Skyler J, Krischer J, Greenbaum C, Mahon J, Rafkin-Mervis L, Cuthbertson D,

Cowie C, Herold K, Eisenbarth G, Palmer J, the Diabetes Prevention Trial-1 Study Group:

Glucose Excursions between States of Glycemia with Progression to Type 1 Diabetes in the

Diabetes Prevention Trial Type 1 (DPT-1). Diabetes 59: 2386-2389, 2010. PMID 20682683,

PMCID: PMC3279560

48) * Xu P, Wu Y, Zhu Y, Dagne G, Johnson G, Cuthbertson D, Krischer J, Skyler J, Sosenko J,

and the Diabetes Prevention Trial-1 Study Group: Prognostic Performance of Metabolic

Indexes in Predicting Onset of Type 1 Diabetes. Diabetes Care 33: 2508-2513, 2010. PMID

20807869, PMCID: PMC2992179

49) Petrich de Marquesini LG, Fu J, Connor KJ, Bishop AJ, McLintock NE, Pope C, Wong FS,

Dayan CM: IFN-gamma and IL-10 Islet-Antigen-Specific T Cell Responses in Autoantibody-

Negative First-Degree Relatives of Patients with Type 1 Diabetes. Diabetologia 53:1451–

1460, 2010. PMID 20369219, (TrialNet Ancillary Study)

Desmond A Schatz MD

67

50) Grayson BL, Smith ME, Thomas JW, Wang L, Dexheimer P, Jeffrey J, Fain PR, Nanduri P,

Eisenbarth GS, Aune TM: Genome-Wide Analysis of Copy Number Variation in Type 1

Diabetes. Plos One 5: e15393, 2010. PMID 21085585, PMCID: PMC2981564, (TrialNet

Ancillary Study)

51) * Sosenko JM, Mahon J, Rafkin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer JP,

Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, the Diabetes Prevention

Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups: A Comparison

of the Baseline Metabolic Profiles Between Diabetes Prevention Trial-Type 1 and TrialNet

Natural History Study Participants. Pediatric Diabetes 12: 85-90, 2011. PMID 20522170,

NIHMS213978, PMCID: PMC2955175 TrialNet and DPT-1 Published Manuscripts - Rev.

6/17/15 (Includes Ancillary Study Manuscripts)

52) * Greenbaum CJ, McCulloch-Olson M, Chiu HK, Palmer JP, Brooks-Worrell B: Parenteral

Insulin Suppresses T Cell Proliferation to Islet Antigens. Pediatric Diabetes 12: 150-155,

2011. PMID 20522167, NIHMS213975, PMCID: PMC2957543

53) * Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J, the DPT-

1 Study Group: Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for

Repeat Screening Throughout Childhood. Diabetes Care 34: 358-362, 2011. PMID

21270193, PMCID: PMC3024349

54) * Greenbaum CJ, Buckingham B, Chase HP, Krischer J. Metabolic Tests to Determine Risk for

Type 1 Diabetes in Clinical Trials. Diabetes Metab Res Rev 27: 584-589, 2011. PMID

21488143, NIHMS287843, PMCID: PMC3162108

55) * Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, on behalf of the

DPT-1 & TrialNet Study Groups. Long Term Outcome of Individuals Treated with Oral

Insulin: Diabetes Prevention Trial-Type 1 (DPT-1) Oral Insulin Trial. Diabetes Care 34:

1585-1590, 2011. PMID: 21610124, PMCID: PMC3120180

56) * Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ,

Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial –

Type 1 Study Groups: The Validation of the Diabetes Prevention Trial-Type 1 Risk Score

and the Detection of Pre-Diabetes in the TrialNet Natural History Study. Diabetes Care 34:

1785-1787, 2011. PMID: 21680724, PMCID: PMC3142063

57) Orban T, Bundy B, Becker DJ, DiMeglio L, Gitelman SE, Goland R, Gottlieb PA,

Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Raskin P, Rodriguez H, Russell WE,

Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet

Abatacept Study Group: Co-Stimulation Modulation with Abatacept in Patients with Recent-

Onset Type 1 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. Lancet 378:

412-419, 2011. PMID 21719096, PMCID PMC3462593, NIHMS315090

58) Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP

for the TrialNet Natural History Study Group: Development of Autoantibodies in the

TrialNet Natural History Study (NHS). Diabetes Care 34:1897-1901, 2011. PMID 21750277,

PMCID: PMC3161292

59) Wherrett D, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,

Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Raskin P, Rodrigues

H, Schatz D, Wilson DM, Krischer JP, Skyler JS, the TrialNet GAD Study Group: Antigen-

Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in Patients with Recent-

Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. Lancet 378: 319-

327, 2011. PMID 21714999, PMCID: PMC3580128, NIHMS315091

Desmond A Schatz MD

68

60) Herold K, Pescovitz M, McGee P, Krause-Steinrauf H, Spain L, Bourcier K, Asare A, Liu Z,

Lachin J, Dosch HM, for the Type 1 Diabetes TrialNet Study Group: Increased T Cellular

Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20

Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. J Immunology 187: 1998-

2005, 2011. PMID 21775681, PMCID: PMC3150302, NIHMS303803 TrialNet and DPT-1

Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study Manuscripts)

61) Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, Type

1 Diabetes TrialNet Anti-CD20 Study Group: Rituximab Selectively Suppresses Specific

Islet Antibodies. Diabetes 60: 2560-2565, 2011. PMID 21831969, PMCID: PMC3178300.

62) * Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T,

Eisenbarth G, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups:

A Longitudinal Study of GAD65 and ICA512 Autoantibodies during the Progression to Type

1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. (Brief Report) Diabetes

Care 34: 2435-2437, 2011. PMID 21911777, PMCID: PMC3198298

63) Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer JP, Winter WE, Skyler JS,

Krischer JP and the Type 1 Diabetes TrialNet Study Group: Comparison of Two Insulin

Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies.

Clin Chim Acta 412: 2128-2131, 2011. PMID 21843518, PMCID: PMC3150302,

NIHMS303803

64) Pescovitz M, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin

JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A, the Type 1 Diabetes

TrialNet Study Group: Effect of Rituximab on Human In Vivo Antibody Immune Responses.

J Allergy Clin Immunol 128:1295-1302, 2011.e5, PMID 21908031, PMCID: PMC3659395

65) Lachin J, Friedenberg-McGee P, Greenbaum CJ, Spain L, Palmer J, Pescovitz MD, Gottlieb

P, Skyler J, for the Type 1 Diabetes TrialNet Study Group: Sample Size Requirements for

Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. PLOS

One 6(11): e26471, 2011. PMID 22102862, PMCID: PMC3213096

66) Yu L, Boulware DC, Beam CA, John C. Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley

PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL for the Type 1 Diabetes

TrialNet Study Group: Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1

Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care

35: 1213-1218, 2012. PMID 22446173, PMCID: PMC3357246

67) * Sosenko JM, Skyler JS, Herold KC, Palmer JP: The Metabolic Progression to Type 1

Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention

Trial-Type 1. Diabetes 61: 1331-1337, 2012. PMID 22618768, PMCID: PMC3357303

68) Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM,

McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1

Diabetes TrialNet Study Group: Fall in C-peptide Over First Two Years from Diagnosis:

Evidence of At Least Two Distinct Phases from Composite TrialNet Data. Diabetes 61:

2066-2073, 2012. PMID 22688329, PMCID: PMC3402330

69) * Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ,

Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, The TrialNet and Diabetes Prevention Trial-

Type 1 Study Groups: The Application of the Diabetes Prevention Trial Risk Score TrialNet

and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study Manuscripts)

meeting (DPTRS) for Identifying a Pre-Clinical State of Type 1 Diabetes. Diabetes Care 35:

1552-1555, 2012. PMID 22547092, PMCID: PMC3379597

Desmond A Schatz MD

69

70) Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M,

Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-

Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups: Performance of HbA1c

as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care

35: 1821-1825, 2012. PMID 22699293, PMCID: PMC3425003

71) * Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP and the DPT-1 Study

Group: Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in

a High Risk Population - Receiver Operating Characteristic Analysis. Diabetes Care 35:

1975-1980, 2012. PMID 22787174, PMCID: PMC3447832

72) Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A,

Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA,

Bluestone JA, Buckner JH, Greenbaum CJ; for the Diabetes TrialNet and the Immune

Tolerance Network: Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes

Augments Tregs yet Transiently Impairs β-Cell Function. Diabetes 61: 2340-2348, 2012.

PMID 22721971, PMCID: PMC3425404

73) * Sajjadi SJ, Qian X, Zeng B: Network-Based Methods to Identify Highly Discriminating

Subsets of Biomarkers. 2012 IEEE International Workshop on Genomic Signal Processing

and Statistics (GENSIPS), “Data Mining and Modeling Methods in Next-Generation

Sequencing and Cancer Systems Biology”. Washington DC, December 2-4, 2012, IEEE

Xplore, 139-142.

74) * Adl AA, Qian X, Xu P, Vehik K, Krischer JP: Feature Ranking Based on Synergy Networks

to Identify Prognostic Markers in DPT-1. 2012 IEEE International Workshop on Genomic

Signal Processing and Statistics (GENSIPS), “Data Mining and Modeling Methods in Next-

Generation Sequencing and Cancer Systems Biology”. Washington DC, December 2-4, 2012,

IEEE Xplore, 66-69.

75) Alkanani AK, Rewers M, Waugh K, Barriga K, Gottlieb PA, Zipris D: Dysregulated Toll-like

Receptor-induced Interleukin-1β and Interleukin-6 Responses in Subjects at Risk for the

Development of Type 1 Diabetes. Diabetes 61: 2525-2533, 2012. PMID 22751696, PMCID:

PMC3447890, (TrialNet Ancillary Study)

76) Han DM, Cai X, Wen J, Matheson D, Skyler JS, Kenyon NS, Chen Z: Innate and Adaptive

Immune Gene Expression Profiles as Biomarkers in Human Type 1 Diabetes. Clin Exp

Immunol 170:131-138, 2012. PMID 23039883, PMCID: PMC3482359, (TrialNet Ancillary

Study)

77) Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A

for the Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group: Epstein Barr

& Other Herpesvirus Infections in Patients with Early Onset Type 1 Diabetics Treated with

Daclizumab & Mycophenolic Mofetil. Clinical Infectious Diseases 56: 248-254, 2013. PMID

23042974, PMCID: PMC3526252. TrialNet and DPT-1 Published Manuscripts - Rev.

6/17/15 (Includes Ancillary Study Manuscripts)

78) * Adl AA, Qian X, Xu P, Vehik K, Krischer JP: Feature Ranking Based on Synergy Networks

to Identify Prognostic Markers in DPT-1. EURASIP J Bioinform Syst Biol Sept 19, 2013:12.

PMID 24050757, PMCID PMC3849336.

79) Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ,

Herold KC, Marks JB, Sanda S, Raskin P, Schatz D, Wherrett DK, Wilson DM, Krischer JP,

Skyler JS, Pickersgill L, de Koning E, Ziegler A-G, Boehm B, Badenhoop K, Schloot N, Bak

JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H,

Desmond A Schatz MD

70

Mandrup-Poulsen T: Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two

Multicenter, Randomized Double-Masked, Placebo-Controlled Trials. Lancet 381: 1905-

1915, 2013. PMID 23562090, PMCID PMC3827771.

80) Kroll JL, Beam C, Li S, Viscidi R, Pescovitz M, Weinberg A, the Type 1 Diabetes TrialNet

Anti CD-20 Study Group: Reactivation of Latent Viruses in Individuals Receiving Rituximab

for New Onset Type 1 Diabetes. J Clin Virol 57: 115-119, 2013. PMID 23422292. PMCID:

PMC3640764, (TrialNet Ancillary Study)

81) Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Groups,

Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA,

Bremer AA, Slover R, Cantwell M: The Effects of Inpatient Hybrid Closed-Loop Therapy

Initiated within 1 Week of Type 1 Diabetes Diagnosis. Diabetes Technol Ther 15: 401-408,

2013. PMID 23570538, PMCID: PMC3643224.

82) Elding Larsson H, Jönsson I, Åke Lernmark Å, Ivarsson S, Radtke JR, Hampe CS and the

Diabetes Prediction in Skåne (DiPiS) and Type 1 Diabetes TrialNet studies: Decline in Titers

of Anti-Idiotypic Antibodies Specific to Autoantibodies to GAD65 (GAD65Ab) Precedes

Development of GAD65Ab and Type 1 Diabetes. Plos One 8(6): e65173, 2013. PMID

23785410. PMCID: PMC3681789, (TrialNet Ancillary Study)

83) * Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC,

Rafkin L, Schatz D, Eisenbarth G, the Type 1 Diabetes TrialNet and the Diabetes Prevention

Trial-Type 1 Study Groups: The Prediction of Type 1 Diabetes by Multiple Autoantibody

Levels and Their Incorporation into an Autoantibody Risk Score in Relatives of Type 1

Diabetes Patients. Diabetes Care 36: 2615-2620, 2013. PMID 23818528, PMCID: PMC

3747899.

84) Weinberg A, Boulware D, Dighero B, Orban T, for the Type 1 Diabetes Abatacept Study

Team: Effect of Abatacept on Immunogenicity of Vaccines in Individuals with Type 1

Diabetes. Vaccine 31: 4791-4794, 2013. PMID 23962535, PMCID: PMC3803163.

85) Krischer JP, the Type 1 Diabetes TrialNet Study Group: The Use of Intermediate Endpoints

in the Design of Type 1 Diabetes Prevention Trials. Diabetologia 56: 1919-1924, 2013.

PMID 23744306, PMCID: PMC3743228.

86) * Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE,

Matheson D, Herold KC, Palmer JP, and the Type 1 Diabetes TrialNet and the Diabetes

Prevention Trial-Type 1 Study Groups: Acceleration of the Loss of the First-Phase Insulin

Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1

Participants. Diabetes 62: 4179-4183, 2013. PMID 23863814, PMCID: PMC3837047.

TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study

Manuscripts)

87) Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA,

Bremer AA, Slover R, Tamborlane WV; Diabetes Research in Children Network (DirecNet)

and Type 1 Diabetes TrialNet Study Groups: Effectiveness of Early Intensive Therapy on

Beta-Cell Preservation in Type 1 Diabetes. Diabetes Care 36: 4030-4035, 2013. PMID

24130350, PMCID: PMC3836135.

88). McCarlie VW, Hartsfield Jr JK, Blum JS, Gonzalez-Cabezar C, Chin JR, Eckert GJ, Morford

L, Pescovitz M, Rodriguez H, Fontaina M, Gregory RL: Total IgA and IgA Reactivity to

Antigen I/II Epitopes in HLA-DRB1*04 Positive Subjects. Open J Immuol 3: 82-92, 2013.

PMID: 24386612, PMCID: PMC3875298 (TrialNet Ancillary Study)

Desmond A Schatz MD

71

89) Valle A, Giamporcaro GM, Scavini1 M, Stabilini A, Grogan P, Bianconi E, Sebastiani G,

Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini

S, Piemonti L, Marchetti P, Dotta F, Bosi E, Battaglia M: Reduced Circulating Neutrophils

Precedes and Accompanies Type 1 Diabetes. Diabetes 62: 2072-2077, 2013. PMID

23349491, PMCID: PMC3661622 (TrialNet Ancillary Study).

90) Pescovitz M, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottieb PA,

Marks JP, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM,

Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Anti-CD20 Study Group: B-

lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results. Diabetes

Care 37: 453-459, 2014. PMID 24026563, PMCID: PMC3898764.

91) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA,

Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; the

Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups: Use of the

Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the

Risk Classification of Type 1 Diabetes. Diabetes Care 37: 979-984, 2014. PMID 24550217,

PMCID: PMC3964487.

92) Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,

Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Russell WE, Schatz D, Wherrett

D, Wilson DM, Krischer JP, Skyler JS, the Type 1 Diabetes TrialNet Abatacept Study Group:

Costimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes:

Follow-up One Year After Cessation of Treatment. Diabetes Care 37: 1069-1075, 2014.

PMID 24296850, PMCID: PMC3964491.

93) * Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP, and the DPT-1 Study Group:

Distribution of C-Peptide and its Determinants in North American Children at Risk for Type

1 Diabetes. Diabetes Care 37: 1959-1965, 2014. PMID 24760262, PMCID: PMC4067394.

94) Max Andersen ML, Nielsen LB, Svensson J, Porksen S, Hougaard P, Beam C, Greenbaum C,

Becker D, Petersen JS, Hansen L, Mortensen HB: Disease Progression Among 446 Children

with Newly Diagnosed Type 1 Diabetes Located in Scandinavia, Europe and North America

during the Last 27 Years. Pediatric Diabetes 15: 345-354, 2014. PMID 24731251.

95) Beam CA, Gitelman SE, Palmer J and the Type 1 Diabetes TrialNet Study Group:

Recommendations for the Definition of Clinical Responders Diabetes 63: 3120-3127, 2014.

PMID 24722251, PMCID: PMC4141373

97) Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L,

Peakman M, and the Type 1 Diabetes TrialNet Abatacept Study Group: Reduction in CD4

Central Memory T-cell subset in Co-Stimulation Modulator Abatacept-Treated Patients with

Recent-Onset Type 1 Diabetes is Associated with Slower C-Peptide Decline. Diabetes 63:

3449-3457, 2014. PMID 24834977, PMCID: PMC4171657

98) Loechelt B, Green M, Gottlieb P, Blumberg E, Weinberg A, Quinlan S, Baden L, Marks J,

Type 1 Diabetes TrialNet: Screening and Monitoring of Infectious Complications when

Immunosuppression Agents are Studied in the Treatment of Autoimmune Disorders. J

Pediatric Infect Dis Soc 2014; June 26 Epub ahead of print, doi: 10.1093/jpids/piu055

accepted 5/14/14.

99) Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estominho M, Kronenberg-Versteeg D,

Bingley PJ, Todd JA, Guy C, Dunger DB, Powrie J, Willlcox A, Foulis AK, Richardson SJ,

de Rinaldis E, Morgan NG, Lorenc A, Peakman M: Blood and Islet Phenotypes Indicate

Desmond A Schatz MD

72

Immunological Heterogeneity in Type 1 Diabetes. Diabetes 63: 3835-3845, 2014. PMID

24939426. PMCID: PMC4207393 (available 11/1/15), (TrialNet Ancillary Study)

100) Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M: Analysis of Beta

Cell Death in Type 1 Diabetes by Digital Droplet PCR. Endocrinology 155: 3694-3698,

2014. PMID 25004096, PMCID: PMC4138562 (available 9/1/15), (TrialNet Ancillary Study)

101) Lin Y, Qian Xiaoning, Krischer J, Vehik K, Lee H-S, Huang S: A Rule-Based Prognostic

Model for Type 1 Diabetes by Identifying and Synthesizing Baseline Profile Patterns. PLOS

One 9: e91095, 2014. PMID 24926781 PMCID: PMC4057076.

102) Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J,

Skyler JS, Clare-Salzler M, Type 1 Diabetes TrialNet Nutritional Intervention to Prevent

(NIP) Type 1 Diabetes Study Group: Effect of Docosahexaenoic Acid (DHA)

Supplementation on Inflammatory Cytokine Levels in Infants at High Genetic Risk of Type 1

Diabetes. Pediatric Diabetes 16: 271-279, 2015. 2014; Jul 12, Epub ahead of print, PMID:

25039804, PMCID: PMC4291300 (available 6/1/16).

103) Smith MJ, Packard TA, O’Neill SK, Henry Dunand CJ, Huang M, Fitzgerald-Miller L,

Stowell D, Hinman RM, Wilson PC, Gottlieb PA, Cambier JC: Loss of Anergic B Cells in

Pre-diabetic and New Onset T1D Patients. Diabetes 64: 1703-1712, 2015. PMID: 25524915,

PMCID: PMC4407867 (available on 5/1/16), (TrialNet Ancillary Study)

104) Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D,

Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP, the Diabetes Type 1 TrialNet &

Diabetes Prevention Trial-Type 1 Study Groups: A New Approach for Diagnosing Type 1

Diabetes in Autoantibody Positive Relatives of Patients with Type 1 Diabetes Based on

Prediction & Natural History. Diabetes Care 38: 271-276, 2015. PMID 25519451, PMCID:

PMC4302258 (available 2/1/16). TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15

(Includes Ancillary Study Manuscripts)

105) Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J,

Rewers M, Yu L, and the Type 1 Diabetes TrialNet Study Group: Electrochemiluminescence

Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of

Type 1 Diabetes Risk. Diabetes Technol Ther 17: 119-127, 2015. PMID 25562486, PMID:

PMC4321773 (available 2/1/16), (TrialNet Ancillary Study)

106) Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M,

Sosenko JM, Krischer JP, Palmer JP, and the Type 1 Diabetes TrialNet Study Group: Beta

Cell Death and Dysfunction during Type 1 Diabetes Development in At-risk Individuals. J

Clin Invest 125: 1163-1173, 2015. PMID 25642774, PMCID: 4362259 (available 6/2/15),

(TrialNet Ancillary Study)

107) Valle A, Barbagiovanni G, Jofra T, Stabilini A, Perol L, Baeyens A, Anand Santosh, Cagnard

N, Nicola G, Piaggio E, Battaglia M: Heterogeneous CD3 Expression Levels in Differing T-

cell Subsets Correlate with the In Vivo Anti-CD3‒mediated T-cell Modulation. J Immunol

194: 2117-2127, 2015. PMID 25646305, PMCID: PMC in process. (TrialNet Ancillary

Study)

108) DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye Tandy, Weinzimer

SA, Bremer AA, Buckingham B for the Diabetes Research in Children Network (DirecNet)

and Type 1 Diabetes TrialNet Study Group: Changes in Beta Cell Function during the

Proximate Post-Diagnosis Period in Persons with Type 1 Diabetes. Pediatric Diabetes 2015;

Feb 27 Epub ahead of print. PMID 25720763, PMCID: PMC as supplied by publisher.

Desmond A Schatz MD

73

109) Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP: The Effect of the

DPT-1 Intravenous Insulin Infusion & Daily Subcutaneous Insulin on Endogenous Insulin

Secretion & Post-Prandial Glucose Tolerance. Diabetes Care 38: 891-896, 2015. PMID

25720600, PMCID: PMC4407749 (available 5/1/16).

110) Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ,

Rafkin LE, Matheson D, Herold KC, Palmer JP, The Diabetes Type 1 TrialNet and Diabetes

Prevention Trial-Type 1 Study Groups: The Development and Utility of a Novel Scale that

Quantifies the Glycemic Progression toward Type 1 Diabetes over Six Months. Diabetes

Care 38: 940-942, 2015. PMID 25758770, PMCID: PMC4407750 (available 5/1/16).

111) Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ, Type 1 Diabetes

TrialNet Study Group: Heterogeneity in Recent Onset Type 1 Diabetes – a Clinical Trial

Perspective. Diabetes Metab Res Rev 2015 Feb 17 Epub ahead of print. PMID 25689602,

PMCID: PMC as supplied by publisher.

112) * Ismail H, Krischer J, Chase HP, Cuthbertson D, Palmer J: First Test Effect in Intravenous

Glucose Tolerance Testing. Pediatric Diabetes 16: 129-137, 2015. (2013, Aug 15 Epub

ahead of print) PMID 23944770, PMCID: PMC3838455 (available 3/1/16).

113) Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R,

Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network

(DirecNet) and Type 1 Diabetes TrialNet Study Groups: CGM Measured TrialNet and DPT-1

Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study Manuscripts) Glucose

Values Have a Strong Correlation with C-peptide, A1c, and IDAAC, But Do Poorly in

Predicting C-peptide Levels in the Two Years Following Onset of Diabetes. Diabetologia 58:

1167-1174, 2015. PMID 25773405, PMCID: PMC4416994 (available 6/1/16).

114) Zipris D, Alkanani AK Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, Frank DN:

Alterations in Intestinal Microbiota Correlate with susceptibility to Type 1 Diabetes.

Accepted by Diabetes on May 29, 2015. Published TrialNet and DPT-1 Related Manuscripts

– Rev. 6/17/15

115) Skyler J, Ricordi C: Perspectives in Diabetes: Stopping Type 1 Diabetes: Attempts to Prevent

or Cure Type 1 Diabetes in Man. Diabetes 60: 1-8, 2011. PMID 21193733, PMCID:

PMC3012160.

116) Creusot RJ, Trucco M, Clare-Salzler MJ, Fathman CG: It’s Time to Bring Dendritic Cell

Therapy to Type 1 Diabetes. Diabetes 63: 20-30, 2014. PMID 24357690, PMCID:

PMC3968436.

117) Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM;

Type 1 Diabetes TrialNet Study Group: The shape of the glucose concentration curve during

an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 2017 Sep 27. doi:

10.1007/s00125-017-4453-6. [Epub ahead of print] PMID: 28956083

118) Sanda S; Type 1 Diabetes TrialNet Study Group: Increasing ICA512 autoantibody titers

predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 2017 Jul 14.

doi: 10.1111/pedi.12542. [Epub ahead of print] PMID: 28707353

119) Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C,

Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group:

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in

Type 1 Diabetes Relatives. J Clin Endocrinol Metab 102 (8): 2881-2886, 2017. doi:

10.1210/jc.2017-00569. PMID: 28531305

Desmond A Schatz MD

74

120) Steck AK, Xu P, Geyer S, Redondo MJ, Antinozzi P, Wentworth JM, Sosenko J, Onengut-

Gumuscu S, Chen WM, Rich SS, Pugliese A; Type 1 Diabetes TrialNet Study Group: Can

Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk

for Type 1 Diabetes? J Clin Endocrinol Metab 102 (8): 2873-2880, 2017. doi:

10.1210/jc.2016-4003. PMID: 28520980

121) Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L,

Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group: Use of self-collected capillary

blood samples for islet autoantibody screening in relatives: a feasibility and acceptability

study. Diabet Med 34 (7): 934-937, 2017. doi: 10.1111/dme.13338. Epub 2017 Mar 8. PMID:

28226181

122) Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ,

Rodriguez H, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group:

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

Diabetes Care 40 (5): 698-701, 2017. doi: 10.2337/dc16-2331. Epub 2017 Feb 15. PMID:

28202550

123) Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group. A model-based approach to

sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev 32 (8): 827-

834, 2016. doi: 10.1002/dmrr.2800. Epub 2016 Apr 21. PMID: 26991448

124) Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1

Diabetes TrialNet Study Group: GAD vaccine reduces insulin loss in recently diagnosed type

1 diabetes: findings from a Bayesian meta-analysis. Diabetologia 60 (1): 43-49, 2017. Epub

2016 Oct 4. PMID: 27704166

125) Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet

Study Group: The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and

Inflammation in Type 1 Diabetes Mellitus. J Immunol 197 (8): 3076-3085, 2016. Epub 2016

Sep 21. PMID: 27655844

126) Narsale A, Moya R, Robertson HK; Type 1Diabetes TrialNet Study Group, Davies JD: Data

on correlations between T cell subset frequencies and length of partial remission in type 1

diabetes. Data Brief 8: 1348-51, 2016. doi: 10.1016/j.dib.2016.07.059. eCollection 2016 Sep.

PMID:27579340

127) Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK;

Type 1 Diabetes TrialNet Study Group: Do Electrochemiluminescence Assays Improve

Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes

Care 39 (10): 1738-44, 2016. doi: 10.2337/dc16-0302. Epub 2016 Jul 25. PMID: 27456836

128) Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet

Study Group: Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes:

Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care 39 (10): 1664-70, 2016.

doi: 10.2337/dc16-0360. Epub 2016 Jul 15. PMID: 27422577

129) Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group: Prognostic Classification Factors

Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1

Diabetes-A Recursive Partitioning Analysis. Diabetes Care 39 (6): 1036-44, 2016. doi:

10.2337/dc15-2292. Epub 2016 Apr 12. PMID: 27208341

130) Moya R, Robertson HK, Payne D, Narsale A, Koziol J; Type 1 Diabetes TrialNet Study

Group, Davies JD: A pilot study showing associations between frequency of CD4(+) memory

cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol

166-167: 72-80, 2016. doi: 10.1016/j.clim.2016.04.012. Epub 2016 Apr 22. PMID:27114212

Desmond A Schatz MD

75

131) Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P,

Evans-Molina C; Type 1 Diabetes TrialNet Study Group: The relationship between BMI and

insulin resistance and progression from single to multiple autoantibody positivity and type 1

diabetes among TrialNet Pathway to Prevention participants. Diabetologia 59 (6): 1186-95,

2016. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19. PMID:26995649

132) Steck AK, Fouts A, Miao D, Zhao Z, Dong F, Sosenko J, Gottlieb P, Rewers MJ, Yu L;

TrialNet Study Group: ECL-IAA and ECL-GADA Can Identify High-Risk Single

Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes

Technol Ther 18 (7): 410-414, 2016. doi: 10.1089/dia.2015.0316. Epub 2016 Mar 18. PMID:

26991969

133) Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L,

Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko

JM; Type 1 Diabetes TrialNet Study Group: HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02

Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the

Stages of Disease Progression. Diabetes 2016 65(4): 1109-1119, 2016. doi: 10.2337/db15-

1105. Epub 2016 Jan 28. PMID: 26822082

134) Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes

TrialNet Canakinumab Study Group, Mandrup-Poulsen T; AIDA Study Group, Hessner MJ:

Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes

during clinical trials conducted at disease onset. Eur J Immunol 46 (4): 1030-1046, 2016. doi:

10.1002/eji.201546005. Epub 2016 Jan 21. PMID: 26692253

135) Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group: The

implications of autoantibodies to a single islet antigen in relatives with normal glucose

tolerance: development of other autoantibodies and progression to type 1 diabetes.

Diabetologia 59 (3): 542-549, 2016. doi: 10.1007/s00125-015-3830-2. Epub 2015 Dec 16.

PMID: 26676824

136) Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold

KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1

Diabetes TrialNet Study Group: Defining pathways for development of disease-modifying

therapies in children with type 1 diabetes: a consensus report. Diabetes Care 38 (10): 1975-

1985, 2015. doi: 10.2337/dc15-1429. Review. PMID:26404927

138) Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware

DC; TrialNet Study Group: Use of Dried Capillary Blood Sampling for Islet Autoantibody

Screening in Relatives: A Feasibility Study. Diabetes Technol Ther 17 (12): 867-871, 2015.

doi: 10.1089/dia.2015.0133. Epub 2015 Sep 16. PMID: 26375197

139) Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR; Type 1

Diabetes TrialNet Study Group: Screening and Monitoring for Infectious Complications

When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders. J

Pediatric Infect Dis Soc 4 (3): 198-204, 2015. doi: 10.1093/jpids/piu055. Epub 2014 Jun 26.

PMID: 26336066

140) DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye T, Weinzimer SA,

Bremer AA, Buckingham B; Diabetes Research in Children Network (DirecNet); Type 1

Diabetes TrialNet Study Group: Changes in beta cell function during the proximate post-

diagnosis period in persons with type 1 diabetes. Pediatr Diabetes 17 (4): 237-243, 2016.

doi: 10.1111/pedi.12271. Epub 2015 Feb 27. PMID: 25720763

Desmond A Schatz MD

76

141) Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes

TrialNet Study Group: Heterogeneity in recent-onset type 1 diabetes - a clinical trial

perspective. Diabetes Metab Res Rev 31 (6): 588-594, 2015. doi: 10.1002/dmrr.2643. Epub

2015 Apr 23. PMID:25689602

142) Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M,

Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group: β cell death and

dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 125 (3):

1163-1173, 2015. doi: 10.1172/JCI78142. Epub 2015 Feb 2. PMID:25642774

143) Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J,

Rewers M, Yu L; Type 1 Diabetes TrialNet Study Group: Electrochemiluminescence assays

for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1

diabetes risk. Diabetes Technol Ther 17 (2): 119-127, 2015. doi: 10.1089/dia.2014.0186.

Epub 2015 Jan 6. PMID:25562486

144) Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D,

Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study

Group; Diabetes Prevention Trial-Type 1 Study Group: A new approach for diagnosing type

1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Diabetes Care 38 (2): 271-276, 2015. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

PMID:25519451

145) Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J,

Skyler JS, Clare-Salzler M; Type 1 Diabetes TrialNet Nutritional Intervention to Prevent

(NIP) Type 1 Diabetes Study Group: Effect of docosahexaenoic acid supplementation on

inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr

Diabetes 16 (4): 271-279, 2015. doi: 10.1111/pedi.12170. Epub 2014 Jul 12. PMID:

25039804

146) Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L,

Peakman M; Type 1 Diabetes TrialNet Abatacept Study Group: Reduction in CD4 central

memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset

type 1 diabetes is associated with slower C-peptide decline. Diabetes 63 (10): 3449-3457,

2014. doi: 10.2337/db14-0047. Epub 2014 May 16. PMID: 24834977

147) Max Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum C,

Becker D, Petersen JS, Hansen L, Mortensen HB: Disease progression among 446 children

with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America

during the last 27 yr. Pediatr Diabetes. 15 (5): 345-354, 2014. doi: 10.1111/pedi.12098.

Epub 2013 Nov 25. PMID: 24731251

148) Beam CA, Gitelman SE, Palmer JP; Type 1 Diabetes TrialNet Study Group:

Recommendations for the definition of clinical responder in insulin preservation studies.

Diabetes 63 (9): 3120-7, 2014. doi: 10.2337/db14-0095. Epub 2014 Apr 10. PMID:

24722251

149) Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA,


D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept

Study Group: Costimulation modulation with abatacept in patients with recent-onset type 1

diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37 (4): 1069-75, 2014.

doi: 10.2337/dc13-0604. Epub 2013 Dec 2. PMID: 24296850

150) Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P,

Desmond A Schatz MD

77

Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group: A

type 1 diabetes genetic risk score predicts progression of islet autoimmunity and

development of type 1 diabetes in individuals at risk. Diabetes Care. 2018 Jul 12. pii:

dc180087. doi: 10.2337/dc18-0087. [Epub ahead of print] PMID: 30002199

151) Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study

Group: Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet

Autoimmunity and Type 1 Diabetes. Diabetes Care. 2018 Jul 30. pii: dc180288. doi:

10.2337/dc18-0288. [Epub ahead of print] PMID: 30061316

152) Sanda S, Type 1 Diabetes TrialNet Study Group. Increasing ICA512 autoantibody titers

predict development of abnormal oral glucose tolerance. Pediatr Diabetes. 19 (2): 271-276,

2018. doi: 10.1111/pedi.12542. Epub 2017 Jul 14.

TEDDY Publications

1) Hagopian W, Lernmark Å, Rewers M, Simell O, She JX, Ziegler A, Krischer J, Akolkar B:

TEDDY – The Environmental Determinants of Diabetes in the Young – An Observational

Clinical Trial. Annals of the New York Academy of Science, Volume: Immunology of Diabetes

IV: Progression in Understanding 1079: 320-326, 2006. doi: 10.1196/annals.1375.049

PMID: 17130573

2) Peng H, Hagopian W: Environmental Factors in the Development of Type 1 Diabetes.

Reviews in Endocrine & Metabolic Disorders 7 (3):149-162, 2006. doi: 10.1007/s11154-006-

9024-y PMID: 17203405

3) The TEDDY Study Group: The Environmental Determinants of Diabetes in the Young

(TEDDY) Study: Study Design. Pediatric Diabetes 8(5): 286-298, 2007. doi:

10.1111/j.1399-5448.2007.00269.x PMID: 17850472

4) Kiviniemi M, Hermann R, Nurmi J, Ziegler A, Knip M, Simell O, Veijola R, Lövgren T,

Ilonen J and the TEDDY Study Group: A High Throughput Population Screening System for

the Estimation of Genetic Risk for Type 1 Diabetes - An Application for the TEDDY (The

Environmental Determinants of Diabetes in the Young) Study. Diabetes Technology and

Therapeutics 9 (5): 460-472, 2007. doi: 10.1089/dia.2007.0229 PMID: 17931054

5) Moyers S, Richesson RL, Krischer J: Trans-Atlantic Data Harmonization in the Classification

of Medicines and Dietary Supplements: A Challenge for Epidemiologic Study and Clinical

Research. International Journal of Medical Informatics 77 (1): 58-67, 2008. doi:

10.1016/j.ijmedinf.2006.12.003 Epub 2007 Feb 7. PubMed ID: 17289429, PubMed Central

ID: PMC2259273

6) TEDDY Study Group: The Environmental Determinants of Diabetes in the Young (TEDDY)

Study. Annals of the New York Academy of Science. Volume: Immunology of Diabetes V

1150: 1-13, 2008. doi: 10.1196/annals.1447.062 PubMed ID: 19120261; PubMed Central

ID: PMC2886800

7) Richesson RL, Smith S, Malloy J, Krischer J: Achieving Standardized Medication Data in

Clinical Research Studies: Two Approaches and Applications for Implementing RxNorm.

Journal of Medical Systems 34 (4): 651-657, 2010. doi: 10.1007/s10916-009-9278-5. Epub

2009 Apr 3. PMID: 20703919; PubMed Central ID: PMC2977947

8) Dantonio P, Meredith-Molloy N, Hagopian W, She J, Akolkar B, Cordovado S, Hendrix M,

Henderson L, Hannon W, Vogt R: Proficiency Testing of Human Leukocyte Antigen-DR and

Human Leukocyte Antigen-DQ Genetic Risk Assessment for Type 1 Diabetes Using Dried

Desmond A Schatz MD

78

Blood Spots. Journal of Diabetes Science and Technology 4 (4): 929-941, 2010. doi:

10.1177/193229681000400424. PMID: 20663459; PubMed Central ID: PMC2909527

9) Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K,

Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization

of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National

Institute of Diabetes and Digestive and Kidney Diseases Consortia. Journal of Clinical

Endocrinology & Metabolism 95 (7): 3360-3367, 2010. doi: 10.1210/jc.2010-0293. Epub

2010 May 5. PMID: 20444913; PubMed Central ID: PMC2928900

10) Johnson SB, Lee H-S, Baxter J, Lernmark B, Roth R, Simell T, for the TEDDY Study

Group: The Environmental Determinants of Diabetes in the Young (TEDDY) Study:

Predictors of Early Study Withdrawal Among Participants with No Family History of Type 1

Diabetes. Pediatric Diabetes 12 (3 Pt 1): 165-171, 2011. doi: 10.1111/j.1399-

5448.2010.00686.x. Epub 2010 Oct 28. PMID: 21029290; PubMed Central ID:

PMC3032020

11) Ziegler AG, Pflueger M, Winkler C, Achenbach P, Akolkar B, Krischer J, and Bonifacio E:

Accelerated Progression from Islet Autoimmunity to Diabetes is Causing the Escalating

Incidence of Type 1 Diabetes in Young Children. Journal of Autoimmunity 37 (1): 3-7, 2011.

doi: 10.1016/j.jaut.2011.02.004. Epub 2011 Mar 3. PMID: 21376535; PubMed Central ID:

PMC3110538

12) Sterner Y, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Schatz D, Lernmark Å for

the TEDDY Study Group: Country-specific birth weight and length in type 1 diabetes high-

risk HLA genotypes in combination with prenatal characteristics. Journal of Perinatology 31

(12): 764-769, 2011. doi: 10.1038/jp.2011.26. Epub 2011 Apr 28. PMID: 21527903; PubMed

Central ID: PMC3226663

13) Hagopian W, Erlich H, Lernmark Å, Rewers M, Ziegler AG, Simell O, Akolkar B, Vogt R,

Blair A, Ilonen J, Krischer J, and She JX: The Environmental Determinants of Diabetes in the

Young (TEDDY): Genetic Criteria and International Diabetes Risk Screening of 421,000

infants. Pediatric Diabete. 12 (8): 733-743, 2011. doi: 10.1111/j.1399-5448.2011.00774.x.

Epub 2011 May 12. PMID: 21564455; PubMed Central ID: PMC3315186

14) Lernmark B, Johnson SB, Vehik K, Smith L, Ballard L, Baxter J, McLeod W, Roth R,

Simell T, on behalf of the TEDDY Study Group: Enrollment Experiences in a Pediatric

Longitudinal Observational Study: The Environmental Determinants of Diabetes in the

Young (TEDDY) Study. Contemporary Clinical Trials 32 (4): 517-23, 2011. doi:

10.1016/j.cct.2011.03.009. Epub 2011 Mar 17. PMID: 21419878; PubMed Central ID:

PMC3118988

15) Norris JM: Infant and Childhood Diet and Type 1 Diabetes Risk: Recent Advances and

Prospects. Current Diabetes Reports 10 (5): 345-349, 2010. doi: 10.1007/s11892-010-0131-5

PMID: 20640941

16) Uusitalo U, Kronberg-Kippilä C, Aronsson CA, Schakel S, Schoen S, Mattisson I, Reinivuo

H, Silvis K, Sichert-Hellert W, Stevens M, Norris JM, Virtanen SM, and the TEDDY Study

Group: Food Composition Database Harmonization for Between Country Comparisons of

Nutrient Data in the TEDDY Study. Journal of Food Composition and Analysis 24 (4-5):

494-505, 2011. doi: 10.1016/j.jfca.2011.01.012 PMID: 22058606; PubMed Central ID:

PMC3205351

17) Larsson HE, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C, Knip M, Veijola R, Lindblad

B, Samuelsson U, Holl R, Haller MJ, on behalf of the TEDDY Study Group, SEARCH Study

Desmond A Schatz MD

79

Group, Swediabkids Study Group, DPV Study Group, and Finnish Diabetes Registry Study

Group: Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in

Young Children Participating in Longitudinal Follow-up. Diabetes Care 34 (11): 2347-2352,

2011. doi: 10.2337/dc11-1026. Epub 2011 Oct 4. PMID: 21972409; PubMed Central ID:

PMC3198296

18) Gesualdo P, Ide L, Rewers M, Baxter J: Effectiveness of an Informational Video Method to

Improve Enrollment and Retention of a Pediatric Cohort. Contemporary Clinical Trials 33

(2): 273-278, 2012. doi: 10.1016/j.cct.2011.11.010. Epub 2011 Nov 12. PMID: 22101229;

PubMed Central ID: PMC3268864

19) Baxter J, Vehik K, Johnson SB, Lernmark B, Roth R, Simell T, and the TEDDY Study

Group: Differences in Recruitment and Early Retention Among Ethnic Minority Participants

in a Large Pediatric Cohort: The TEDDY Study. Contemporary Clinical Trials 33 (4): 633-

640, 2012. doi: 10.1016/j.cct.2012.03.009. Epub 2012 Mar 29. PMID: 22484339; PubMed


20) Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M,

Rewers MJ, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial–

Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups: Performance of HbA1c

as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care 35

(9): 1821-1825, 2012. Epub 2012 Jun 14. PMID: 22699293; PubMed Central ID:

PMC3425003

21) Lernmark B, Lynch K, Ballard L, Baxter J, Roth R, Simell T, Johnson S, and the TEDDY

Study Group: Reasons for staying as a participant in The Environmental Determinants of

Diabetes in the Young (TEDDY) longitudinal study. Journal of Clinical Trials Epub 2012

Jun 11; 2(2). doi: 10.4172/2167-0870.1000114. PMID: 23894727; PubMed Central ID:

PMC3723141

22) Salami F, Ländin M, Hyöty H, Vaziri-Sani F, Aronsson CA, Vehik K, Delli AJ, Hagopian

WA, Rewers M, Ziegler AG, Simell O, Akolkar B, Krischer JP, She JX, Lernmark A, and

TEDDY Study Group: Detection of Lactobacilli in monthly mail-in stool samples from 3-18

months old infants at genetic risk for type 1 diabetes. International Journal of Prebiotics and

Probiotics 7 (3-4): 135-144, 2012. PMID: 25045339; PubMed Central ID: PMC4101081

23) Aronsson CA, Vehik K, Yang J, Uusitalo U, Hay K, Joslowski G, Riikonen A, Ballard L,

Virtanen SM, Norris JM, on the behalf of the TEDDY Study Group: Use of dietary

supplements in pregnant women in relation to sociodemographic factors - a report from the

TEDDY-study. Public Health Nutrition 16 (8): 1390-1402, 2013. doi:

10.1017/S1368980013000293. Epub 2013 Mar 4. PMID: 23452986; PubMed Central ID:

PMC4112516

24) Nokoff N, Rewers M: Pathogenesis of type 1 diabetes: lessons from natural history studies of

high-risk individuals. Annals of the New York Academy of Sciences 1281: 1-15, 2013. doi:

10.1111/nyas.12021. Epub 2013 Jan 29. PMID: 23360422; PubMed Central ID:

PMC3715099

25) Eringsmark Regnéll S, Lernmark A: The environment and the origins of islet autoimmunity

and Type 1 diabetes. Diabetic Medicine 30 (2): 155-160, 2013. doi: 10.1111/dme.12099

PMID: 23252770; PubMed Central ID: PMC3552102

26) Lee HS, Briese T, Winkler C, Rewers M, Bonifacio E, Hyoty H, Pflueger M, Simell O, She

JX, Hagopian W, Lernmark A, Akolkar B, Krischer J, Ziegler AG, and the TEDDY Study

Group: Next-generation sequencing for viruses in children with rapid onset type 1 diabetes.

Desmond A Schatz MD

80

Diabetologia 56 (8): 1705-1711, 2013. doi: 10.1007/s00125-013-2924-y. Epub 2013 May 9.


27) Vehik K, Fiske SW, Logan CA, Agardh D, Cilio CM, Hagopian W, Simell O, Roivainen M,

She JX, Briese T, Oikarinen S, Hyoty H, Ziegler AG, Rewers M, Lernmark A, Akolkar B,

Krischer J, Burkhardt BR, and the TEDDY Study Group: Methods, Quality Control and

Specimen Management in an International Multi-Center Investigation of Type 1 Diabetes:

TEDDY. Diabetes/Metabolism Research and Reviews 29 (7): 557-567, 2013. doi:

10.1002/dmrr.2427 PMID: 23674484; PubMed Central ID: PMC3992860

28) Larsson HE, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, Lernmark A, Rewers

M, Simell O, She JX, Ziegler AG, Rewers M, and the TEDDY Study Group: Children

followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease.

Pediatric Diabetes 15 (2): 118-126, 2014. doi: 10.1111/pedi.12066. Epub 2013 Aug 27.


29) Aronsson CA, Uusitalo U, Vehik K, Yang J, Silvis K, Hummel S, Virtanen SM, Norris JM,

and the TEDDY Study Group: Age at first introduction to complementary foods is associated

with sociodemographic factors in children with increased genetic risk of developing type 1

diabetes. Maternal and Child Nutrition Epub 2013 Sept 13. doi: 10.1111/mcn.12084 PMID:

24034553; PubMed Central ID: PMC4122645

30) Smith LB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, Johnson SB, and the TEDDY

Study Group: Factors Associated with Maternal-Reported Actions to Prevent Type 1

Diabetes in the First Year of the TEDDY Study. Diabetes Care 37 (2): 325-331, 2014. doi:

10.2337/dc13-0449. Epub 2013 Sep 16. PMID: 24041684; PubMed Central ID:

PMC3898752

31) Hummel S, Vehik K, Uusitalo U, McLeod W, Aronsson CA, Frank N, Gesualdo P, Yang J,

Norris JM, Virtanen SM, and the TEDDY Study Group: Infant feeding patterns in families

with a diabetes history - observations from The Environmental Determinants of Diabetes in

the Young (TEDDY) birth cohort study. Public Health Nutrition 17 (12): 2853-2862, 2014.

doi: 10.1017/S1368980013003054. Epub 2013 Nov 26. PMID: 24477208; PubMed Central

ID: PMC4162845

32) Leon-Novelo L, Kemppainen KM, Ardissone A, Davis-Richardson A, Fagen J, Gano K,

Triplett EW, and TEDDY Study Group: Two Applications of Permutation Tests in

Biostatistics. Boletín de la Sociedad Matemática Mexicana 19 (2): 255–266, 2013. PubMed


33) Lee HS, Burkhardt B, McLeod W, Smith S, Eberhard C, Lynch K, Hadley D, Rewers M,

Simell O, She JX, Hagopian W, Lernmark A, Akolkar B, Ziegler AG, Krischer J, and the

TEDDY Study Group: Biomarker discovery study design for type 1 diabetes in The

Environmental Determinants of Diabetes in the Young (TEDDY) study.

Diabetes/Metabolism Research and Reviews 30 (5): 424-434, 2014. doi: 10.1002/dmrr.2510


34) Johnson SB, Lynch KF, Lee HS, Baxter J, Lernmark B, Roth R, Simell T, Smith L, and the

TEDDY Study Group: At High Risk for Early Withdrawal: Using a Cumulative Risk Model

to Increase Retention in the First Year of the TEDDY Study. Journal of Clinical

Epidemiology 67 (6): 609-611, 2014. doi: 10.1016/j.jclinepi.2014.01.004. Epub 2014 Apr 13.


35) Yang J, Lernmark A, Uusitalo U, Lynch KF, Veijola R, Winkler C, Larsson HE, Rewers MJ,

She JX, Ziegler AG, Simell OG, Hagopian W, Krischer JP, Vehik K, and the TEDDY Study

Desmond A Schatz MD

81

Group: Prevalence of Obesity was Related to HLA-DQ in 2-4 Year Old Children at Genetic

Risk for Type 1 Diabetes. International Journal of Obesity 38 (12): 1491-1496, 2014. doi:

10.1038/ijo.2014.55. Epub 2014 Apr 3. PMID: 24694666; PubMed Central ID:

PMC4185013

36) Liu E, Lee HS, Aronsson CA, Hagopian W, Koletzko S, Rewers M, Eisenbarth G, Bingley

P, Bonifacio E, Simell V, Agardh D, for the TEDDY Study Group: Risk of Pediatric Celiac

Disease According to HLA Haplotype and Country. New England Journal of Medicine 371

(1): 42-49, 2014. doi: 10.1056/NEJMoa1313977 PMID: 24988556; PubMed Central ID:

PMC4163840

37) Roth R, Lynch K, Ballard L, Lernmark B, Baxter J, Simell T, Smith L, Johnson SB, and the

TEDDY Study Group: Maternal anxiety about a child’s diabetes risk in the TEDDY study:

the potential role of life stress, postpartum depression, and risk perception. Pediatric

Diabetes 16 (4): 287-298, 2015. doi: 10.1111/pedi.12168. Epub 2014 Aug 1. PubMed ID:

25082392; PubMed Central ID: PMC4312746

38) Berrios C, Jung J, Primi B, Wang M, Pedamallu C, Duke F, Marcelus C, Cheng J, Garcea

RL, Meyerson M, DeCaprio JA, and the TEDDY Study Group: Malawi Polyomavirus Is a

Prevalent Human Virus That Interacts with Known Tumor Suppressors. Journal of Virology

89 (1): 857-862, 2015. doi: 10.1128/JVI.02328-14. Epub 2014 Oct 15. PMID: 25320321;


39) Torn C, Hadley D, Lee HS, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler AG,

Schatz D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkanen J, Ilonen J,

Rich S, She JX, Steck A, Krischer J, and the TEDDY Study Group: Role of Type 1 diabetes

associated SNPs on risk of autoantibody positivity in the TEDDY Study. Diabetes 64 (5):

1818-1829, 2015. doi: 10.2337/db14-1497. Epub 2014 Nov 24. PMID: 25422107; PubMed


40) Kemppainen KM, Ardissone A, Davis-Richardson A, Fagen J, Gano K, Leon-Novelo L,

Vehik K, Casella G, Simell O, Ziegler AG, Rewers MJ, Lernmark A, Hagopian W, She JX,

Krischer JP, Akolkar B, Schatz D, Atkinson M, Triplett EW, and the TEDDY Study Group:

Early childhood gut microbiomes show strong geographic differences among subjects at high

risk for type 1 diabetes. Diabetes Care 38 (2): 329-332, 2015. doi: 10.2337/dc14-0850. Epub

2014 Dec 17. PMID: 25519450; PubMed Central ID: PMC4302256

41) Aronsson CA, Lee HS, Liu E, Uusitalo U, Hummel S, Yang J, Hummel M, Rewers M, She

JX, Toppari J, Ziegler AG, Krischer J, Virtanen SM, Norris JM, Agardh D, for the TEDDY

Study Group: Age at Gluten Introduction and Risk of Celiac Disease. Pediatrics 135 (2):

239-245, 2015. doi: 10.1542/peds.2014-1787. Epub 2015 Jan 19. PMID: 25601977;


42) Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, She J, Simell O,

Akolkar B, Krischer J, Schatz D, Rewers M, and the TEDDY Study Group: Predictors of

Progression from the Appearance Of Islet Autoantibodies To Early Childhood Diabetes: The

Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care 38 (5): 808-

813, 2015. doi: 10.2337/dc14-2426. Epub 2015 Feb 9. PMID: 25665818; PubMed Central

ID: PMC4407751

43) Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark A, Hagopian WA, Rewers MJ, She

JX, Simell OG, Toppari J, Ziegler AG, Akolkar BA, Bonifacio E, and the TEDDY Study

Group: The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk

Desmond A Schatz MD

82

children: the TEDDY study. Diabetologia 58 (5): 980-987, 2015. doi: 10.1007/s00125-015-

3514-y. Epub 2015 Feb 10. PMID: 25660258; PubMed Central ID: PMC4393776

44) Agardh D, Lee HS, Kurppa K, Simell V, Aronsson CA, Jörneus O, Hummel M, Liu E,

Koletzko S, for the TEDDY Study Group: Clinical Features of Celiac Disease in a

Prospective Birth Cohort at Genetic Risk: TEDDY study. Pediatrics 135 (4): 627-634, 2015.

doi: 10.1542/peds.2014-3675. Epub 2015 Mar 2. PMID: 25733751; PubMed Central ID:

PMC4379464

45) Lönnrot M, Lynch K, Larsson HE, Lernmark A, Rewers M, Hagopian W, She JX, Simell O,

Ziegler AG, Akolkar B, Krischer J, Hyöty H, and the TEDDY Study Group: A method for

reporting and classifying acute infectious diseases in a prospective study of young children:

TEDDY. BMC Pediatrics 25:24, 2015. doi: 10.1186/s12887-015-0333-8. PMID: 25884839;


46) Hadley D, Hagopian W, Liu E, She JX, Simell O, Akolkar B, Ziegler AG, Krischer JP,

Rewers M, Chen WM, Onengut-Gumuscu S, Bugawan TL, Rich SS, Erlich H, Agardh D,

and the TEDDY Study Group: HLA-DPB1*04:01 protects genetically susceptible children

from coeliac disease autoimmunity in the TEDDY study. American Journal of

Gastroenterology 110 (6): 915-920, 2015. doi: 10.1038/ajg.2015.150. Epub 2015 May 26.


47) Haghighi M, Johnson SB, Qian X, Lynch KF, Vehik K, Huang S; TEDDY Study Group: A

Comparison of Rule-based Analysis with Regression Methods in Understanding the Risk

Factors for Study Withdrawal in a Pediatric Study. Sci Rep 6: 30828, 2016. doi:

10.1038/srep30828. Erratum in: Sci Rep 7: 39723, 2017. PMID: 27561809

48) Vehik K, Lynch KF, Schatz DA, Akolkar B, Hagopian W, Rewers M, She JX, Simell O,

Toppari J, Ziegler AG, Lernmark Å, Bonifacio E, Krischer JP; TEDDY Study Group:

Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.

Diabetes Care 39 (9): 1535-1542, 2016. doi: 10.2337/dc16-0181. Epub 2016 Jun 16. PMID:

27311490

49) Törn C, Liu X, Hagopian W, Lernmark Å, Simell O, Rewers M, Ziegler AG, Schatz D,

Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkänen J, Ilonen J, Rich SS, She

JX, Sharma A, Steck A, Krischer J; TEDDY Study Group: Complement gene variants in

relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY

Study. Sci Rep 6: 27887, 2016. doi: 10.1038/srep27887. PMID: 27306948

50) Swartling U, Lynch K, Smith L, Johnson SB; TEDDY Study Group: Parental Estimation of

Their Child's Increased Type 1 Diabetes Risk During the First 2 Years of Participation in an

International Observational Study: Results From the TEDDY study. J Empir Res Hum Res

Ethics. 11 (2): 106-114, 2016. doi: 10.1177/1556264616648589. Epub 2016 May 30. PMID:

27241873

51) Sharma A, Liu X, Hadley D, Hagopian W, Liu E, Chen WM, Onengut-Gumuscu S, Simell V,

Rewers M, Ziegler AG, Lernmark Å, Simell O, Toppari J, Krischer JP, Akolkar B, Rich SS,

Agardh D, She JX; TEDDY Study Group: Identification of Non-HLA Genes Associated with

Celiac Disease and Country-Specific Differences in a Large, International Pediatric Cohort.

PLoS One 11 (3): e0152476, 2016. doi: 10.1371/journal.pone.0152476. eCollection 2016.

PMID: 27015091

52) Elding Larsson H, Vehik K, Haller MJ, Liu X, Akolkar B, Hagopian W, Krischer J,

Lernmark Å, She JX, Simell O, Toppari J, Ziegler AG, Rewers M; TEDDY Study Group:

Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early

Desmond A Schatz MD

83

Childhood: The Environmental Determinants of Diabetes in the Young Study. Diabetes 65

(7): 1988-1995, 2016. doi: 10.2337/db15-1180. Epub 2016 Mar 18. PMID: 26993064

53) Lernmark B, Lynch K, Baxter J, Roth R, Simell T, Smith L, Swartling U, Johnson SB; Teddy

Study Group: Participant Experiences in the Environmental Determinants of Diabetes in the

Young Study: Common Reasons for Withdrawing. J Diabetes Res 2016:2720650, 2016. doi:

10.1155/2016/2720650. Epub 2015 Nov 22. PMID: 26682228

54) Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, Lernmark Å, Rewers

M, Hagopian W, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer J, Norris JM,

Virtanen SM; TEDDY Study Group: Association of Early Exposure of Probiotics and Islet

Autoimmunity in the TEDDY Study. JAMA Pediatr 170 (1): 20-28, 2016. doi:

10.1001/jamapediatrics.2015.2757. PMID: 26552054

55) Andrén Aronsson C, Lee HS, Koletzko S, Uusitalo U, Yang J, Virtanen SM, Liu E,

Lernmark Å, Norris JM, Agardh D; TEDDY Study Group: Effects of Gluten Intake on Risk

of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clin Gastroenterol

Hepatol 14 (3): 403-409.e3, 2016. doi: 10.1016/j.cgh.2015.09.030. Epub 2015 Nov 25.

PMID: 26453955

56) Uusitalo U, Lee HS, Aronsson CA, Yang J, Virtanen SM, Norris J, Agardh D;

Environmental Determinants of the Diabetes in the Young (TEDDY) study group: Gluten

consumption during late pregnancy and risk of celiac disease in the offspring: the TEDDY

birth cohort. Am J Clin Nutr 102 (5): 1216-1221, 2015. doi: 10.3945/ajcn.115.119370. Epub

2015 Oct 7. PMID: 26447157 Free PMC Article

57) Johnson SB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, Smith L; TEDDY Study

Group: Predicting Later Study Withdrawal in Participants Active in a Longitudinal Birth

Cohort Study for 1 Year: The TEDDY Study. J Pediatr Psychol 41 (3): 373-383, 2016. doi:

10.1093/jpepsy/jsv092. Epub 2015 Sep 27. PMID: 26412232

58) Beyerlein A, Liu X, Uusitalo UM, Harsunen M, Norris JM, Foterek K, Virtanen SM, Rewers

MJ, She JX, Simell O, Lernmark Å, Hagopian W, Akolkar B, Ziegler AG, Krischer JP,

Hummel S; TEDDY study group: Dietary intake of soluble fiber and risk of islet

autoimmunity by 5 y of age: results from the TEDDY study. Am J Clin Nutr 102 (2): 345-

352, 2015. doi: 10.3945/ajcn.115.108159. Epub 2015 Jul 8. PMID: 26156735

59) Yang J, Lynch KF, Uusitalo UM, Foterek K, Hummel S, Silvis K, Aronsson CA, Riikonen A,

Rewers M, She JX, Ziegler AG, Simell OG, Toppari J, Hagopian WA, Lernmark Å, Akolkar

B, Krischer JP, Norris JM, Virtanen SM, Johnson SB; TEDDY Study Group: Factors

associated with longitudinal food record compliance in a paediatric cohort study. Public

Health Nutr 19 (5): 804-813, 2016. doi: 10.1017/S1368980015001883. Epub 2015 Jun 19.

PMID: 26088478

60) Lynch KF, Lee HS, Törn C, Vehik K, Krischer JP, Larsson HE, Haller MJ, Hagopian WA,

Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Hyöty H, Bonifacio E,

Lernmark Å; TEDDY Study Group: Gestational respiratory infections interacting with

offspring HLA and CTLA-4 modifies incident β-cell autoantibodies. J Autoimmun pii:

S0896-8411 (17): 30558-30559, 2017. doi: 10.1016/j.jaut.2017.09.005. [Epub ahead of print]

PMID: 28941965

61) Krischer JP, Liu X, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG,

Akolkar B; TEDDY Study Group: The Influence of Type 1 Diabetes Genetic Susceptibility

Regions, Age, Sex, and Family History to the Progression from Multiple Autoantibodies to

Desmond A Schatz MD

84

Type 1 Diabetes: A TEDDY Study Report. Diabetes 2017 Sep 13. pii: db170261. doi:

10.2337/db17-0261. [Epub ahead of print] PMID: 28903990

62) Köhler M, Beyerlein A, Vehik K, Greven S, Umlauf N, Lernmark Å, Hagopian WA, Rewers

M, She JX, Toppari J, Akolkar B, Krischer JP, Bonifacio E, Ziegler AG; TEDDY study

group: Joint modeling of longitudinal autoantibody patterns and progression to type 1

diabetes: results from the TEDDY study. Acta Diabetol 2017 Aug 30. doi: 10.1007/s00592-

017-1033-7. [Epub ahead of print] PMID: 28856522

63) Lönnrot M, Lynch KF, Elding Larsson H, Lernmark Å, Rewers MJ, Törn C, Burkhardt BR,

Briese T, Hagopian WA, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Krischer JP,

Hyöty H; TEDDY Study Group: Respiratory infections are temporally associated with

initiation of type 1 diabetes autoimmunity: the TEDDY study. Diabetologia 2017 Aug 2. doi:

10.1007/s00125-017-4365-5. [Epub ahead of print] PMID: 28770319

64) Koletzko S, Lee HS, Beyerlein A, Aronsson CA, Hummel M, Liu E, Simell V, Kurppa K,

Lernmark Å, Hagopian W, Rewers M, She JX, Simell O, Toppari J, Ziegler AG, Krischer J,

Agardh D; TEDDY Study Group: Caesarean Section on The Risk of Celiac Disease in the

Offspring: The Teddy Study. J Pediatr Gastroenterol Nutr 2017 Jul 27. doi:

10.1097/MPG.0000000000001682. [Epub ahead of print] PMID: 28753178

65) Johnson SB, Lynch KF, Roth R, Schatz D; TEDDY Study Group: My Child Is Islet

Autoantibody Positive: Impact on Parental Anxiety. Diabetes Care 40 (9): 1167-1172, 2017.

doi: 10.2337/dc17-0166. Epub 2017 Jun 29. PMID: 28663383

66) Beyerlein A, Uusitalo UM, Virtanen SM, Vehik K, Yang J, Winkler C, Kersting M, Koletzko

S, Schatz D, Aronsson CA, Elding Larsson H, Krischer JP, Ziegler AG, Norris JM, Hummel

S; TEDDY Study Group: Intake of Energy and Protein is Associated with Overweight Risk at

Age 5.5 Years: Results from the Prospective TEDDY Study. Obesity (Silver Spring) 25 (8):

1435-1441, 2017. doi: 10.1002/oby.21897. Epub 2017 Jun 26. PMID: 28650578

67) Krischer JP, Lynch KF, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler

AG, Akolkar B; TEDDY Study Group: Genetic and Environmental Interactions Modify the

Risk of Diabetes-Related Autoimmunity by 6 Years of Age: The TEDDY Study. Diabetes

Care 40 (9): 1194-1202, 2017. doi: 10.2337/dc17-0238. Epub 2017 Jun 23. PMID: 28646072

68) Roth R, Baxter J, Vehik K, Hopkins D, Killian M, Gesualdo P, Melin J, Simell B, Strauss E,

Lernmark Å, Johnson SB; TEDDY Study Group: The feasibility of salivary sample

collection in an international pediatric cohort: The the TEDDY study. Dev Psychobiol 59 (5):

658-667, 2017. doi: 10.1002/dev.21523. Epub 2017 May 26. PMID: 28555778

69) Lundgren M, Steed LJ, Tamura R, Jonsdottir B, Gesualdo P, Crouch C, Sjöberg M, Hansson

G, Hagopian WA, Ziegler AG, Rewers MJ, Lernmark Å, Toppari J, She JX, Akolkar B,

Krischer JP, Haller MJ, Elding Larsson H; TEDDY Study Group: Analgesic antipyretic use

among young children in the TEDDY study: no association with islet autoimmunity. BMC

Pediatr 17 (1): 127, 2017. doi: 10.1186/s12887-017-0884-y. PMID: 28511706

70) Haghighi M, Johnson SB, Qian X, Lynch KF, Vehik K, Huang S; TEDDY Study Group:

Corrigendum: A Comparison of Rule-based Analysis with Regression Methods in

Understanding the Risk Factors for Study Withdrawal in a Pediatric Study. Sci Rep 7: 39723,

2017. doi: 10.1038/srep39723. No abstract available. PMID: 28462922

71) Novais T, Dauphinot V, Krolak-Salmon P, Mouchoux C: How to explore the needs of

informal caregivers of individuals with cognitive impairment in Alzheimer's disease or

related diseases? A systematic review of quantitative and qualitative studies. BMC Geriatr 17

(1): 86, 2017. doi: 10.1186/s12877-017-0481-9. Review. PMID: 28415968

Desmond A Schatz MD

85

72) García-García ML, Calvo C, Rey C, Díaz B, Molinero MD, Pozo F, Casas I: Human

metapnuemovirus infections in hospitalized children and comparison with other respiratory

viruses. 2005-2014 prospective study. PLoS One 12 (3): e0173504, 2017. doi:

10.1371/journal.pone.0173504. eCollection 2017. PMID: 28301570

73) Yang J, Tamura RN, Aronsson CA, Uusitalo UM, Lernmark Å, Rewers M, Hagopian WA,

She JX, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Norris JM, Virtanen SM, Agardh D;

Environmental Determinants of Diabetes in The Young study group: Maternal use of dietary

supplements during pregnancy is not associated with coeliac disease in the offspring: The

Environmental Determinants of Diabetes in the Young (TEDDY) study. Br J Nutr. 117 (3):

466-472, 2017. doi: 10.1017/S0007114517000332. Epub 2017 Mar 2. PMID: 28249640

74) Smith LB, Lynch KF, Kurppa K, Koletzko S, Krischer J, Liu E, Johnson SB, Agardh D;

TEDDY study group: Psychological Manifestations of Celiac Disease Autoimmunity in

Young Children. Pediatrics. 139 (3). pii: e20162848, 2017. doi: 10.1542/peds.2016-2848.

Epub 2017 Feb 20. PMID: 28219962

75) Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA, Haller MJ, Ahmed S,

Akolkar B, Lernmark Å, Rewers MJ, Krischer JP; and the TEDDY Study Group: Residual

beta-cell function in diabetes children followed and diagnosed in the TEDDY study

compared to community controls. Pediatr Diabetes 2017 Jan 27. doi: 10.1111/pedi.12485.

[Epub ahead of print] PMID: 28127835

76) Hummel S, Beyerlein A, Tamura R, Uusitalo U, Andrén Aronsson C, Yang J, Riikonen A,

Lernmark Å, Rewers MJ, Hagopian WA, She JX, Simell OG, Toppari J, Ziegler AG,

Akolkar B, Krischer JP, Virtanen SM, Norris JM; TEDDY Study Group: First Infant Formula

Type and Risk of Islet Autoimmunity in The Environmental Determinants of Diabetes in the

Young (TEDDY) Study. Diabetes Care 40 (3): 398-404, 2017. doi: 10.2337/dc16-1624.

Epub 2017 Jan 17. PMID: 28096222

77) Kemppainen KM, Lynch KF, Liu E, Lönnrot M, Simell V, Briese T, Koletzko S, Hagopian

W, Rewers M, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Lernmark

Å, Hyöty H, Triplett EW, Agardh D; TEDDY Study Group: Factors That Increase Risk of

Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life. Clin

Gastroenterol Hepatol 15 (5): 694-702.e5, 2017. doi: 10.1016/j.cgh.2016.10.033. Epub 2016

Nov 10. PMID: 27840181

LECTURES, TALKS PRESENTED AT PROFESSIONAL MEETINGS (since 1989)

National/International (Invited):

“Immune abnormalities in pre-diabetes.” Research Seminar Series, Johannesburg, South

Africa, 1990

“The pathogenesis, prediction and prevention of insulin dependent diabetes.” Pediatric Grand

Rounds, Johannesburg, South Africa, 1992

“Oral antigen therapy for the prevention of Type 1 Diabetes.” Juvenile Diabetes Foundation

International, San Francisco, CA, 1994

Desmond A Schatz MD

86

“Progress toward the prevention of Type 1 Diabetes - the Diabetes Prevention Trials.”

Annual Meeting of the Society for Pediatric Research, Seattle, WA, 1994

“Parenteral insulin for prevention of Type 1 Diabetes - pilot studies.” DPT-1 Study Group,

54th Annual Meeting of the American Diabetes Association, New Orleans, LA, 1994

“The beginning of the end of Type 1 diabetes.” XXth Annual Meeting of the International

Society for Pediatric and Adolescent Diabetes, Atami, Japan, 1994

“The use of GAD65 antibodies in the prediction of insulin-dependent diabetes.” Satellite

symposium of the 15th International Diabetes Federation Congress, Kobe, Japan, 1994

“IDD prediction in relatives and the general population.” International Symposium of Type 1

(Insulin-Dependent) Diabetes, Nagasaki, Japan, 1994

“Design and implementation of the Diabetes Prevention Trial.” Council on Diabetes in

Youth. 55th Annual Meeting of the American Diabetes Association, Atlanta, GA, 1995

“Rationale and design of the American Diabetes Prevention Trial (DPT-1).” Finnish Diabetes

Research Society Summer Meeting, Tampere, Finland, 1995

“Diabetes Prevention Trial- Type 1 (DPT-1): Rationale and update.” 59th Annual Meeting of

the American Diabetes Association, San Diego, CA, 1999

“Prevention of Type-1 Diabetes.” Pediatric Grand Rounds, Johannesburg, South Africa, 1995

“Precocious puberty.” Teaching Conference, Johannesburg, South Africa, 1995

“Diabetes Prevention Trial - Type 1 Diabetes.” Lisbon, Portugal, 1996

“Prevention of Type 1 Diabetes.” 5as Jornadas de Diabetes da Madeira, Funchal, Madeira,

1996

“Prediction - the view from Florida.” Prediction of IDDM - status and trends. Workshop of

ENDIT and IDIG, Gentofte, Denmark, 1996

“Research update - Pre - Type 1 Diabetes.” American Diabetes Association Staff Leadership

Conference, Naples, FL, 1996

“Pediatrics into the Millennium: The beginning of the end of insulin dependent diabetes

mellitus.” Pediatric Update, West Palm Beach, FL, 1998

“Two years before the millennium: what's new in the definition, pathogenesis and

complications of diabetes mellitus. Use of antibody markers in defining prediabetes.”

American Association of Clinical Chemistry, Chicago, IL, 1998

“Diabetes Prevention Trial: Update and Mechanism.” 59th Annual Meeting of the American

Diabetes Association, San Diego, CA, 1999

“Pathogenesis and Possible Fetal Origins of Type 1 diabetes.” International Conference on

Fetal Origins of Adult Disease. National Institute of Health, Rockville, MD, 1999

“The prediction of Type 1 diabetes in the general population.” Fourth Immunology of

Diabetes Society Congress, Fiuggi, Italy, 1999

“Genetic versus antibody screening for the prediction of Type 1 diabetes.” Fourth

Immunology of Diabetes Society Congress, Fiuggi, Italy, 1999

“Strategies for early detection and prevention of IDDM.” 2000 Endocrine Society Meeting,

Toronto, Canada, 2000

“Update on Major Trials for Prevention of Type 1 Diabetes in Relatives.” 9th Annual

Bellinson-Schneider Symposium, Maagan Village, Israel, 2000

“To screen, on not to screen for Type 1 diabetes.” 2nd International Novo Nordisk

Symposium on Diabetes in Childhood and Adolescence.” Copenhagen, Denmark, 2001

“Future of Type 1 diabetes.” Grand Rounds. Dept of Pediatrics, University of Witwatersrand,

Johannesburg, South Africa, 2001

Desmond A Schatz MD

87

“Update on worldwide efforts to prevent Type 1 diabetes.” Australia Diabetes Association

Meeting, Coolingatta, Australia, 2001

“TrialNet: a new US initiative to prevent diabetes.” Annual meeting of ENDIT. Copenhagen,

Denmark, 2001

“Prediction of Type 1 diabetes, possibilities and limitations.” State of Art Lecture, German

Diabetes Association, Dresden, Germany, 2002

“Screening strategies for the prediction of type 1 diabetes.” Cuban Diabetes Society, Havana,

Cuba, 2002

“The use of islet autoantibodies in type 1 diabetes.” Cuban Diabetes Society, Havana, Cuba,

2002

“Is primary Type 1 diabetes prevention feasible?” Ana Zager Memorial Lecture, Haifa,

Israel, 2005

“Type 1 diabetes can be prevented - a debate.” Steno Symposium, Copenhagen, Denmark,

2005

“What should be the length and follow up of prevention and intervention studies of Type 1

diabetes?” Prevention of Type 1 diabetes: new frontiers, Rome, Italy, 2006

“Immunopathogenesis of Type 1 diabetes.” ISPAD Postgraduate Course, Shanghai, China,

2006

“Prevention and amelioration of Type 1 diabetes.” ISPAD Postgraduate Course, Shanghai,

China, 2006

“Novel approaches to curing Type 1 diabetes.” ISPAD Postgraduate Course, Shanghai,

China, 2006

“Cellular therapies for Type 1 diabetes.” D-Cure Meeting, Barcelona, Spain, 2007

“Future of Type 1 diabetes.” Children with diabetes, Orlando, Florida, 2010

“Immunosuppression studies aimed at interdicting and preventing type 1 diabetes (T1DM).”

ISPAD, Buenos Aries, Argentina, 2010

“New approaches to intervening in type 1 diabetes.” ESPE summer school, Prague, Czech

Republic, 2010

“Immunomodulation of type 1 diabetes.” 43rd International Symposium, Rome, Italy, 2011

“The Beginning of the End of Type 1 Diabetes.” Ira M. Rosenthal MD Annual Memorial

Lecture, Chicago, IL, 2011

“Overview of Immunotherapy Trials Aimed at Preventing Loss and Preserving Beta Cell

Mass.” 71st Scientific Sessions, San Diego, CA, 2011

“Comment on Progress toward Prevention & Cure of Type 1 diabetes.” ISPAD, Miami, FL,

2011

“Pediatrician’s Perspective.” Sanofi Diabetes Type 1 Summit, Barcelona, Spain, 2013

“A Pediatrician’s Perspective of the Current State of Diabetes Management.” JDRF T1D in

the At-Risk Setting Workshop, Keystone, CO, 2013

“Practical Ways to Achieve Targets in Diabetes Care: How to Achieve Better Target A1c in

Children.” JDRF T1D in the At-Risk Setting Workshop, Keystone, CO, 2013

“Screening for Type 1 Diabetes.” JDRF T1D in the At-Risk Setting Workshop, Keystone,

CO, 2013

“Searching for the right combination to interdict Type 1 diabetes: man-to-mouse-to-man.”

Boston Children’s Hospital Grand Rounds, Boston, MA, 2014

“The importance of communicating to parents about type 1 diabetes and Type 2 diabetes –

signs and symptoms.” Sansum Diabetes Research Institue, Santa Barbara, CA, 2014

Desmond A Schatz MD

88

“Strategies/Targets for Prevention/Preservation of Beta Cells.” Endocrine Fellows Series,

Chicago, IL, 2014

“Treating to Target: Are we achieving goals in pediatric and adult patients.” Endocrine

Fellows Series, Chicago, IL, 2014

"Data on current insulin treated pilots and review of other countries' regimes.” American

Diabetes Expert Panel, Alexandria, VA, 2014

“Prevention and Cure of Diabetes-where to next.” ISPAD, Toronto, Canada, 2014

“Current Benefits of Screening/Risk Detection.” Defining the early stages of type 1 diabetes,

Bethesda, MD, 2014

“Type 1 Diabetes TrialNet: an update.” The Carousel of Hope Pathways for future treatment

& managment of diabetes, Beverly Hills, CA, 2014

“Prevention of T1D, international Trials.” Diabetes Prediction and Prevention Study (DIPP),

Turku, Finland, 2014

“Medical Devices: The ADA view.” Advanced Technologies & Treatments for Diabetes

(ATTD), Paris, France, 2015

“T1DM in children & adolescents:treatment goals & quality of care: why is it so difficult to

manage?” National Diabetes Summit, Sao Paulo Brazil, June 30, 2015

“Why it matters.” Children with Diabetes, Orlando FL, July 9, 2015

“Towards the prevention and reversal of type 1 diabetes. What next?” Dr. Mohan’s

International Diabetes Update, Chennai, South India, July 31, 2015

“Type 1 diabetes in adolescents target and approach to better management.” Dr. Mohan’s

International Diabetes Update, Chennai, South India, July 31, 2015

“Diabetes research in adolecents & young adults-challenges & limitations.” Minkowski

Course, Kaunas, Lithuania, August 4, 2015

“Beginning of end of Type 1 diabetes.” Lilly 2015 Diabetes Day, Ljubljana, Slovenia, Dec 4,

2015

“Beginning of End of Type 1 Diabetes”. Kaplan Lecture UCLA, Los Angeles, CA, Jan 21,

2016

“Towards a biological cure of type 1 diabetes: challenges and opportunities.” UCLA, Los

Angeles, CA, Jan 22, 2016

“Developing disease modifying therapies in children with type 1 diabetes.” Advanced

Technologies & Treatments for Diabetes (ATTD), Milan, Italy, Feb 4, 2016

“Immune intervention for type 1 diabetes.” Advanced Technologies & Treatments for

Diabetes (ATTD), Milan, Italy, Feb 4, 2016

“The beginning of the end of type 1 diabetes.” Rzeszow, Poland, April 7, 2016

“Treating to target: are we achieving goals in pediatric patients?” Rzeszow, Poland, April 7,

2016

"Transitions of Type 1 Diabetes Care from Adolescence to Adulthood: Addressing the

Challenges of Patients, Families and Providers." PAMS/ADA, Bangalore, India,Sept 28,

2016

“Heterogeneity of Type 1 diabetes: why it matters.” PAMS/ADA Bangalore, India, Sept 26,

2016

“Progress toward prevention and cure of Type 1 diabetes.” PAMS/ADA Bangalore, India,

Sept 28, 2016

“Treating to Targets in Children with Type 1 Diabetes.” PAMS/ADA Bangalore, India, Sept

27, 2016

Desmond A Schatz MD

89

“Towards the prevention of T1DM.” PAMS/ADA Bangalore, India Sept 28,2016

“Challenging cases in T1DM.” PAMS/ADA Bangalore, India Sept 27, 2016

“Diabetes at 212°: Confronting the Invisible for the Next Generation.” ISPAD, Valencia,

Spain, Oct 27, 2016

“Immune Intervention for Type 1 Diabetes”. ATTD, Paris, France, Feb 17, 2017

“Type 1 diabetes biological heterogeneity: why does it matter?” ATTD, Paris, France, Feb

17, 2017

“Size does matter in diabetes.” International Endocrine Conference/University of Quito

Quito, Ecuador, May 1, 2017

“Hyperglycemic Emergencies: Ketoacidosis and Hyperosmolar coma.” Webcast, Elsevier,

July 19, 2017

“Progression toward the prevention of T1DM.” ADA/PAMS Bangalore, India, August 18,

2017

“A pragmatic approach to improving the care of the adolescent with diabetes”. ADA/PAMS,

Bangalore, India, August 19, 2017

“Highlights of ADA-2017.” ADA/PAMS Bangalore, India, August 19, 2017

“The many faces of T1D.” ADA/PAMS Bangalore, India, August 20, 2017

“The Heterogeneity of Type 1 Diabetes: The quest for a personalized approach to

prevention." EAPM, Belfast, Ireland, November 27, 2017

“Update on worldwide efforts to prevent type 1 diabetes.” ATTD, Vienna, Austria, February

16, 2018

“Interesting cases of Type 1 Diabetes.” Chellarams Diabetes Summit, Pune, India, March 10,

2018

“Type 1 diabetes thereapy progress in the last 10 years.” Chellarams Diabetes Summit, Pune,

India, March 10, 2018

“A journey into the near future: Options, solutions and technologies in the treatment of

pediatric patients with type 1 diabetes.” T1DM National Congress, Lodz, Poland, April 12,

2018

“Immune Intervention for Type 1 diabetes.” Advanced Technologies & Treatments for

Diabetes (ATTD). Berlin, Germany, February 20, 2019

“Beta Cell replacement strategies 2019.” Advanced Technologies & Treatments for Diabetes

(ATTD). Berlin, Germany, February 23, 2019

Regional (Invited):

“Defective immunoregulation in prediabetes.” Research in Progress Lecture Series, Barbara

Davis Diabetes Center, Denver, CO, 1989

“Evaluation of Growth.” University of Florida Family Practice Review, Amelia Island, FL,

1989

“Normal and abnormal pubertal development.” University of Florida Family Practice

Review, Amelia Island, FL, 1989

“Endocrine abnormalities in Prader Willi Syndrome.” Symposium on Prader Willi Syndrome,

Gainesville, FL, 1990

“Short stature for the pediatrician in practice.” Pediatric Postgraduate Seminar Series,

Lakeland Regional Medical Center, Lakeland, FL, 1991

Desmond A Schatz MD

90

“The prediction and prevention of type 1 diabetes: closer to reality.” Pediatric Postgraduate

Seminar Series, Lakeland Regional Medical Center, Lakeland, FL, 1991

“Growth hormone therapy update.” Pediatric Postgraduate Seminar Series, Lakeland

Regional Medical Center, Lakeland, FL, 1993

“Growth hormone therapy into the 90s and beyond.” Annual Meeting of the University of

Florida Pediatric Alumni, Jacksonville, FL, 1994

“The beginning of the end of type 1 diabetes.” Annual Meeting of the Georgia Chapter of the

Juvenile Diabetes Foundation, Atlanta, GA, 1995

“Strategies toward the prevention of IDD.” Florida Chapter of American Diabetes

Association/Sacred Heart Hospital, Pensacola, FL, 1995

Is your family at risk for diabetes?” Diabetes Wellness Seminar. American Diabetes

Association Regional Meeting, Savannah, GA, 1995

“Progress toward the prevention of Type 1 diabetes - Diabetes Prevention Trial (DPT-1).”

Cleveland Chapter of the Juvenile Diabetes Foundation, Cleveland, OH, 1995

“Diabetes Research Update: progress toward the prevention and cure of IDD.” Grand

Rounds, Sacred Heart Hospital, Pensacola, FL, 1996

“Immune aspects and potential intervention for Type 1 diabetes. Symposium.” Update in

Diabetes and Endocrinology" sponsored by St Louis University/Deaconess Medical Center,

St Louis, MO, 1996

“Diabetes research, prevention and transplantation - where are we?" Diabetes Care '96:

Challenges to self management education, Gainesville, FL, 1996

“Prediction and prevention of IDDM.” Endocrine Symposium, Memphis, TN, 1996

“Prevention of insulin-dependent diabetes.” Diabetes Update 1997, Diabetes Branch NIDDK,

National Institutes of Health, Bethesda, MD, 1997

“Prospects for prevention of Type 1 (autoimmune) diabetes.” Distinguished Lecture Series,

Children's Hospital of Los Angeles, Los Angeles, CA, 1997

“The beginning of the end of Type 1 diabetes.” Albert Einstein College of Medicine,

Monefiore Medical Center, Bronx, NY, 1997

“The beginning of the end of Type 1 diabetes.” Pediatric Grand Rounds, Childrens Hospital

at Strong, University of Rochester Medical Center, Rochester, NY, 1998

“When can we possibly prevent and cure Type 1 diabetes.” Jacksonville Diabetic

Association, Jacksonville, FL, 1998

“Update on the prevention of Type 1 diabetes.” Emory University, Atlanta, GA, 1998

“The beginning of the end of Type 1 diabetes.” Second Annual Pediatric Endocrinology

Symposium, Miami Children's Hospital, Miami, FL, 1998

“Update on worldwide attempts to prevent or correct type 1 diabetes mellitus.” Children's

Hospital, University of Washington, Seattle, WA, 1998

“The beginning of the end of Type 1 diabetes.” Brookdale University Hospital and Medical

Center, Brooklyn, New York, 1999

“Towards a better understanding of the natural history of pre-Type 1 diabetes.” Barbara

Davis Diabetes Center, Denver, CO, 2000

“Does Type 1 diabetes begin in-utero?” Cleveland Clinic Symposium, Cleveland, OH, 2000

“Update on worldwide attempts to prevent or correct type 1 diabetes mellitus.” Cleveland

Clinic Symposium, Cleveland, OH, 2000

“Contemporary Management of Type 1 diabetes.” Update in Diabetes and Endocrinology, St

Louis, MO, 2000

Desmond A Schatz MD

91

“Fetal/early origins of Type 1 diabetes.” Research Symposium, University of Minnesota,

Minneapolis, MN, 2000

“The beginning of the end of Type 1 diabetes.” University of Minnesota, Minneapolis, MN,

2000

“Future of Type 1 diabetes in America.” 6th Annual Southern Regional Conference on

Diabetes, Jacksonville, FL, 2001

“Screening approaches for pre-type 1 diabetes.” Center for Disease Control (CDC), Atlanta,

GA, 2001

“The future of Type 1 diabetes.” American Diabetes Association Postgraduate Course,

Naples, FL, 2003

“Intensive management of Type 1 diabetes in children.” American Diabetes Association

Postgraduate Course, Naples, FL, 2003

“What’s new in Type 1 diabetes research?” Grand Rounds, University of Florida, Dept of

Pediatrics at Sacred Heart Hospital, Pensacola, FL, 2002

“The future of Type 1 diabetes.” Grand Rounds, Emery University, Atlanta, GA, 2003

“The future of Type 1 diabetes.” Grand Rounds, University of Washington, Seattle WA, 2003

“Novel approaches at the University of Florida to curing Type 1 diabetes.” University of

Washington, Seattle, WA, 2003

“Toward prevention and cure of Type 1 diabetes.” Yale University, Dept of Pediatrics, New

Haven, CT, 2004

“Should we be screening for pre-type 1 diabetes?” New England Pediatric Endocrine Group,

Hartford, CT, 2004

“Should we be screening for pre-type 1 diabetes?” 64th Annual Meeting of the American

Diabetes Association, Orlando, FL, 2004

“The future of Type 1 diabetes.” Mount Sinai Hospital Postgraduate Diabetes Course, New

York, NY, 2004

“The future of Type 1 diabetes.” Mount Sinai Hospital Postgraduate Diabetes Course, New

York, NY, 2004

“New Horizons in Type 1 diabetes.” Southern Pediatric Endocrine Society, St Augustine, FL,

2005

Ibid. Diabetes University, Columbus, GA, 2005

“From DPT-1 to TrialNet: Progress toward preventing Type 1 diabetes.” Washington

University, St Louis, MO, 2005

“Can type 1 diabetes be prevented?” Washington University, St Louis, MO, 2005

“Achieving glycemic goals: consideration of regimens that closely mimic normal insulin

patterns.” Pri-Med Update, Jacksonville, FL, 2006

“Advances in preventing and curing Type 1 diabetes.” Diabetes Symposium, Charlotte, NC,

2007

“Burden and challenges of diabetes 2009.” Cellular mechanisms of diabetic eye disease,

Gainesville, FL, Jan 2009

“Type 1 diabetes research update.” JDRF, Sarasota, FL, 2011

“Diabetes 101.” Grand Rounds, Sarasota Memorial Hospital, Sarasota, FL, 2011

“Type 1 diabetes research update.” JDRF, Naples, FL, 2011

“Diabetes 101.” Grand Rounds, NCH, Naples, FL, 2011

“Getting Involved in Diabetes Research.” Children with Diabetes, Orlando FL, 2011

“New Onset Therapy-Why it Matters.” Children with Diabetes, Orlando FL, 2011

Desmond A Schatz MD

92

“The Beginning of the End of Type 1 Diabetes.” Central Florida Pediatric Society, Orlando

FL, 2012

"JDRF research update: Clinical roadmap to a cure.” Children with Diabetes, Orlando, FL,

July 4, 2014

“ADA Standards of Care 2015.” University of Arizona, Tucson AZ, Mar 14 2015

“Critical questions: How, and at what point? Should type 1 diabetes be diagnosed?”

Research conference on Differentation of Diabetes, Oct 10 2015

ADA Diabetes Panel, Delray Beach, Nov 5, 2015

“The environmental determinants of type 1 diabetes (TEDDY) study: what have we learned

so far?” Dr. Jay Skyler Grand Rounds, Miami, FL, Feb 15, 2016

"Toward a biological cure of type 1 diabetes: challenges & opportunities." Grand Rounds,

Miami, FL, Feb 16, 2016

“Diabetes @ 212o Confronting the Invisible Disease.” ADA 76th Scientific Session, New

Orleans, LA, June 12, 2016

“Transition of care from adolescence to adulthood: addressing the challenges of patients,

families and providers.” Denver, CO, July 13, 2016

“Type 1 diabetes is a heterogeneous disease & different in children compared to adults.”

Keystone, CO, July 15, 2016

“Rationale for new targets in T1D children.” Keystone, CO, July 16, 2016

“TrialNet ongoing trials: an update.” Keystone, CO, July 16, 2016

“Prevention & treatment: from probiotics to immunotherapy.” Children with Diabetes,

Orlando, FL, July 7, 2016

“Epidemiology & prevention of Type 1 diabetes.” Grand Rounds, Cleveland, OH, Nov 11,

2016

“Exploring the natural history of Type 1 diabetes: Progress and Opportunities.” Portland, OR,

Nov 15, 2016

“Managing the sick patient at home.” Type 1 Diabetes Care and Management Program.

Orlando, FL Mar 29, 2017

“Understanding hypoglycemia in T1DM.” Type 1 Diabetes Care and Management Program,

Orlando, FL, Mar 29, 2017

“Diabetes at 212°.” Orlando, FL, July 6, 2017

“Heterogeneity of Type 1 diabetes: No Longer Can it be Ignored.” SCTR Retreat on Diabetes

& Metabolic Disease, Charleston, SC, April 19, 2018

“Preventing Type 1 Diabetes: Where do we stand?” Children with Diabetes, Orlando, FL,

July 12, 2018

“Managing Type 1 in Youth.” Diatribe panel Children with Diabetes, Orlando, FL, July 12,

2018

“We are FAMILY! TrialNet and the Pros and Cons of Testing Family Members for

Type 1.” Taking Control of your Diabetes (TCOYD), San Diego, CA, August 18, 2018

“Prevention of T1DM: Where are we in 2019?” Endocrine Society 101st Annual Meeting,

New Orleans, Louisana, March 26, 2019

“Progress towards a cure” EPIC conference, Aurora CO May 11, 2019

“Searching for Endotypes: Heterogeneity of Type 1 Diabetes can no longer be ignored”

University of Kentucky, May 23, 2019

“Insulin affordability update” ADA Clinical Conference, Orlando FL May 25, 2019

“Cost Benefit of Pre-Type 1 Screening—Is It Time to Reevaluate Our Recommendations?”,

Desmond A Schatz MD

93

ADA 79th Scientific Session, San Francisco June 7, 2019

“Efficacy of New-Onset Type 1 Diabetes (T1D) Intervention Trials: Variation in 1-Year

Outcomes” ADA 79th Scientific Session, San Francisco June 7, 2019

june 2019 curriculum vitae - university of florida · june 2019 curriculum vitae desmond arthur...

Documents